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Abstract 
 
Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion 
channels formed from homologous subunits, of which there are many different 
subtypes. The ability to combine different types of subunits into an individual 
pentamer enables a wide diversity of functional properties to meet a range of 
physiological needs. In the brain, the vast majority of high-sensitivity 3H-nicotine 
binding sites are due to  nAChRs containing α4 and β2 subunits. These subunits 
assemble into pentamers with alternate stoichiometries (α4β2)2β2 and (α4β2)2α4. 
These two receptors differ in sensitivity to ACh, unitary current amplitude, 
selectivity for different agonists, antagonists an, and potentiation by ions or drugs. 
The alternate stoichiometries are present in neurones and although they tend to co-
express, there are regions in the brain such as the striatum, where only one 
stoichiometry is present. 
Recent studies of the (α4β2)2α4 nAChR have shown that this receptor type 
functions with three agonist sites, two of these are on the α4/β2 interfaces of the 
receptor and are thus classical nAChR agonist sites, whereas the other site is on the 
α4/α4 interface, the signature interface of this receptor type. Pharmacological studies 
have shown convincingly that the site at the α4/α4 interface accounts for the unique 
pharmacology of the (α4β2)2α4 nAChRs. In the case of the (α4β2)2β2, there is a 
signature β2(+)/β2(-) interface that homology models suggest may house an agonist 
site. The β2(+)/β2(-) interface forms between the fifth subunit of the receptor and 
another β2 subunit that also contributes, through its complementary face, to an 
agonist site. In common with the (α4β2)2α4 nAChR, the α4/β2 interfaces of 
(α4β2)2β2 house each an agonist site. To test the possibility of an operational agonsit 
site at the β2(+)/β2(-) interface, and to answer the question of whether the unique 
functional behaviour of the (α4β2)2β2 can be ascribed to an additional agonist site, 
the work presented here used targeted single point-mutations, functional analysis and 
the substituted cysteine scanning approach. By using these approaches, it was found 
that the β2(+)/β2(-) interface does not house an agonist site; however, it was found 
that this interface is an important site for inter-subunit communication and that this 
communication encodes agonist efficacy elements. 
 The inter-subunit communication occurs between residues of the E loop of 
the fifth subunit of the receptor and conserved aromatic residues in loop B of the 
complementary subunit of one of the agonist sites found on α/β interfaces. By 
alanine substituting agonist sites on the α4/β2 interfaces and determining the 
consequences of the mutations on the pattern of covalent reaction between a 
methanethiosulphonate compound and one of the β2 subunits contributing to the 
β2(+)/β2(-) interface, it was found that the agonist sites communicate with the 
β2(+)/β2(-) interface via the interactions between the E loop residues and conserved 
aromatic residues. Further studies with a compound that enabled direct 
measurements of changes in agonist efficacy relative to that ACh established that 
agonist efficacy is dependent on primarily on binding of the agonist to the agonist 
sites on the α4/β2 interfaces and then on the E loop-conserved aromatic residues 
interactions. The results are discussed in the context of recent cryo-electron 
microscopy structures of the muscle nAChR that show, for the first time, that the 
fifth subunit of nAChRs may play a key role in gating of the ion channel.  
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1.1 Study of the Mind and Brain 
 
The final frontier of medical science is often referred to as the challenge of 
providing biological explanation of complex high order processes such as 
consciousness and behaviour; how these arise from apparently simple physical 
matter and how they differ between individuals. 
The earliest recording of study of the brain dates back to ancient Egyptian 
civilisation, in a document known as the Edwin Smith Surgical Papyrus. This not 
only contains accurate descriptions of cranial structures including the external brain 
surface, but accounts of somatic disorders caused by damage to the brain, historically 
introducing its power to govern widespread effects (Wilkins, 1992). 
 Roughly 10 centuries later, over two millennia ago, Hippocrates proposed 
that in order to begin to understand the mind, we must first study the brain; a 
historical notion re-enforced by 20th century neural science. More recently in western 
science, at the turn of the 19th century, Auguste Comte, the French philosopher 
recognised that studies of the mind required objective observation, and thus 
investigations into psychological phenomena should be integrated in biological 
sciences (Gardner and Martin, 2000). 
Recently, advancement of scientific techniques and interdisciplinary research 
has seen remarkable progress of research that although still largely concerned with 
internal representations of information and subjective states of mind, has firm 
empirical grounding in biological science. Revelations of genetics, allowing 
sequencing of proteins integral to specialised cell function has enabled us to study 
the complex composition of the brain, greatly expanding our knowledge of the 
physical processes from which senses, learning and perceiving arise. 
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1.1.2 - Insight to “Building Blocks” of the Brain and its Behaviours 
 Towards the end of the 19th century, anatomist Santiago Ramon y Cajal 
observed that the reality of the composition of cortical communication networks are 
discrete units, neurons, with spaces between them termed synapses (Ramon y Cajal, 
1988,  Boya and Alamo, 2006). These specialised cells communicate to one another, 
transmitting signals across the synapses between neurons in precise fashion and are 
connected in functional groups.  
 Ramon y Cajal realised two important factors of cell signalling and brain 
function. The first, the ‘principle of dynamic polarization’ states that signals 
transmitted along these connections of neurons can only travel in one direction. 
Secondly, the ‘principle of connectional specificity’ encompasses the fact that 
network formation is not random, but specific and functional connections are made 
between cells (Kandel, 2000). These core principles are still at the center of our 
understanding of processes occurring in the brain.  
 At this point it was long known that live muscle and nerve cells have inherent 
abilities to produce electricity. This idea was later developed by experiments 
showing that this electrical activity of a given cell could predictably affect that of an 
adjacent cell, leading to conclusions that it was these electrical properties that 
governed transmission of information through and between neurons (Kandel, 2000). 
This was famously investigated by British physiologists Hodgkin and Huxley in 
1965. Through their studies of the giant squid axon they revealed the existence of the 
action potential; electrical signals conducted through nervous tissue by the 
movement of ions. 
Dependent on their physiology, signals from neurons can be excitatory or  
inhibitory and one neuron may have up to 10,000 inputs of both inhibitory and 
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excitatory signals from other cells. Dependent on the pattern of these signals that 
accumulates at a given time, the post synaptic cell may or may not reach the 
depolarisation threshold required to initiate an action potential that will then in turn 
inhibit or excite any of the 1000s of neurons they are pre-synaptic to. With a total of 
around 100 billion cells in the human brain, the intricacies of particular pathways 
begin to be seen. 
1.2  Synaptic Signalling in the Nervous System 
 
 Neurones communicate with each other and target cells using structures 
termed synapses. There are electrical synapses and chemical synapses. The former 
are gap junctions that allow cytoplasmic continuity between synapsed cells; they are 
rare in mammalian neurones (Kandel, 2000). Chemical synapses are the predominant 
structure by which mammalian neurones signal (Kandel, 2000). Chemical synapses 
consist of a presynaptic terminal and a postsynaptic cell separated by a narrow space 
termed synaptic gap. The presynaptic terminal, the end part of an axon, contains 
vesicles filled with neurotransmitter and the apparatus needed for the release of the 
neurotransmitter into the synaptic gap. The post-synaptic cell contains postsynaptic 
receptors in the membrane facing the synaptic gap. The key functional feature of 
chemical synapses is the interaction between the released neurotransmitter and the 
neurotransmitter receptors of the post-synaptic cell. Membrane depolarisation 
brought about by the arrival of action potentials to the presynaptic terminal causes 
influx of calcium ions through voltage gated calcium channels, prompting vesicles 
containing neurotransmitter to fuse with the presynaptic membrane facing the 
synaptic gap. Fusion releases neurotransmitter into the synaptic cleft, which 
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increases the concentration of the neurotransmitter in the gap, thus favouring the 
diffusion of the chemical messenger towards the post synaptic cell where it will bind 
the postsynaptic gap receptors. 
A major class of post-synaptic receptors are ligand gated ion channels 
(LGIC’s). These proteins are ion channels integrated into the cell membrane; they 
are not only found in neurones but also in muscle cells, cells of the auto-immune 
system, hormone-releasing cells (e.g. pancreatic cells), where they also play key 
roles in cell signalling. Binding of neurotransmitters to the agonist site in LGIC’s 
gates the ion channel allows influx or outflow of ion across the channel. As a result 
of the movement of ions through the channel, the post-synaptic neuron generates 
post-synaptic potentials, which can be excitatory (EPSP) or inhibitory (IPSP), 
depending on the nature of the ionic current that passed through the ion channel. 
EPSP may lead to the generation of action potentials, depending if the level of 
overall membrane depolarisation is sufficient to elicit action potentials. Conversely, 
IPSP cause membrane hyperpolarization as it defers from the threshold value for 
transmission of excitatory stimuli, thus these events are seen as inhibitory. 
Considering the vast number of cells synapsing onto a single neuron and the 
probability of action potential transmission being a result of the summation of this 
alteration of membrane potential, this can be a very fine tuned process. 
Neurotransmitter-receptor complexes dissociate within milliseconds and the 
receptors return to a resting state. The ligands are then recycled back into the 
presynaptic neuron through transporters and diffusion. Many chemical structures act 
as neurotransmitters, including amino acids and hormones. A major neurotransmitter 
system is the cholinergic system and this thesis focuses on one component of this 
system, the α4β2 nicotinic acetylcholine receptor.  
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1.3 The Cholinergic System  
 
The cholinergic system is a widespread system implicated in many central 
nervous system (CNS) functions and pathologies. In the peripheral nervous system, 
the action of ACh on its receptors is the predominant form of fast acting point to 
point contact across the synapses in autonomic ganglia and the neuromuscular 
junction. Conversely, the role of ACh and the cholinergic system in the brain is said 
to be mostly neuromodulatory (Wonnacott, 1997). 
The neurotransmitter used by the cholinergic system is acetylcholine (ACh). 
ACh was the first neurotransmitter to be discovered, which occurred in 1914. At that 
time, it was termed  “Vagustoff” due to its origins from the vagus nerve (Tansey, 
2006). The modern name is derived from the fact that it is an acetylated choline 
molecule, synthesised from choline and acetyl-CoA by the enzyme choline 
acetyltransferase. Once ACh dissociates from the receptors to which it binds and 
activates, it is broken down into choline and acetate by the enzyme 
acetylcholinesterase. This facilitates ACh clearance from the synapse once the 
synaptic transmission is complete as choline is then taken up into the presynaptic cell 
by the choline transporter. 
1.3.1- Neuromodulation by Cholinergic Neurons 
 Neuromodulation is described as the alteration of a neuron or group of 
neurons signalling by external excitatory or inhibitory inputs. A neuromodulator  
modifies behaviour of target cells by changing their state without directly causing 
excitation or inhibition (Ito and Schuman 2008). ACh modulates neuronal signalling 
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by number of ways such as influencing presynaptic neurotransmitter release, altering 
neuronal firing patterns, or combinations of these (Exley and Cragg 2008; Rice and 
Cragg, 2004; Zhang and Sulzer, 2004); however, these effects are always mediated 
through ACh-selective receptors located in the cell body, axon or presynaptic 
terminals of the target neuron (Wonnacott, 1998) 
 Many studies have revealed the neuromodulatory effects of ACh in the brain 
via these processes and shown their mechanisms pertaining to cognition and 
behaviour (Poorthuis et al, 2014). Letzkus et al, (2011) demonstrated rapid ACh 
mediated alteration of neuron excitation required for fear conditioning alongside 
direct activation of cholinergic neurons in regions of the cortex contributing to 
learning. ACh has also been shown to amplify sensory signals to the cortex while 
inhibiting excitatory feedback of a stimulus in order to aid information retrieval, 
reinforcing learning and memory processes (Hasselmo, 2006), as well as improving 
the signal-to-noise ratio in a learning environment (Yu and Dayan, 2005). Activation 
of cholinergic receptors has also been shown to co-ordinate firing of neurons 
suggesting its importance in synchronisation of neuronal activity (Bucher and 
Goaillard 2011; Kawai et al., 2007). Differences in the time-scale of ACh release at 
the local microcircuit level may further refine the role of ACh in complex 
behaviours, highlighting in turn the intricacies and complexities of processes 
underlying them (Hasselmo and Sarter, 2011; Giocomo and Hasselmo, 2007; Yu and 
Dayan, 2005). It is this complex neuromodulatory role of ACh in the brain that has 
made it difficult to use the cholinergic system for therapeutic intervention in diseases 
in which ACh signalling is involved, in comparison to neurotransmitter systems that 
signal predominantly post-synaptically (e.g., GABA, glutamate) 
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1.3.2 Receptors of the Cholinergic System 
 In common with many signalling systems in the brain, the cholinergic system 
signals through metabotropic (muscarinic acetylcholine receptors, mAChRs) and 
ligand-gated ion channels (nicotinic acetylcholine receptors, nAChRs). These 
receptors have been named according to their ability to bind the plant alkaloid 
nicotine and mushroom toxin muscarine respectively. mAChRs are G-protien 
coupled receptors initiating and mediating long lasting intracellular metabolic 
responses, whereas nAChRs are ligand-gated ion channels that mediate fast ionic 
currents when bound to ACh. 
Neuromodulation is typically attributed to metabotropic receptors due to their 
ability to alter many downstream cellular processes and their long term effects. 
However, nAChRs in the brain also appear to play primarily modulatory roles 
(Wonnacott, 1997). In addition, mAChR alteration of nAChR mediated of 
neurotransmitter release in the CNS and interaction of the two receptor classes as a 
mode of neuromodulation has been reported (Luchicchi et al, 2014; Grili et. al., 
2008). This has suggested that the overall cholinergic effect exerted upon specific 
circuits greatly depends on the expression patterns of both nAChRs and mAChRs 
(Wilkie et al., 1996). mAChR-nAChR interactions appear to modulate activity in the 
pre-limbic area of the rat prefrontal cortex, a cortical region known to be involved in 
cognitive processes (Vidal and Changeux, 1993). 
 Cross-talk between mACh and nAChRs has been demonstrated to exist 
particularly in the presynaptic location of the modulatory receptors studied (Marchi 
and Grilli, 2010). Thus, it stands that presynaptic nAChRs interact with other 
metabotropic or ionotropic receptors on the same cell, producing an integrated 
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response of the neuron with antagonistic or synergistic outcomes. Additionally this 
can then have a resultant effect upon consequences at the post synaptic cell and its 
receptors. mAChR activation has been shown to be instigated by activity of nAChRs 
coexisting on the same dopamine releasing terminals. Conversely, co-ordinated 
activation of mAChRs and nAChRs has been shown to modulate pre-synaptic 
GABA release (Grilli et al., 2008; Grilli et al., 2009). Functional effects of receptor 
type interplay has also been shown experimentally such as regulation of muscarinic 
receptor signalling via cholinergic interneurons being critical in decision making 
behaviours modulated by striatal activity (Goldberg, Ding and Surmeier, 2012). 
 Overall control and specificity of cholinergic signalling appears to be 
mediated by many interlinked factors including differences in sites of receptor 
expression, interplay of both mAChRs and nAChRs and their affinities for ACh, 
concentration of ACh in and around the synapse, rates of synaptic clearance and the 
interconnection of all these contributors. Additionally time-scale differences of ACh 
release further refines the action of ACh at the local microcircuit level in complex 
behaviours (Zhang et. al., 2010; McQuiston, 2014) . 
 
1.4  nAChRs 
nAChRs belong to the superfamily of pentameric ligand gated ion channels 
(pLGICs). In humans, this superfamily comprises the Cys loop receptors (including 
muscle and neuronal nAChR, 5-HT3, GABA-A, and glycine receptors), which 
mediate all fast CNS synaptic inhibition and much of fast peripheral excitation 
(Miller and Smart, 2010). Cys loop receptor subunits assemble as a pentamer of 
identical (homomeric receptors) or different (heteromeric receptors) subunits around 
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a central ion channel. These receptors exist in at least four distinct, interconvertible 
states: resting (agonist unbound, closed), flipped (agonist-bound, closed), open 
(agonist-bound, open) and desensitised (agonist-bound, closed), and the binding of 
agonists, antagonist and allosteric compounds alters the equilibrium between these 
states. Agonists such as neurotransmitters bind the agonist site, which is located in 
the extracellular domain (ECD) of the receptors, and this triggers rapid opening of an 
intrinsic ion channel. Prolonged exposure to the agonist induces the non-conducting 
(desensitised) state of the ion pore. 
1.4.1 Cellular Expression of nAChRs 
In the brain, nAChRs have been found dispersed along the cell body, 
processes, axons and pre-synaptic terminals (Wonnacott, 1997; Léna et al. 1999; 
McGehee et al. 1995; Kawai et al. 2007; Galindo-Charles et al. 2008). In these 
regions, α4β2 nAChRs have been shown to be modulatory rather than synaptic 
(Wonnacott et al., 1989; Dickinson et al., 2008). As non-synaptic receptors, they 
have been found to modulate the pre-synaptic release of ACh as well 
neurotransmitters such as dopamine, serotonin, GABA and ATP (Marchi and Grilli 
2010; Grilli et al. 2009; Exley and Cragg 2008; Galindo-Charles et al. 2008; Gurano 
et al., 2012). 
Anatomical studies of rats and humans have also identified cholinergic 
synapses of comparable structure to those of other point-to-point neurotransmitters, 
in the neocortex and anterior temporal lobe (Turrini et al., 2001). In a number of 
brain areas, nicotine directly applied to neurons has been shown to consequentially 
induce significant nAChR inward currents, mediated β2 subunit containing nAChRs 
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(Picciotto et al., 1995; Picciotto et al., 1998; Léna and Changeux 1999). Also, post-
synaptic nAChRs expressed on serotonergic neurons have been shown to be 
important in their funtiuon (Galindo-Charles et al., 2008). This further supports 
nAChRs directly influencing cell polarisation by postsynaptic receptors. 
 Although debated in the literature, another cellular location derived 
mechanism of ACh action is volume transmission via extra synaptically expressed 
nAChRs (Descarries et al. 1997; Descarries and Mechawar 2000). This raises the 
question of whether cholinergic signalling can occur at a distance from its site of 
release, following its diffusion through the extracellular space, or, strictly via regular 
synapses comprising compatible pre- and postsynaptic cells in close proximity 
(Agnati et al., 1995; Sarter et al, 2009). The idea of ACh volume transmission in the 
brain has been suggested by many lines of evidence such as the diffuse nature of 
cholinergic innervation, lack of post-synaptic specialisation of cells within the 
cholinergic system and anatomical and temporal mismatches between of ACh release 
and cholinergic receptor stimulation (Contant et al., 1996; Zhang et al, 2010). 
1.4.2 pLGIC Structure 
In the last 16 years extraordinary progress has been made in resolving the 
atomic structures that underlie the function of the pLGICs. The current view of the 
function and structure of the pLGICs is based on cryo-electro microscopy (EM)  
structures of the Torpedo muscle nAChR in an agonist unbound presumed closed 
state (4Å) (Unwin, 2005) and agonist-bound presumed desensitised state (6.2Å 
resolution) (Unwin and Fujiyoshi, 2012), cryo-EM structures of the glycine receptors 
in presumed open, closed and desensitised states (Du et al., 2015), high-resolution 
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crystal structures of the snail homologue ACh binding protein (AChBP) (Brejc et al., 
2001; Celie et al., 2005), extracellular binding domains of the nAChR α1 (Dellisanti 
et al., 2007), α7 (Li et al., 2011), α9 (Zouridakis et al., 2014) and α2 (Kouvatsos et 
al., 2016) subunits, full-length crystal structures of prokaryotic pLGICs homologues 
from Erwina chrysanthemi (ELIC) (Hilf et al., 2008) and Gliobacter violaceous 
(GLIC) (Boquet et al., 2009), solved in presumed closed and open channel 
conformation, the Caenorhabditis elegans glutamate-gated ion channel in an open 
channel conformation (Althoff et al., 2014), full-length human GABA-A (Miller and 
Ariescu, 2014), murine 5-HT3 (Hassaine et al., 2014) and human α4β2 nACh 
(Morales-Perez et al., 2016) receptors in a presumed desensitised conformation, as 
well as molecular dynamics analysis of pLGICs (Calimet et al., 2013). The 
discussion that follows focuses on current views of the structure and function of the 
pLGICs. 
The recently reported ECD and full-length structures mentioned above have 
provided significant insight into the structure of the pLGICs. In agreement with the 
structure of the AChBP (Brejc et al., 2001; Celie et al., 2005), all pLGICs share a 
conserved organisation with five identical or homologous subunits arranged around a 
central ion pore (Figure 1.1). Each subunit has a large hydrophilic extracellular N 
terminal domain (ECD) that is folded in a highly conserved immunoglobulin-like β-
sandwich made of 10 β-strands (β1-β10) that arrange into an inner and outer β-sheet, 
stabilised through highly conserved hydrophobic amino acids (Corringer et al., 2012) 
(Figure 1.1). The strands are connected through loops that play a critical role in 
agonist binding, structure and coupling agonist binding to gating (Corringer et al., 
2012). The loops vary in length and structure among the pLGICs. For example, 
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prokaryotic pLGICs lack the name-sake Cys loop (joining β strands β6 and β7) 
found in all Cys-loop pLGICs (Hilf et al., 2008; Bocquet et al., 2009).  
The transmembrane domain (TMD) of pLGICs comprises four 
transmembrane α helices (M1 to M4) connected by linkers (M1-M2, M2-M3, M3-
M4), as well as intracellular domains and a highly variable extracellular C-terminal 
(post-M4) (Corringer et al., 2012) (Figure 1.1). M2 α-helices form the walls of the 
ion channel and each subunit contributes to it (Unwin, 2005). M1, M3 and M4 face 
the lipid bilayer and have been shown to host binding site for allosteric modulators 
(Young et al., 2008; Olsen et al., 2013; Nury et al., 2011) and lipids (Bocquet et al., 
2009). In common with the ECD loops, the TMD α-helices are linked by loops, 
which play a key role in such aspects of receptor function as gating (Corringer et al., 
2012) and coupling agonist-triggered agonist binding site movements to channel 
gating (Miller and Smart, 2010).  
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1.4.2. The agonist site 
There are 2-5 neurotransmitter binding sites at subunit interfaces within the 
ECD, and these are functionally coupled to the transmembrane ion channel located 
ca. 50 Å away. In the nAChR, the subunit contributing the principal face of the  
Figure 1.1. Ribbon  diagrams of nAChR β2 subunit and α4β2 pentamer to demonstrate 
assembly. (A) Single (β2) subunit of nAChR highlighting the three structural domains; the 
ECD (extracellular domain - green), TMD (trans-membrane domain - teal) and ICD 
(intracellular domain – pale green) Orientation of the principal (+) and complimentary (-) 
faces is also shown. (B) Five subunits come together to form pentamer in membrane. 
Cartoon of membrane is shown and extracellular (E) and intracellular (I) spaces labled. (C) 
View of pentamer from extracellular space. Pseudo symmetrical arrangement around ion 
pore can be seen as well as orientation of the principal (+) and complementary (-) faces of 
each subunit and subunit interfaces. 
 
 
1.4.3 - Extracellular domain (ECD) and Agonist Binding Site   
The binding site is located at the interface between two subunits. The best 
functionally and biochemically characterised agonist site is that of the muscle 
nAChR. Early affinity labelling, together with extensive mutagenesis studies, 
identified and mapped the ACh binding site at the interface between two adjacent 
subunits with the contribution from three regions from a principal subunit (α1), 
termed loops A, B and C and four regions of a complementary subunit (γ or and δ) 
termed loops D, E, F and G (Corringer et al., 2000) (Figure 1.2). 
X-ray structures of the agonist site have been resolved for the AChBP (Brejc 
et al., 2001), GLIC (Hilf and Dutzler, 2009; Bocquet et al., 2009), ELIC (Hilf and 
Dutzler, 2008), GluCl (Hibbs and Gouaux, 2011), human GABA-A (Miller and 
Aricescu, 2014), murine 5-HT3 (Hassaine et al., 2014) and human α4β2 nACh 
90° 
x5 
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receptors (Morales-Perez et. al., 2016). Binding loop structures of nAChR α1 
(Dellisanti et al., 2007), α7 (Li et al., 2011), α9 (Zouridakis et al., 2014) and α2 
(Kouvatsos et al., 2016) subunits have also been resolved. In human α4β2 nAChR 
and AChBP, loops A (Y), B (W), C (two Y), and D (W) form an aromatic pocket that 
stabilises the agonist occupation of the pocket by chelating the ammonium group of 
ACh with the tryptophan residue from loop B establishing a direct cation-π 
interaction (Morales-Perez et. al., 2016, Zhong et al., 1998; Xiu et al, 2009) (Figure 
1.2). Recent crystallisation of human α4β2 nAChR further showed residues 
contributed by the complimentary subunit of the interface to protrude into the 
binding pocket with possible roles in stabilising the binding interaction. These 
include V110, F119, L121 of the E-loop and the D170 residue from loop F serving 
an important role to stabilise C-loop interactions (Morales-Perez et. al., 2016). 
There are small differences in the overall binding of agonist across the 
pLGICs family. For example, in GluCl, the neurotransmitter L-glutamate binds 
through its ammonium group to corresponding aromatic residues from loop A (F), B 
(Y), and C (Y), whereas the lateral carboxylate groups form salt-bridging 
interactions with Arg and Lys residues from loops D and F of the complementary 
subunit (Hibbs and Gouaux, 2011). In the GABA-A homomeric receptor β3, the 
agonist site is also formed by four aromatic residues protruding from both the 
principal and complementary subunit, one from loop B (Y), two from loop C (Y and 
F) and one from loop D (Y), along with Glu155 delimiting the top of the binding 
pocket. Electrophysiological studies have shown previously that Glu155 was 
implicated in gating (Newell et al., 2004). Analogous interactions are required for 
ligand binding and activation in nAChRs (Miller and Aricescu, 2014; Purohit et al., 
2012). Thus, electrophysiological studies have shown that only three aromatic 
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residues are crucial in adult nAChRs, whereas the four of them are important in the 
foetal form (Auerbach, 2015). Co-crystallization of ELIC in complex with the mild 
agonist bromopropylamine at 4.0 Å resolution (Zimmermann and Dutzler, 2011) or 
its competitive antagonist ACh (Pan et al., 2012) showed that agonist binding also 
occurs at subunit interfaces in the bacterial homologues. Thus, the overall 
architecture of the agonist site is highly conserved in the pLGIC family. 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Cartoon of ECD subunit interface of α4β2 nAChR. (A) Inner and outer β-
sheets are distinct colours for clarity, α4 subunit outter sheet in magenta, inner sheet in 
orange; β2 subunit outer sheet in teal, inner sheet in light blue. Functional loops also 
highlighted as green, except for loop A (orange) and loop B (magenta) for clarity. Close up 
region highlights important aromatic residues of binding pocket. α4β2 numbering used but 
homology to torpedo as follows; Y126 = Y93, W149 = W182, Y190 = Y221, Y198 = Y230 
and W55/W57 = W82. (B) Structure of acetylcholine, highlighting quaternary ammonium 
group central to pi-cation interactions of ligand with the agonist binding residues. 
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1.4.4 The Ion Pore 
The hydrophobic region that spans the cell membrane forms the ion channel. This 
region, the transmembrane domain (TMD) is covalently linked to the ECD. The 
TMD of each subunit is a cluster of 4 membrane spanning α-helices, termed M1-M4, 
dictated by the order in which they continue in amino acid sequence (Figure 1.3). 
They are structurally connected by functionally important loops that add flexibility 
to this region, allowing its movement during activation of the receptor complex and 
opening of the ion pore (Miyazawa et al, 2003; Miller and Smart, 2010). The pre-M1 
region joins ECD to the M1 α-helix. This helix traverses the membrane towards the 
cell cytoplasm with the rest following roughly parallel in alternate directions. The 
loop M1-M2 between M1 and M2 is the first intracellular section and features a 
glycine residue conferring to its flexibility (Miyazawa et al, 2003; Miller and Smart, 
2010). M2-M3 loop also boasts this functional feature and sits in the region between 
the ECD and TMD known as the coupling ECD-TMD interface. A larger 
intracellular loop (M3-M4) and intracellular helix (MX) adjoins the final helices M4, 
which ends with the final short C-terminal region that is extracellular (Unwin, 2005, 
Morales-Perez et. al., 2016). 
The ion channel is lined with the M2 α-helices from each subunit. Lining of 
the pore is achieved by presence of conserved residues that form concentric circles 
of amino acid side chains with important properties once the subunits come together. 
These are numerated upto 20’ – 20’ being residues forming the ring at the position 
adjacent to the ECD (Miyazawa et al., 2003). The pore-lining helices contain three 
rings of charged/polar amino acids that confer ion selectivity. In the closed 
conformation of the muscle nAChR, the helices bend towards the centre of the 
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channel leading to a narrow region formed by three rings of hydrophobic amino 
acids at the 9’-14’ region: αL251, αV255, αV259, and the corresponding residues 
from the other four subunits (White and Cohen, 1992; Miyazawa et al, 2003; 
Arevalo et al, 2005; Unwin, 2005). At the level of αL251 and αV255, the channel 
constriction is too narrow (approx. 6Å) and too hydrophobic to allow hydrated 
sodium or potassium ions passing through, which has led to the view that this area is 
the ion channel gate (Miyazawa et al., 2003). The gate is stabilised by hydrophobic 
interactions between residues.  
In the α4β2 nAChR crystal, the narrowest point is shown to be further down 
the pore away from the ECD at the -1’ ring. Here each subunit contributes a 
glutamate side chain protruding to pore (α4E247 and β2E239), resulting in a 3.8Å 
diameter and increased electronegative environment (serving to attract positive 
charge ions to gate thus acting as selectivity filter). Here the ‘gate’ is stabilised in the 
closed conformation via hydrogen bond interactions with the backbone of -2’ glycine 
residues from adjacent subunit (Morales-Perez et. al., 2016). 
It is thought that conformational changes induced by gating break these 
interactions stabilising the constricted pore, resulting in the widening of the pore 
(Miyazawa et al., 2003; Unwin and Fujiyoshi, 2012). This type of ionic permeation 
is conserved across the cationic pLGICs. Thus, for example, permeation through the 
prokaryotic GLIC is similar to that just described for the nAChR (Sauguet et al., 
2013).  
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Figure 1.3. Cartoon of α4β2 nAChR showing alpha helices of TMD. (A) View of 
membrane spanning helices of an α4(+)/β2(-) interface from inside pore. M2 of each subunit 
can be seen as closest together as well as closest to inner channel pore. Residues of M2 that 
come together to form concentric rings of side-chains that line the pore are shown as grey 
sticks. Connecting loops of TMD are highlighted, as well as important loops of ECD-TMD 
interface. (B) Pentamer TMD helices as viewed from extracellular space. It is clearly seen 
here that M2 helices line the pore with functionally important residues coming together to 
form gate, and M4 of subunits positioned farthest away from channel and in most contact 
with cell membrane. 
 
As previously mentioned, the nAChR receptors are selective to cations, and it 
is properties of the pore lining M2 region that governs this. Structurally the M2 
regions are furthest apart at the top of the channel, next to the ECD, where it is lined 
with aspartate and glutamate residues (Unwin, 2005; Hilf & Dutzler, 2008). This 
creates a large electronegative space ideal for accumulation of positively charged 
Na+, K+ and dependent on stoichiometry, Ca++ ions. It has additionally been 
suggested that these structural features are associated with activation profiles and 
functional states of the receptor such as desensitisation in which an agonist is bound, 
but pore remains in the closed state (Yakel, 2010). Differences in properties of the 
20’ side chain ring are further suggested to account for differences in conductance 
across stiochiometries (Tapia et al., 2007) 
B A 
1’ 
MX 
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1.4.5 - Gating 
Agonist binding is coupled to gating and this is achieved through the recruitment of 
several ECD and TMD loops and regions (Prevost et al., 2012; Corringer et al., 
2000, 2010). Coupling is achieved at the ECD-TMD interface by a principal pathway 
that couples the pre-M1 region in the ECD to the M2-M3 linker through the β1-β2 
loop (Lee and Sine, 2005; Jha et al., 2007) and the canonical FPF motif of the β6-β7 
loop (the Cys loop) (Lee et al., 2009) (Figure 1.3). More recently, it has been shown 
that gating is also affected by more peripheral pathways that couple M4 to M1 and 
M3 (Carswell et al., 2015) and, post-M4 to the Cys loop (daCosta and Baenziger, 
2009; daCosta et. al., 2011). It is movement of these structures and interactions 
between them that drives the agonist binding signal to the ion channel gate. For 
example in the muscle nAChR, following application of agonist, a salt bridge 
between a lysine in β-strand 7 and an aspartate at β-strand 10 associated with the 
receptor at resting closed state is interrupted by activation mediated movement of a 
tyrosine of the ECD to a close enough proximity (Mukhtasimova et al., 2005). This 
shows ECD movement elicited by agonist will affect interactions in this region that 
will in turn cause changes in M2-M3 and eventually in the TMD. These movements, 
starting in β-strand 7 and β-strand 10, are thought to start the series of 
conformational changes prior to channel gating (Mukhtasimova et al., 2005). 
The extraordinary progress that have been made in the last 10 years in terms 
of atomic structure, analysis of the microscopic function of pLGICs (e.g., rate-
equilibrium free energy relationship [REFER] analysis) and molecular dynamics 
have led to the current view that a progressive stepwise isomerization (previously 
considered as  conformational wave) that starts from the principal subunit of the 
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agonist binding site (loops A, B, and C), propagates to the ECD/TMD interface by a 
rigid-body rearrangement of the extracellular β-sandwich and travels down to the 
TMD (first M2, then M4 and M3) to eventually open the gate (Calimet et al., 2013; 
Sauguet et al., 2014a; Grosman et al., 2000; Purohit et al., 2007). The X-ray 
structures of the prokaryotic GLIC pH4 (open channel) and ELIC or GLIC pH7 
(closed channel) showed a global twist on receptor's activation (Bocquet et al., 
2009). This structural rearrangement has been described as a concerted anti-
clockwise movement of the ECD relative to the TMD. The X-ray structure of the 
prokaryotic pLGICs (Hilf and Dutzler, 2008, 2009; Bocquet et al., 2009) also 
showed that the important conformational changes on activation as well as the 
significant tilting of the M2 helices observed in cryo-EM structures of the nAChR 
(Unwin, 2005) were not accounted for by the twisting model. Molecular Dynamics 
studies of the GluCl pLGIC contributed new insight into the molecular mechanism 
for gating of the receptor channel (Nury et al., 2010; Calimet et al., 2013). By 
monitoring the spontaneous relaxation of the open-channel structure upon agonist (or 
positive allosteric modulator such as ivermectin) unbinding (Nury et al., 2010; 
Calimet et al., 2013), these studies showed that global twisting initiates the closing 
transition by facilitating the un-tilting of the M2 helices, which does not occur in the 
untwisted (active) state of the receptor. Thus receptor un-twisting appears to 
contribute to activation by “locking” the ion channel in its open state. Furthermore, 
the simulation of GluCl with ivermectin removed (Calimet et al., 2013) predicted 
that a tilting of the extracellular β-sandwich in the outward direction would be 
implicated in coupling the agonist binding site and the ion channel. This tilting is 
nowadays termed blooming of the ECD domain in the resting state and has been 
recently demonstrated by the X-ray structure of GLIC at pH 7 (Sauguet et al., 
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2014).). Also, the most recent structure of GluCl solved in the absence of agonist 
confirmed that that the rearrangements of the ECD during receptor activation 
resemble “the closure of a blossom” (Althoff et al., 2014). Thus, together, these 
studies confirm the occurrence of both twisting and blooming during the 
conformational transitions through which pLGICs undergo during gating. Of 
importance, the postulation of twisting and blooming implies that agonists as well as 
positive allosteric modulator binding should promote activation by favouring the 
contracted form of the ECD, whereas antagonist or negative allosteric modulators 
should favour the blooming conformation (Figure 1.4).  
 
Figure 1.4. Cartoon showing the twisting and blooming conformation changes 
sassociated to gating isomerisation. Adapted from Cechinni and Changeux, 2015. 
 
1.4.5.1-  The molecular events behind twisting and blooming  
In the current model, from data of multiple studies, the movements leading to 
channel activation are initiated by re-arrangement of hydrogen bonds of conserved 
residues close to the aromatic residues co-ordinating the agonist in the agonist pocket 
(Unwin, 2005; Xiu et al, 2005; Absalom et al, 2003; Lee and Sine, 2005). This  
includes the central binding residue α1W149, often being shown as the hydrogen 
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bond acceptor of the protonated nitrogen of agonists (Hibbs et al., 2009). Following 
this, residues from both the principal and complementary faces of the agonist site 
move inwards towards the bound agonist, creating distances between them suitable 
for van der Waals interactions. The most significant of these is the 11Å movement of 
loop C in an anti-clockwise motion, towards the channel pore. This is known as loop 
C capping of agonist as the ligand that becomes 'trapped' in the binding cavity. Here 
the signature cysteines of loop C (Cys192-Cys193) interact with the ligand and the 
now closer F loop of the complementary binding face (Celie et al., 2004; Hansen et 
al., 2005; Billen et al, 2012). 
Although these subsequent interactions are important events, it is the 
exaggerated loop C movement that appears to initiate re-arrangement of the β-
sandwich that results in energy transition and structural alterations down to the 
coupling region at its base. In line with considerations of the ECD re-arrangement 
occurring as a rigid twisting movement, Unwin and Fujiyoshi (2012) supposed from 
their data that the capping of loop C pulls the outer sheet of the β sandwich in the 
direction of its rotation. This would cause the adjustment of outer sheet comparative 
to the inner sheet and prompt the re-organisation of residues involved in interactions 
that stabilise the closed and open states. An important example of this is re-location 
of the conserved aromatic residues αW149 in loop B and αY190 in loop B and C 
loop (Cadugan and Auerbach, 2010). Substitutions of these side chains showed a 
direct correlation between the mutations of residues and the presence of long-lived 
spontaneous openings (Purohit, et al, 2007), supporting the importance of the 
positioning of these aromatic residues and their interactions in stabilising the closed 
state. When this is compromised (by substitutions or structural re-arrangements 
prompted by binding) the conformational change of nAChR is initiated.  
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  Although all three binding loops of the principal subunit face are shown to 
move following ligand binding, loop A, closest to the gate, appears to move the 
least. Loop B and loop C undergo synchronised movement towards the bound 
agonist; loop B by rotating clockwise and loop C by a twisting and rotating 
movement (Unwin, 2005). Loop B importantly joins the outer to the inner β-sheets 
of the ECD, thus participating directly in effecting their relative displacements, 
shown to lead to opening of the channel (Unwin and Fujiyoshi , 2012; Cecchini and 
Changeux, 2015).  
It has been proposed that in the closed channel, α subunits assume tense and 
“distorted” configurations relative to non-α subunits. The region showing largest 
disparities between α and non-α subunit structure was seen close to the centre of the 
β sheet sandwich, resulting from larger degree of separation between the inner and 
outer-sheet arrangements of  α subunits. The tense conformation of α subunits are 
stabilised by residue interactions only present within the β sheets of α subunits 
(Unwin, 2002). Inter-subunit interactions also appear to stabilise the closed 
conformations. In the muscle nAChR, the α subunit loop B faces the inner sheet 
strands β5 and β6 of the (-) face γ and δ. Likewise, inner sheet residues on the 
complementary face of α subunits are within distance to interact with A, B and C 
loops of β and γ subunits. Several putative contacts are seen between subunits in 
these regions, the majority being salt bridges; for example possibly between αD152 
and γR78 or δR81 and αR79 with βD155 or γE154 (Unwin, 2002, Unwin, 2005). No 
such structural features are seen at the δ(+)/β(-) interface, supporting proposal that 
these interactions would serve to stabilise α subunit conformation (Unwin, 2005). 
Following agonist binding dependent re-structuring of the ECD, these 
interactions are broken and the α subunits “relax”. This reduces the distortion, 
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making α and non-α subunits of a similar configuration, promoting symmetry of the 
open pentamer (Unwin, 2002). Conversion of the α subunits to a non-α like pose 
involves rotational movements of the inner β sheets of approximately 10º in both α 
subunits relative to the non-α subunits, thought to play a key role in the gating 
mechanism due to the close association of inner sheets with the pore-lining M2 
helices through the loop β1–β2 (Unwin, 2002).  
In this process, both inner and outer-sheets of the β-sandwich move 
independently but as rigid bodies, accompanied by small readjustments of their 
connecting loops. The inner sheet is thought to be the primary structural element 
determining the gating function of the channel, rotating to displace the β1–β2 loop 
adjacent to the M2 helix lining the channel pore. The outer sheet appears to provide 
the structural framework required to instigate the inner sheet rotation, 
accommodating the displacements involved. The rotation axis of each α subunit was 
shown to be similar; 8–9Å from the disulphide bridge of the Cys loop, passing 
through the hydrophobic core of the ligand-binding domain, through the base of the 
β9–β10 hairpin and between helices M1, M3 and M4 (Unwin, 2002). Together these 
data suggest the occurrence of conformational transitions in the α subunits prior to 
their non-α counterparts, and a similarity between the axis of all subunits to show the 
accumulative concerted movement of the pentamer as a whole. 
An additional set of interactions unique to α subunit may stabilise the 
“untwisted” configuration of the β9-β10 hairpin within the open state. A salt-bridge 
between Y190 on β9–β10 and K145 on β7 at one end, and a hydrophobic contact 
between αI210 on β9–β10 and the Cys loop at the other end, both shown to be 
important to receptor gating (Akk et. al., 1996; Mukhtasimova et al., 2005). In the 
rest (unbound, closed) state, K145 is bridged with D200, importantly suggesting the 
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formation of new bonds and inter-subunit interactions of the ECD stabilising the 
open channel conformation of the receptor following activation (Mukhtasimova et 
al., 2005).  This may occur within all subunit interfaces throughout the pentamer. 
 The β9 and β10 hairpin of the α subunits incorporates the C loop, and its 
capping is also said to importantly disrupt a salt bridge residue between αR109 and 
αE45 at the base of strands β9 and β10 (Lee and Sine, 2005). As this is in close 
proximity to the coupling interface between ECD and TMD, a direct connection 
between movement of loop C and transmission of binding signal down to the region 
of the channel gate is proposed. 
In summary, the “twist and bloom” mechanism comprises two distinct stages 
of activation, the first (binding and rearrangement of ECD) involving finer 
movements and alterations finalises in an intermediate activation state. The 
following pore opening movement is on a global scale, at which level individual 
subunits may sterically interact in a concerted movement of the whole pentamer as 
seen with pushing movments of ECD (Unwin & Fujiyoshi, 2012). From studies of 
the muscle nAChR, the only subunit in which ECD displacement is coupled tightly 
to TMD helices displacement through the loops of the coupling region appears to be 
the β subunit (Unwin & Fujiyoshi, 2012). The unique outward displacement of β 
subunit ECD relative to TMD is as an exaggerated movement causing an equal 
tilting of the TMD helices in the opposite sense (Figure 1.5). This movement is 
prompted by movements of the αγ subunit following binding. The β subunit 
movement is thus thought to be central to gating as Unwin & Fujiyoshi’s (2012) 
comparison of open and closed conformations of nAChR isolated this as the only 
structural alteration accross the two domains that coud communicate the effect of 
ACh binding downwards to the membrane and thus channel gate. 
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Figure 1.5. Rigid subunit domain movement of nAChRs. A and B depicts the rigid 
movements in bound Torpedo nAChR that lead to gating. Adapted from Unwin and 
Fujiyoshi, 2012. 
 
1.4.5.2 - Gating and agonist efficacy 
Monod-Wyman-Changeux model of agonist activation of allosteric proteins 
defines a symmetry in the protein in absence of ligands, and state that ligands are 
able to displace the equilibrium between the different active and inactive 
conformations, stabilizing the state for which they have a higher affinity (Changeux 
2013; Changeux, 2012). It is this that distinguishes ligands as agonists or 
antagonists. 
 The efficacy of a given agonist is defined by its ability to elicit a response at 
maximum concentration, often defined in relation to the endogenous 
neurotransmitter as = 1. For example, the maximum response of a nAChR to ACh is 
known as 1. Any full agonist will have a maximum response level the same as the 
endogenous neurotransmitter, and therefore = 1. A partial agonist however, would 
produce a response lower than this at any given concentration, and not be able to 
equal or surpass 1, thus expressing an efficacy value as a fraction. Conversely, a 
super agonist is able to produce maximum responses larger than that of the 
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endogenous neurotransmitter, expressing a maximum efficacy value of greater than 
1.  
A breakthrough in the understanding of what determines agonist efficacy was 
made independently by Lucia Sivilotti and her team in London (Lape et al., 2008) 
and Stephen Sine in the USA (Mukhtasimova et al., 2009). Using advanced kinetic 
analysis of microscopic currents elicited by agonists it was found that agonist 
efficacy is not related to the ability of agonist to induce gating, agonist and partial 
agonists showed the same ability, but rather it is the ability of agonist-bound 
receptors to reach closed conformation immediately preceding the open 
conformation (Lape et al, 2008). Sivilotti and her team termed these closed states 
“flipping states” (Lape et al, 2008; Colquhoun and Lape, 2012). The flipping states 
are equivalent to functional states termed priming states by Mukhtasimova et al. 
(2009) (Figure 1.6). 
 
 
 
Figure 1.6 The flipped state. (A) Agonist binds to the receptor at rest state. This induces 
conformational changes resulting in receptor reaching the flipped state. This flipped state has 
increased affinity for agonist but the channel remains closed. Following the flipped state the 
receptor switches to the open conformation. (B) Schematic of the flipping mechanism in 
tetramethylammonium (TMA) activated muscle nAChR. ‘A’ represents agonist, ‘R’ and 
‘R*’ represent the receptor in the resting closed and activated ipen states respectively and 
‘F’denotes the flipped conformation (Adapted from Lape et al., 2008) 
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The studies by Lape et al. (2008) and Mukhtasimova et al. (2009) imply that 
partial agonism is a reduced ability to flip, rather than a reduced ability to open the 
receptor. In terms of affinity, it is a ligands low affinity for the flipped state, relative 
to the resting state, that makes an agonist partial, rather than low affinity for the open 
state, relative to the resting state, as previously supposed. Overall, this places 
interaction energies defining agonist efficacies earlier in the chain of events that 
follow binding than if defining state was an open state. 
 
1.5 nAChR Subunits and the Receptors They Form 
 
Of the nAChR’s there are many subtypes, each with individual 
pharmacological characteristics and physiological roles. The diversity and 
subsequent complexity of this array of receptors is primarily down to the fact that 
there are many genes encoding for various subunits that come together in multiple 
combinations to form unique pentamers. The subunits are classified as α (1-10) and 
non α (β1- β4, δ, γ and ε), primarily based on presence (α) or absence (non α) of an 
enlarged loop C. The subunits are then further grouped into 4 sub families (I, II, III, 
IV), based on sequence, structure and anatomical expression. 
Sub family I contains the α9 and α10 found in epithelial and nervous tissue 
and is considered alongside sub family II as ancient proteins. α9α10 nAChRs display 
a unique pharmacology, somewhere between that of nicotinic and muscarinic 
receptors (Verbitsky et al, 2000) and are the exclusive stoichiometry of α9 and α10 
subunits, despite the ability of  α9 to form homomeric receptors (Sgard et al, 2002). 
These are found in the organ of Corti in the inner ear (Elgoyhen et al, 2001) but also 
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in the pain perception pathway, specifically in dorsal root ganglion neurons (Lips et 
al, 2002) as well as in epithelial tissue (Kummer et al, 2008) 
 Sub family II contains α7 and α8 subunits. Insofar, α7 and α8 subunits are 
the only nAChR subunits found to be able to form functional homomeric nAChRs. 
α8 subtype has only been located in avian neurons. α7 pentamers have been shown 
to express widely in the mammalian brain  and are highly permeable to Ca2+ ions as 
well as Na+ and K+. α7β2 nAChRs have recently been suggested to exist via 
detection of this pentamer mRNA(Azam et al, 2003) in rat brain cholinergic neurons 
and heterologous co-expression of these two subunits in oocytes or brain slices 
yields receptors that display slower desensitisation than that of α7 homomers 
(Murray et al, 2012; Khiroug et al, 2002). A physiological role of these heteromeric 
α7β2 nAChRs, mainly expressed in prefrontal cortex and forebrain (Moretti et. al., 
2014, Tamsen et. al., 2015), has been shown as presynaptic modulation of glutamate 
release (Dickinson et al, 2008). Until these studies it was thought that members of 
subfamily II and III did not combine to assemble receptors, but this reveals 
possibilities of existence of many more pharmacologically and structurally distinct 
nAChRs. 
 Sub family III encompasses the remaining subunits; α2- α5 and β2 - β4 that 
form heteromeric receptors in many combinations and include autonomic, peripheral 
and CNS nAChRs. Expression of several different types of heteromeric nAChR 
containing α2, α3, α4,α5, β2 and β4 subunits has been ascertained, and biochemical 
and immunoprecipitation studies suggest that they assemble to form α2β2*, α3β2* 
and α4β2*nAChRs (* noting that some other subunit assembles with the subunits 
denoted), spread in equivalent amounts (Grady et al., 2009). α3 and β4 subunits 
come together to form α3β4 receptors, the nAChRs responsible for synaptic 
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transmission in autonomic neurons. These may further combine with α5 subunits and 
are accordingly referred to as α3β4* with * indicating the presence of one or more 
additional types of subunit (Lukas et al., 1999). α3β4* nAChRs are present mostly in 
adrenal and dorsal medulla and autonomic ganglia and can also be found in areas 
such as retina, interpeduncular nucleus and pineal gland (Grady et al., 2009, 2010). 
α5 and β3 are known to be unable to generate functional ACh binding sites as they 
need to assemble with either α4-β2, α6* or α3-β4/β2 subunits to generate functional 
receptors. β2 subunit is also found in many cortical areas and may combine with 
many other subunits to form functional receptors, including α3, α4, α6, and β3. This 
is the subunit primarily responsible for nicotine binding and often confers a high 
sensitivity profile to receptors. Studies have shown the α2β2* nAChR type widely 
expressed in primate brain regions (Han et al., 2003) although in mice this receptor 
subtype is mainly co-localised with α3β4* nAChRs in retina and IPn (Moretti et al., 
2004). α6- containing receptors have more restricted distribution in the CNS; they 
are present in the ventral tegmental area, striatum and retina (Gotti et al., 2009). α6 
KO mice from the ventral tegmental area have shown a direct correlation between 
the rewarding effects of nicotine and the expression of these subunit types in 
midbrain.  
The α4 subunit is exclusively and widely expressed in the CNS and α4β2 
nAChRs are the most abundant and widespread nAChR subtypes in the brain, where 
they exhibit high affinity for nicotine (Gotti et al., 2009). The α4β2 pair may also 
combine with additional subunit types to be α4β2* for example α4β2α5. The α4-β2 
pair has been also found co-localised with α6β3* receptors in the striatum, forming 
receptors with a mix of binding sites of α4 and β2 subunits and α6 and β2 subunits.  
This area receives innervation from midbrain dopaminergic neurons, and both 
Chapter 1 – Thesis Introduction 
 
43 
 
subtypes of receptors are key elements in the regulation of mesostriatal dopamine 
dopamine release (Laviolette and van der Kooy, 2004). 
 Sub family IV comprises the α1, β1, δ, γ and ε subunits, grouped so due to 
their exclusive assembly into the adult skeletal (α1γα1δβ1) and embryonic 
(α1εα1δβ1) muscle nAChRs and was the latest group to evolve. 
 The existence of nine neuronal types of α subunits and three types of β 
subunits indicates a high structural and functional diversity of nAChRs in CNS, 
supported by experimental studies (Chavez-noriega et al. 1997; Gotti et al. 2009; Wu 
and Lukas 2011). These will in turn present differing roles in the cholinergic system, 
increasing its modulatory capabilities and complexity. For example, evidence 
supports the possibility that α7 and α4β2 nAChR subtypes, which are differently 
permeable to Ca2+ ions, trigger neurotransmitter release via different mechanisms 
(Dickinson et al, 2008; Bancila et al., 2009). 
  
1.6  The α4β2 nAChRs 
 
 This thesis focuses on α4β2 nAChRs. The most abundant and widely 
expressed nAChR in the brain are nAChRs containing  α4 and β2 nAChR subunits, 
which include the α4β2, α5α4β2, α6α4β2 and α6β2α4β2 nAChRs (Dani and 
Bertrand 2007; Gotti et al. 2007) (Figure 1.7). The α4β2 receptors exist in two 
alternate stoichiometries. These are known as the high sensitivity (HS) (α4β2)2β2 
and low sensitivity (LS) (α4β2)2α4 nAChRs, reflecting marked differences in ACh 
sensitivity.  
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Figure 1.7. Diagram of rat brain demonstrating regional expression patterns of 
nAChRs. As can be seen the α4β2 pair subtype is the most widely expressed nAChR 
(adapted from Gotti et al., 2006) 
1.6.1. Expression of α4 and β2 nAChR Subunits in the CNS 
 Receptors containing the α4β2 pair account for about 90% of the high affinity 
central nAChRs in the brain (Grady et al. 2009, 2010) and, as mentioned previously,  
these may combine with additional subunits to produce pentamers, forming further 
functionally distinct receptors. As it is known, α7 and α4β2* subtypes are the 
predominant nAChRs in the brain (Albuquerque et al., 2009) and about 20% of the 
α4β2 containing nAChRs present an α5 subunit in the accessory position to give 
(α4β2)2α5 stoichiometry (Brown et al., 2007). This (α4β2)2α5 receptor subtype has 
proved difficult to localize in the brain, as it shows a very similar pharmacological 
profile to that of (α4β2)2β2 receptors (Kuryatov, Onksen and Lindstrom, 2008). 
 Both the (α4β2)2β2 and (α4β2)2α4 nAChR stoichiometries have been shown 
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to be present and functional in brain regions such as the thalamus and the cortex 
(Marks et al. 1999; Gotti et al., 2008; Marks et al. 2010). The use of the novel 
(α4β2)2α4 selective allosteric modulator NS9283 confirmed that thalamo-cortical 
neurones express both (α4β2)2β2 and (α4β2)2α4 nAChRs (Rode et al., 2012; 
Timmermann et al., 2012). Of importance, these studies also showed that striatal 
neurones express solely high-sensitivity (α4β2)2β2 receptors. This implies that in the 
striatum the release of dopamine is controlled by the HS isoform but not by its LS 
counterpart. More recently, a study of the synapse between motoneurons and 
Renshaw cells, identified the LS (α4β2)2α4 receptor as predominant in this type of 
signalling, suggesting a post-synaptic location and novel role for this stoichiometry 
in central synapses (d’Incamps and Ascher 2014). 
 Chronic exposure of α4β2 nAChRs to competitive ligands such as nicotine 
increases the number of receptors in the cell membrane (up-regulation). Interestingly, 
up-regulation affects the HS (α4β2)2β2 nAChRs (Kuryatov et al., 2005; Moroni et 
al., 2006; Srinivasan et al., 2011). The expression of the HS isoform is also increased 
by reduced temperature, subunit mutations pertaining to adult nocturnal frontal lobe 
epilepsy (ADNFLE), or polymorphism on the α4 subunit, and absolute or relative 
increased levels of  β2 subunit (Lester et al. 2009; Exley et al. 2006; Nelson et al. 
2003, Kim et al., 2003). What it is interesting in this phenomenon is that the increase 
can occur at the expense of the expression of the LS isoform (Nelson et al., 2003; 
Exley et al., 2006; Lester et. al., 2009), suggesting that expression of the α4β2 
nAChR isoforms may respond to environmental cues. 
  Further work is needed to determine the distribution of α4β2 nAChRs 
throughout the brain, which will aid elucidating the contribution of each 
stoichiometry to brain functions and behaviours modulated by α4β2 nAChRs. The 
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success of such studies largely rests on the availability of α4β2 stoichiometry-
specific compounds and so far, few agonists have been developed that show 
preference for high sensivity (α4β2)2β2 nAChRs such as TC-2559 (4-(5-ethoxy-3-
pyridinyl)-N-methyl-(3E)-3-buten-1-amine difumarate, developed by the now 
defunct Targacept drug discovery company (Gatto et al. 2004; Carbone et al. 2009; 
Moroni et al. 2006)  
1.6.2 α4β2 nAChRs and Brain Function and Pathology 
 α4β2 nAChRs are involved in a wide range of brain functions, including 
cognition, attention, mood noniception and reward (Taly et al., 2009) and are thus 
attractive targets for therapeutic intervention. Although the last 10-15 years have 
witnessed the development of many drug discovery projects based on the naChR, 
there has been little success, with the exeption of anti-smoking drugs such as 
varenicline. Perhaps, this lack of success is due to the lack of understanding of how 
the alternate stoichiometries of the α4β2 nAChRs contribute to function or disease, 
or, perhaps, the high level of homology between the nAChR family is an 
unsurmountable obstacle to highly specific drugs. Despite these problems that need 
to be considered when developing drugs, the α4β2 nAChRs is still an interesting 
drug target.  The discussion that follows focuses on the functions or diseases that 
have been widely target for drug discovery exercises. 
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1.6.2.1 -  Nicotine Addiction 
   α4β2 nAChRs exhibit high-affinity for nicotine as well as showing 
involvement in cognitive pathways central to reward and addiction (Picciotto et al. 
2001). Studies investigating the Habenulo-Interpeduncular pathway have found this 
to be relevant for nicotine withdrawal symptoms mediated by β2 containing 
receptors (Moretti et al., 2004; Grady et al., 2009).  
 Early studies of β2 gene knock out mice suggested a central role in nicotine 
addiction of receptors featuring this subunit as these mice do not self-administer 
nicotine (Picciotto et al., 1999). Nicotine also does not appear to exert any effect on 
dopamine release in the ventral tegmental area or the nucleus accumbens of these 
mice – a cholinergic mediated brain processes central to reward (Picciotto et al., 
1999). This is further supported by viral re-introduction of the β2 subunit to these 
knock out mice. This restores the behavioural and neurophysiological aspects of this 
previously eradicated nicotine “addiction” as self-administration was resumed 
alongside nicotine determined dopamine release in the ventral tegmental area and the 
nucleus accumbens (Maskos et al., 2005). Moreover these experiments with β2 
knock out mice have shown expression of these subunit types in midbrain to be 
directly correlated with rewarding effects of nicotine and these knock out mice 
exhibiting hyperactivity as a result of altered dopamine release show reversal of 
these behaviours following re-expression of the β2 subunit in the striatum (Maskos, 
2005). 
GABA has also been implicated in the nicotinic regulation of reward 
pathways within the ventral tegmental area, mediated by α4 containing receptors. In 
mice expressing a gain of function mutation, L9'S, of the α4 subunits in GABAergic 
neurons of the ventral tegmental area, lower doses of nicotine were sufficient to 
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activate these neurons and promote reward seeking behaviour. These studies also 
support the role of the α4 subunit in mechanisms of addiction to nicotine (Ngolab et 
al., 2015). Similarly, an α4L9’A mutation of the α4 subunit increases receptor 
sensitivity to nicotine activation. Incorporation of this subunit to receptors in mice 
caused nicotine addiction behaviours to manifest at a nicotine concentration 50-fold 
lower than the concentration needed to induce the same response in wild type mice. 
As other nAChRs are not activated at such a low concentrations this highlights 
which behaviours are a result of nicotine evoked responses of α4-containing 
receptors, distinguishing their role in addictive behaviour (Tapper et al., 2004). 
 α5 subunit knock out mice have shown a decrease in the affinity for acute 
nicotine administration, suggesting this type of receptors could account for the 
regulation of the rate of response to large doses of nicotine in mice (Kedmi et al.,  
2004). A single-nucleotide polymorphism in the gene coding for the α5 subunit has 
been linked to propensity to nicotine addiction although how this polymorphism may 
affect the addiction and reward pathways is unknown (Kuryatov et al.,  2011). These 
effects of the α5 subunit can further implicate the α4β2 pair in cigarette addiction 
while asserting a role for its presence within pentamers as the accessory subunit to 
modulate receptor activity. 
 These α4β2 receptors may also be implicated in memories associated with 
smoking that re-enforces the addictive behaviour as the nicotine-evoked ACh release 
in hippocampal synaptosomes was shown to be due to the stimulation of α4β2 
subtype (Wilkie et al., 1996). This also implicates this subtype in learning and 
memory processes. The upregulation of the high sensitivity (α4β2)2β2 isoform by 
nicotine may also play a significant role in nicotine craving by smokers. If this 
stoichiometry is dominantly expressed due to chronic exposure to nicotine from 
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cigarette smoke, the dopaminergic reward pathways activated by nicotine are more 
likely to be elicited to a greater degree eliciting a greater degree of reward. 
 Another pharmacological mechanism governing nicotine addictive properties 
could be its desensitisation of α4β2 nAChRs as opposed to their activation. As a 
result of chronic exposure to agonists such as the nicotine self-administered by 
smokers, α4β2 nAChRs undergo long-term desensitisation. This is a state in which 
the pore is closed but ligand remains bound, preventing binding and thus receptor 
activation (Benallegue et al., 2013). When these receptors undergo such effects and 
are temporarily non-functional, it can reduce the activation of inhibitory GABAergic 
neurones in the ventral tegmental area. This will cause a down-stream effect of 
diminished inhibition of the dopaminergic neuronal activity in the ventral tegmental 
area  and nucleus accumbens that these GABA neurons mediate, thus increasing and 
maintaining high levels of activity in the reward pathway, also caused by the initial 
activation of pre-synaptic α4β2 nAChRs of the DA neurons in these areas 
(Mansvelder and McGehee 2002a; Laviolette and van der Kooy 2004). The nicotinic 
modulation of the GABAergic system was antagonized by dihydro-β-erythroidine 
(DhβE), a selective antagonist of the α4β2 nAChRs, supporting presynaptic α4β2 
nAChRs involvement, (Grilli et al. 2009). Subtype dependent desensitisation kinetics 
and distribution has also been shown to be an important mechanism of modulating 
dopaminergic activity and transmission in areas associated with addiction and 
reward;  the striatum, ventral tegmental area and substantia nigra compacta (Exley 
and Cragg 2008; Wooltorton et al. 2003) 
These processes may too involve the high sensitivity (α4β2)2β2 nAChR 
dominance up regulated by nicotine in smokers as this stoichiometry has shown 
greater levels of chronic desensitisation compared to its low sensitivity (α4β2)2α4 
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counterpart (Marks et al., 2010; Benallegue et al., 2013). The most likely scenario is 
of both activation and desensitisation of α4β2 nAChR contributing to nicotine 
addiction through the key aspects of addiction, reward, withdrawal and tolerance 
(Mansvelder and McGehee, 2002; Picciotto et al., 2008). 
  
1.6.2.2 - Anxiety and Depression 
   The α4β2 nAChR subtypes have been implicated in the mood functions of 
the brain, thus making them targets for the chemical treatment of anxiety and 
depressive disorders (Levin and Simon 1998; Ashare and McKee 2012; McKee et al. 
2012; Mineur & Picciotto 2010; Mantione et al. 2012). 
 Presynaptic α4β2* nAChRs are known to express within brain regions highly 
associated with mood and stress such as the ventral tegmental area,  nucleus 
accumbens, locus coerelus, dorsal raphe nucleus, pre-frontal cortex, amygdala and 
hippocampus, from where they have been shown to modulate the release of ACh and 
other important neurotransmitters involved in mood such as serotonin, GABA, and 
dopamine (Picciotto et al. 2012; Garduno et al. 2012). Pharmacological studies of 
knock-out β2 mice suggest that α4β2 receptors are essential for dopamine release in 
the mid brain often linked to affective and mood disorders (Mineur et al. 2016, 2010; 
Maskos 2010). Paterson and Nordberg (2000) attributed the anxiolytic effects of 
nicotine to GABAergic modulation by α4β2 nAChRs as this is reversed following 
blockage of GABA activity. α4β2 nAChRs have also been shown to alter glutamate 
activity within these regions and systems which through long-term potentiation and 
long-term depression may mediate long-term depressive effects and subsequent 
physiological alterations associated with learned negative emotionality and 
maintenance of the depressive state (Garduno et al. 2012).  
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In the dorsal raphe nucleus, the primary region associated with serotoninergic 
system and thus depression, the activation of β2-containing nAChRs, located at 
glutamate terminals, produces changes in synaptic efficacy through a mechanism 
involving voltage gated calcium chanels (Lambe et al. 2003; Mansvelder amd 
McGehee 2002b). According to findings of Garduno et al., (2012), both nicotine and 
exogenous ACh increased the frequency of glutamate-dependent sEPSCs recorded 
from identified 5-HT neurons. This effect was mediated by high sensitivity α4β2 
nAChRs because it was manifest at low nicotine concentrations (300 nM) 
characteristic of this subtype (Zoli et al., 1998; Lambe et al, 2003), blocked by low 
concentrations of the α4β2 preferring antagonist DHβE (100 nM), and unaffected by 
a selective α7 nAChR blocker. 
 Genetic deletion of the α4 subunit from dopaminergic neurons has shown the 
α4-containing nAChRs are necessary for the anxiolytic effects of nicotine (Mineur et 
al., 2013). Point mutant mice with hypersensitive α4 subunit display dopaminergic 
impairment in the substantia nigra alongside altered basal levels of anxiety (Labarca 
et al., 2001), supporting links between α4β2 nAChRs, dopamine and depression. 
Also, a polymorphism in the α4 subunit gene (rs1044396) is associated with negative 
emotionality (Markett et al., 2011). 
 Scope of treatment of mood and anxiety disorders by targeting the activity of 
α4β2 nAChRs has been supported by both clinical and preclinical data and these are 
the nAChRs showing greatest potential for this therapeutic use (Mineur and Picciotto 
2010). α4β2 nAChR preferring competitive antagonists, such as DhβE, have 
demonstrated antidepressant-like effects in mice (Andreasen et al. 2009). The non-
selective nAChR channel blocker mecamylamine also reduced depressive-like 
behaviours (Rabenstein et al, 2006; Andreasen et al., 2009), but this effect was not 
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seen in β2 knock out mice, supporting involvement of β2 containing nAChRs in 
depression and its alleviation (Rabenstein et al, 2006) . However, treatment of 
mecamylamine does not enhance the outcomes of treatment with antidepressants in 
mice, whereas chronic exposure to nicotine does have this effect (Andreasen and 
Redrobe, 2009b). Considering this alongside findings that nicotine treatment alone 
has anti-depressive properties (Andreasen and Redrobe 2009a) suggests different 
mechanisms behind mood modulation by these compounds and furthermore that 
nAChR desensitisation is involved. This is supported by lack of effect following 
acute treatment with agonists that do not desensitise the nAChR as potently as 
nicotine (Andreasen et al., 2009). Together, these findings suggest that a reduced but 
not abolished activity of α4β2 nAChRs is key to reduction of depressive behaviours, 
in turn highlighting the complexity and importance of fine balance of receptor 
activity. 
1.6.2.3 - Nociception 
   Analgesia constitutes a promising therapeutic application of nAChR 
agonists as nicotinic compounds such as nicotine and epibatidine have been found to 
have analgesic properties (Daly et al., 2000). α4β2 nAChRs in particular have been 
implicated in nociception  by knock-out studies of both α4 and β2 subunits showing 
reduced nociception (Picciotto et al., 1999). The absence of analgesic effects of 
nicotine in α5 knock out mice also supports a role of the (α4β2)2α5 subtype in these 
systems (Jackson et al., 2010). 
 Similar to nicotine addiction, the role of α4β2* nAChRs in nociception may 
be mediated via their activation or desensitisation, as suggested by activation of 
α4β2 nAChRs being necessary but not sufficient to produce analgesia in vivo and in 
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vitro (Gao et al., 2010). Additionally compounds that more potently desensitise 
α4β2* nAChRs have been shown to be more effective at producing analgesia, 
suggesting that desensitisation contributes to the efficacy of nicotinic analgesics 
(Zhang et al.  2012). It appears that both activation and desensitisation will 
contribute to nociception but may work synergistically to bring about these effects in 
contrast to addiction in which they function in separate mechanisms. 
 
1.6.2.4. -  Adult Nocturnal Frontal Lobe Epilepsy (ADNFLE) 
   ADNFLE is a rare familial epilepsy characterized by brief nocturnal 
seizures that originate in the frontal lobe and occur mainly during stage II of non-
rapid-eye-movement sleep (Scheffer et al., 1995). ADNFLE is well associated with 
mutations in the α4β2 nAChR as four α4 and five β2 mutations have been linked to 
ADNFLE (Steinlein et al. 2012; Becchetti et al. 2015; Kurahashi and Hirose 1993). 
Little is known about the mechanisms that may induce seizures in ADFNLE patients 
due to the complexity of the cholinergic system, but its involvement in the mediation 
of sleep/wake states may be implicated. As most of the mutations linked to 
ADFNLE are gain of function mutations that increase receptor sensitivity to ACh 
(Bertrand et al., 2002), the consequent over-stimulation of neurons could lead to 
seizures. An alternative hypothesis considers the involvement of GABA in other 
forms of epilepsy and its linkages with the cholinergic system, suggesting alterations 
to pre-frontal GABA release behind seizure onset, possibly arising during maturation 
of neural circuits (Becchetti et al., 2015). This implicates disturbances of the fine 
balance between excitatory and inhibitory modulation of pre-frontal circuits as a 
mechanism of seizure causation, a notion that could aid explanation of cholinergic 
and nAChR involvement in other pathologies. 
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1.6.2.5 – Alzheimer’s Disease (AD) 
    Alzheimer’s disease (AD) is the most common form of dementia, 
characterised by cell malfunction and death in the hippocampus and cortex, leading 
to cognitive decline of sufferers. In initial progression of the disease, the cholinergic 
neurons projecting from the basal forebrain to these areas are amongst the first cells 
to deterirate.  
1.6.3 Alternate Stoichiometries of α4β2 nAChRs 
As previously mentioned, the α4 and β2 subunits assemble into alternate 
stoichiometries. The two predominant subunit stoichiometries differ in their 
sensitivity to ACh (Nelson et al., 2003; Moroni et al., 2006) and are accordingly 
labled as low sensitivity (LS) α4β2 nAChR [(α4β2)2α4] and high sensitivity (HS 
α4β2 nAChR [(α4β2)2β2]. 
These receptors also display distinct unitary current amplitude (Nelson et al., 
2003), selectivity for different agonists and antagonists (Moroni et al., 2006; Zwart 
et al., 2006; Carbone et al., 2009; Timmermann et al., 2012), potentiation by ions or 
drugs (Moroni et al., 2008; Timmermann et al., 2012; Olsen et al., 2013) and pattern 
of desensitisation (Marks et al., 2010; Benallegue et al., 2013).  
Biochemical (Nelson et al. 2003), electrophysiological (Moroni et al., 2009) 
and concatenated receptor (Carbone et al., 2009; Mazzaferro et al., 2011) studies 
have shown the α4β2 to consist of two equivalent α4β2 subunit pairs and a fifth α4 
or β2 subunit. The canonical agonist binding sites are located on the α4/β2 interface 
of the subunit pairs. The principal or (+) face of the binding site is contributed by the 
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α4 subunit, whilst the β2 subunit contributes the complementary or (-) face 
(Mazzaferro et al., 2011). 
Additional to the structurally identical α4(+)/β2(-) binding interfaces, the 
isoforms each contain two structurally equivalent β2(+)/α4(-) interfaces in both 
receptor forms (Mazzaferro et al., 2011, 2014). These interfaces house binding sites 
for inhibitory Zn2+ (Moroni et al., 2008) and the anthelmintic compound morantel 
(Cesa et al.,2011). In contrast, the fifth subunit, contributor varies being an α4 in the 
(α4β2)2α4 nAChR and a β2 subunit in the (α4β2)2β2 nAChR (Carbone et al., 2009; 
Mazzaferro et al. 2011), which results in the signature β2(+)/β2(-) interface of the 
(α4β2)2β2 receptors and the α4(+)/α4(-) binding interface in (α4β2)2α4 receptors that 
likely underlie the functional differences between the receptors (Moroni et al., 2008). 
Significant strides have been made towards understanding the role of the α4(+)/α4(-) 
in receptor function. This interface contains major determinants for sensitivity to 
potentiation by Zn2+ (Moroni et al., 2008) and NS8293 (Harpsoe et al., 2011; Olsen 
et al.,2013) and, critically, it also houses an operational agonist site that plays a 
dominant role in the overall function of the LS isoform (Harpsoe et al., 2011; 
Mazzaferro et al., 2011; Benallegue et al., 2013).  
Because the agonist binding sites form at interfaces between the principal 
face of an α4 subunit and the complementary face of either a β2 or α4 subunit 
(Harpsoe et al., 2011; Mazzaferro et al., 2011), changes in subunit stoichiometry 
alter the number of agonist binding sites per pentamer. In addition, at non-agonist 
binding interfaces, changes in subunit pairing can alter receptor function via 
allosteric effects. Thus understanding the functional consequences of changes in 
stoichiometry of α4 and β2 subunits is of paramount significance towards the design 
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of drugs to treat the various brain diseases in which this family of receptors have 
been implicated, and understanding how cys-loop LGIC’s function. 
1.6.4 Concatenated α4β2 nAChRs  
Insight into the relationship between the stoichiometry of α4β2 nAChR 
function has been achieved using concatemeric receptors in which five subunits are 
covalently linked head to tail in a prederetimed order and stoichiometry (Carbone et 
al., 2009; Mazzaferro et al., 2011; Benallegue et al., 2013; Mazzaferro et al., 2014; 
Lucero et al., 2016). Concatemeric receptors containing two non-consecutive α4 and 
three β2 subunits activate in response to low concentrations of ACh, and mimic the 
high agonist sensitivity of HS (α4β2)2β2 receptors (Carbone et al., 2009; Lucero et 
al., 2016). On the other hand, concatemeric receptors containing three α4 and two 
non-consecutive β2 subunits activate in response to high concentrations of ACh, and 
mimic the low sensitivity of LS (α4β2)2α4 receptors (Carbone et al., 2009; 
Mazzaferro et al., 2011; 2014). Likewise, the agonists sazetidine-A and TC-2559 
activate concatemeric HS (α4β2)2β2 receptors, but not LS (α4β2)2α4 receptors, in 
accord with studies of receptors assembled in the presence of an excess of either the 
β2 or α4 subunit (Moroni et al., 2006; Zwart et al., 2006; Carbone et al., 2009). 
Finally, zinc potentiates agonist-elicited responses of concatemeric LS (α4β2)2α4 
receptor, but not those of concatenated HS (α4β2)2β2 receptors (Carbone et al., 
2009), in agreement with studies of receptors assembled in the presence of an excess 
of either α4 or β2 subunits, respectively (Moroni et al., 2008). This work supports 
the likeness of concatemers to loose subunit assemblies of the α4β2 nAChR as well 
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as confirming subunit composition and order around pore. This was confirmed in the 
case of the (α4β2)2β2 by x-ray crystallography (Morales-Perez et al., 2016). 
The studies that will be described in the following chapters of this thesis have 
used the concatemeric HS (α4β2)2β2 receptors to address the role of the signature 
β2(+)/β2(-) interface of this receptor type. By using homology models of this 
receptor, subunit-targeted mutagenesis and the covalent modification of substituted 
cysteines by a methanethiosulphonate reagent (MTS), this study found that the 
β2(+)/β2(-) interface encodes elements of efficacy. This is the first time that efficacy 
is shown to be affected by subunits not directly involved in agonist binding. The 
results are discussed in terms of their significance for gating and agonist efficacy. 
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1.7 Aims of the Thesis 
 
The broad consideration of this thesis is how the non-binding interfaces 
contribute to the pharmacological signatures of the (α4β2)2β2 nAChRs, in particular 
the stoichiometry specific β2(+)/β2(-) interface. In line with this specific aims were 
to address the following questions: 
 
1) Does the β2(+)/β2(-) interface of HS α4β2 contribute to receptor function and 
pharmacological characteristics? 
2) If so, how is this conducted? Through operational ligand binding site 
analogous to the α4(+)/α4(-) binding interface? 
3) Do the two the β2(+)/α4(-) interfaces act in a comparable manner to the 
β2(+)/β2(-) interface? 
4) What are α4β2 nAChR stoichiometry specific mechanisms underlying 
pharmacological differences that cannot be accounted for by the presence of 
an additional binding site on LS α4β2? 
5) What are the implications for this on current view of allosteric nature of 
receptor activation? 
 
 
Chapter 2 – Materials and Methods 
59 
 
 
 
Chapter 2 
 
-Materials and Methods- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 – Materials and Methods 
60 
 
2.1 Reagents 
 
Standard laboratory chemicals were of Analar grade. Collagenase Type IA, 
ACh, and DhβE were purchased from Sigma-Aldrich (UK). TC-2559 was purchased 
from Tocris Chemicals (UK). MTS, aminoethylmethanethiosulfonate (MTSEA), 
Sodium (2-Sulfonatoethyl)methanethiosulfonate (MTS-ES) and [2-
Trimethylammonium)ethyl]methanethiosulfonate (MTSET) were purchased from 
Toronto Research Chemicals (Canada). 
2.2 Animals 
 
Xenopus laevis (X. laevis) were purchased from Xenopus one (Chicago, 
USA), Xenopus Express, (France) or Portsmouth University (UK). Xenopus care and 
experimental procedures were in accordance with the Home Office regulations and 
were approved by the Animal Use Committee of Oxford Brookes University. Briefly, 
X. laevis were housed in the animal house of Oxford University in black tanks filled 
with dechlorinated water (>15L per toad) kept in a temperature-controlled room 
(18˚C). The animals were kept under a fixed 12 h light/dark cycle. Frogs were fed 
twice a week with amphibian food pellets.  
2.3 Molecular Biology 
 
DNA ligations, maintenance and growth of Escherichia coli bacterial strains 
and the use of restriction enzymes were carried out following the procedures 
described by Sambrook et al., (1989). Plasmid isolation and DNA gel purification 
were carried out using commercially available kits (Omega Biotech, USA and 
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Promega, UK respectively). Capped cRNA coding for wild type and mutant 
concatemeric receptors was transcribed in vitro from SwaI-linearized cDNA template 
using the mMessage mMachine T7 kit (Ambion, UK.). The integrity and size of the 
cRNA transcripts was confirmed using RNA gel electrophoresis. 
2.3.1 - Single Point Mutations 
Point mutations were carried out using the QuikChangeTM Site-Directed 
Mutagenesis Kit (Stratagene, The Netherlands). Oligonucleotides for polymerase 
chain reactions (PCR) were purchased from Eurofins (UK). The full-length sequence 
of wild type and mutated subunit cDNAs were verified by DNA sequencing 
(BiosourceScience, Oxford and Eurofins, UK). In order to increase the number of 
positive clones, the protocol used was slightly modified from the manufacturer’s 
instructions, as described below. 
1. Oligonucleotides primers (35 to 45 long, Melting TM > 80˚C) were synthesised 
carrying the desired mutations in the middle. 
2. The synthesised primers were diluted to a final concentration of 125 ng/μl and used 
in the subsequent PCR reaction. 
3. The PCR mix consisted of the following: 
  
 
DNA template (stock 50 ng/μl) ->
sense primer (125 ng) -> 1 μl 
antisense primer (125 ng) -> 1 μl
dimethyl sulphoxide -> 3 μl 
dNTPs (2 mM) -> 5 μl 
Pfu Buffer 10X -> 5 μl 
High Fidelity Pfu Polymerase -> 1 μl 
Nuclease free water -> 33 μl 
Total 50 μl 
1 μl
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The parameters for the PCR run were as follows: 
 
4. 1μl of the enzyme DpnI was added to the PCR mixture and incubated at 37˚C 
for one hour. This was in order to degrade the parental methylated DNA, 
which corresponds to the template (non-mutated DNA), and to leave intact 
only the newly formed DNA (non-methylated and likely containing the 
desired mutation). 
 
5.  X-Gold competent E. coli cells were transformed with 30 μl of the digestion 
product. After overnight incubation at 37˚C, 3-5 colonies were picked and 
amplified by growing them in 10 ml of  Terrific Broth medium (Sigma-
Aldritch, USA) with ampicillin (80 μg/mL) at 37˚C. After overnight growth, 
the plasmid was isolated from the bacteria using commercially available 
DNA purification kits (Omega, USA), and fully sequenced to confirm the 
presence of the desired mutation and verify the sequence of the non-mutated 
regions. The residue numbering used throughout this thesis includes the 
signal sequence. To obtain the position in the mature form, subtract 28 for α4 
and 26 for β2. 
 
 
 
 
 
 
Stage Number of Cycles Holding Temperature (C) Time (minutes)
1 1 95 1
95 0.5
2 16 55 1
68  1 min per kbp
3 1 68  1 min per kbp
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2.3.2 - Concatenated (α4β2)2α4 and (α4β2)2β2 Receptors 
The fully concatenated form of the (α4β2)2α4 and (α4β2)2β2 isoforms, 
constructs β2_α4_β2_α4_α4 and β2_α4_β2_α4_β2 were engineered as previously 
described by Carbone et al. (2009). Briefly, the signal peptide and start codon were 
removed from all the subunits but the first (a β2 subunit) and the subunits were 
bridged by AGS (alanine, glycine, serine) linkers. The number of AGS triplets was 6 
between β2 and α4 subunits, and 9 between α4 and β2 subunits or between α4 
subunits. Only the last subunit in the construct (an α4 or β2 subunit, dependent on 
isoform) contained a stop codon. The subunits were subcloned into a modified pCI 
plasmid vector (Promega, UK) using unique restriction enzyme sites flanking the N- 
and C- terminals of each subunit.  
Wild type or mutant concatenated receptors were assayed for integrity by 
determining the ACh sensitivity of concatenated receptors co-expressed with an 
excess of β2 or α4 monomers carrying the LT reporter mutation (L9’T in the second 
transmembrane domain). This mutation impacts gating activity of the receptor, 
increasing the receptor sensitivity to agonist to give an observable change to function 
should these substituted subunits be incorporated into the pentamers (Groot-
Kormelink et al., 2004; Carbone et al., 2009).  No changes were observed in 
comparison to receptors expressed in the absence of L9’T mutant subunits. This 
indicates that the concatenated constructs used in this study did not degrade into 
lower-order concatemers or monomers as such degradation products would 
incorporate the β2L9’T or α4L9’T monomers into receptors of higher sensitivity to 
ACh than the intact concatenated (α4β2)2α4 and (α4β2)2β2 receptors (Groot-
Kormelink et al., 2004; Carbone et al., 2009). This thesis focuses on the functional 
properties of the (α4β2)2β2 receptor. Unless otherwise stated, the studies described 
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here were carried out using the concatenated form of the (β2α4)2β2 and this will be 
referred to as β2_α4_β2_α4_ β2. 
2.3.3 - Engineering Mutant β2_α4_β2_α4_ β2 Receptors 
To introduce mutations into specific subunits of β2_α4_β2_α4_ β2 receptors, 
the mutation was first introduced into the appropriate individual subunit subcloned 
into a modified pCI plasmid as described in section 2.3. After confirming the 
presence of the desired mutation and verifying the sequence of the non-mutated 
regions, the subunit cDNA was digested with appropriate unique flanking restriction 
enzymes and then ligated into the desired position in the concatemer using standard 
cDNA ligation protocols with T4 ligase (New England Biolabs, UK). To verify 
incorporation of the mutated subunit into the concatemer, the subunit was excised by 
enzyme restriction digest from the concatemer and then sequenced by standard DNA 
sequencing. For clarity, mutations in the concatemeric receptors are shown as 
superscript positioned in the (+) or (-) face of the mutated subunit (e.g., in 
β2_W182Aα4_β2_α4_ β2 the mutation W182A is located in the (+) face of the α4 
subunit occupying the second position of the linear sequence of the concatemer. 
2.3.4 - Chimeric β2_α4_β2_α4_β2/α4 and β2_α4_β2_α4_α4/β2 
Receptors 
Subunits made of either the N-terminal of the α4 or the β2 subunit and the 
remaining TMD part of the α4 or the β2 subunit, as appropriate, was ligated to 
β2_α4_β2_α4 to construct chimeras β2_α4_β2_α4_β2/α4 and β2_α4_β2_α4_α4/β2. 
Chimeric subunits were constructed by first adding to both the α4 and β2 subunits a 
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BspEI restriction enzyme site at the interface between the ECD and TMD within a 
sequence motif, IRR, that is conserved in the nAChR family. The site was used to cut 
the subunits into two portions, the ECD-IR and the remaining subunit containing the 
four TMDs and the C-terminus (R-TMD-C-terminus). After digestion of the subunits 
with BspEI and after gel purification, the restricted sites were ligated using standard 
DNA ligation procedures to form β2/α4 or α4/β2 chimeras.  
 
2.4 Xenopus laevis Oocyte Preparation 
Xenopus oocytes were collected from adult female Xenopus laevis, 
anaesthetised and sacrificed according to Home Office guidelines. A visceral incision 
was made through the skin and body wall. The ovaries were removed and stored in 
OR2 solution (82 mM NaCl, 2 mM KCl, 2 mM MgCl2 2.5 mM HEPES (N-2- 
hydroxyethylpiperazine-N’-2-ethansulphonic acid) adjusted to pH 7.6 with NaOH). 
Only oocytes at the stage V and VI of maturation were isolated. The theca and 
epithelial layers were removed enzymatically by incubating the oocytes in Type IA 
collagenase (2 mg/ml) dissolved in OR2 and placed on a belly dancer rotator for 1.5 
– 2 hours at room temperature. Oocytes were maintained at 18˚C in an incubator in a 
modified Barth’s medium (88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 0.3 mM 
Ca(NO3)2, 0.41 mM CaCl2, 0.82 mM MgSO4, 15 mM HEPES supplemented with 
streptomycin 1 μg/ml, 1 U/ml penicillin and 50 μg/ml neomycin, pH 7.6 (adjusted 
with NaOH) for 24 hours prior to micro injection of cRNA 
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2.5 Microinjection of cRNA 
Needles for microinjection were prepared from Drummond glass capillaries 
(Sartorius, UK), which were pulled in one stage using a horizontal microelectrode 
puller (Campden Instruments–Model 753). Prior to use, the tip of a selected needle 
was broken using fine forceps to give a narrow tip length of approximately 3 mm 
with an external ranging from to 1.5 – 2.0 μm. The needle was back-filled with light 
mineral oil and loaded on to a Nanoject II microinjector (Drummond, USA). Wild 
type or mutant concatemeric receptor cRNA were injected into the oocyte cytoplasm 
(50.6 – 70.9 nl at 0.1 ng/nl) as illustrated in figure.2.1. Injected oocytes were 
transferred to 96 well sterile dish (one oocyte per well) containing modified Barth’s 
solution and incubated at 18oC 
 
Figure. 2.1. Diagram showing β2_α4_β2_α4_α4 cRNA injection into oocytes. After 2-3 
days post-injection currents were recorded using two-electrode voltage clamp technique. 
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2.6 Electrophysiological Recordings 
 
After at least 3 days post-injection oocytes were selected for 
electrophysiological recordings according to their appearance. Only oocytes with 
integral membrane and no signs of degradation were chosen for electrophysiological 
recordings and dead cells were removed from the plate daily. Oocytes were placed in 
a 30μl recording chamber (Digitimer, UK) and bathed with a modified Ringer 
solution (in mM: NaCl 150, KCl 2.8, HEPES 10, CaCl2 1.8; pH 7.2, adjusted with 
NaOH). A gravity driven perfusion system was used for all the experiments. All 
solutions were freshly made prior to recordings. Oocytes were impaled by two 
electrodes connected to a Geneclamp 500B (Molecular Devices, USA) for standard 
voltage clamp recordings as illustrated in Fig. 2.1. Briefly, electrodes were made 
from borosilicate capillary glass (Harvard Apparatus, GC 150 TF) using a vertical 
two stage electrode puller (Narishige PP-83) to give a tip diameter of 1-2 μm. Prior 
to recordings electrodes were filled with 3 M KCl and only electrodes with a 
resistance between 0.5 and 2 M were used for voltage clamping. Oocytes were 
continually perfused with fresh Ringer solution at a rate of 10 ml/min and switching 
between different solutions occurred through manually activated valves. 
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2.7 Concentration response curves for agonists and 
antagonists 
 
Concentration response curves (CRC’s) for agonists were obtained by 
normalizing agonist-induced responses to the control responses induced by a near-
maximum effective agonist concentration, as previously described (Moroni et al., 
2006; Mazzaferro et al., 2011; Carbone et al., 2009). An interval of 5 min was 
allowed between agonist applications to ensure reproducible recordings. The agonist 
CRC data were first fitted to the one-component Hill equation with Prism v5 
(GraphPad 5 software, GraphPad, CA, USA): 
 
Y = Bottom + (Top – Bottom) / (1 +10^ ((Log EC50 - X) * nH 
 
where Bottom is the Y value at the bottom plateau of the curve, Top is the Y value at 
the top plateau of the curve, EC50 represents the concentration of agonist inducing 
half of the  maximal response (Imax), X is the agonist concentration and nH the Hill 
coefficient.  
When agonists  induced biphasic receptor activation, agonist CRC were fitted 
with the sum of two Hill equations a two-component Hill equation from Prism v 5 
(GraphPad 5 software) : 
  
Y=Bottom + (Top-Bottom) *Frac/(1+10^((LogEC50_1-X)*nH1))  +  Top-Bottom 
* (1-Frac)/(1+10^((LogEC50_2-X)*nH2)) 
 
where LogEC50_1 and LogEC50_2 are the concentrations that give half-maximal 
stimulatory and inhibitory effects in the same units as X. nH1 and nH2 are the a-
dimensional values representing slope factors or Hill slopes. Frac is the proportion of 
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maximal response due to the more potent response phase due to the higher sensitivity 
component of receptor.  
2.8 Substituted cysteine accessibility method (SCAM) 
 
The substituted cysteine accessibility method (SCAM) was used to assess the 
impact of the agonist binding and non-agonist binding interfaces of the 
β2_α4_β2_α4_ β2 receptor on receptor activation and to determine movements 
within ACh binding sites at α4(+)/β2(-) and the β2(+)/β2(-) interface. SCAM was 
first applied to pLGIC to identify the amino acid residues lining the ion channel of 
the muscle nAChR (Karlin & Akabas, 1998). Since then, SCAM has become a 
powerful experimental strategy that has been successfully applied to gain invaluable 
insights into diverse aspects of pLGIC functional and structural such as amino acid 
residues contributing to competitive or allosteric ligands bindings, conformational 
changes induced by agonist or allosteric modulators, and secondary structure of 
functional domains (see for ex., Boileau et al., 1999; Holden & Czajkowski, 2002). 
SCAM involves the introduction of free cysteine residues, one at a time, into a 
protein region and the subsequent application of thiol specific reagents to the 
introduced cysteine residues to determine whether they are modified by the thiol 
reagent (Figure.2.2) (Karlin & Akabas, 1998). Modification of the introduced 
cysteine is monitored using electrophysiological or biochemical assays. 
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Figure 2.2. Covalent MTS modification of substituted cysteine in an identified subunit 
interface.  (A) Using concatenated (α4β2)2β2 nAChRs it is possible to introduce single 
point mutations at identified subunit interfaces. The diagram shows the reaction of MTSET 
with the thiolic group of a cysteine introduced in the complementary face of the β2(+)/β2(-) 
interface.  (B) Representative traces that shows max inhibition of ACh current (green 
arrows) after maximal MTSET concentration (1mM) treatment. MTSET is applied for 60 s 
(black arrow). 
2.8.2 Modification of Interfaces Using Substituted Cystine Accessibility 
Method 
MTSET was used to covalently modify a cysteine residue introduced at the 
L146 position on the complementary (-) face of agonist sites at α4(+)/β2(-) and 
β2(+)/β2(-) interfaces.  Previous studies have shown that β2L146 in loop E is suited 
for cysteine substitution studies: β2L146C has little impact on receptor sensitivity 
but in the presence of MTS reagents produces a profound decrease in the responses 
of α4β2 receptors to ACh (Papke et al., 2011). The following concatemers were 
engineered for the SCAM studies: β2L146C_α4_β2_α4_β2, β2_α4_β2L146C_α4_β2 and 
β2_α4_β2_α4_β2L146C concatemers were constructed (Figure 2.3). Mutant 
ACh (EC80) – 5 seconds 
MTS-ET (1mM) – 10 seconds 
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concatemers were expressed in Xenopus laevis oocytes, and characterised using two 
electrode voltage clamping procedures, as described above. 
 
 
 
 
 
 
 
Figure 2.3. Location of introduced cystine residues in mutant β2_α4_β2_α4_β2 
concatemers. Β2L146C substitutions are on each complementary β2 subunit of the 
interfaces to produce receptors with free thiol groups able to react with MTS-ET within the 
α4(+)/β2(-) binding interfaces and β2(+)/β2(-) interface. 
 
2.8.3 Maximum Effects of Covalent Modification of Introduced 
Cysteines by MTSET Reagent 
The maximal effect of the MTSET reagent on agonist responses was assessed 
as shown in Figure. 2.2. Briefly, oocytes expressing receptors with a free cysteine or 
wild type receptors were first challenged with a control agonist (ACh, TC-2559) 
concentration (EC80) every 6 min until a stable response (defined as <5% within 4 
consecutive responses) was obtained. After a 2 min 10 sec wash period with Ringer’s 
solution, oocytes were perfused with Ringer’s solution containing MTSET (1 mM) 
or MTSES (10 mM) (maximal concentrations; Zhang & Karlin 1997) for 60 s 
(determined as maximal time by preliminary studies ensuring maximum effect after 
this time.)  After this treatment the impaled cells were washed with Ringer’s solution 
for 2min50sec. After washing, the agonist was applied again every 6 min until the 
β2L146C_α4_β2_α4_β2  β2_α4_β2L146C_α4_β2 
 
β2_α4_β2_α4_β2L146C 
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amplitude of the responses was constant (as previously described). The average of 
the current amplitudes prior to application of MTS was the control response current 
(Iinitial), and the average of current amplitudes after rinsing was the average response 
after MTSET application (Iafter MTS). The effect of the MTS reagents was estimated 
using the following equation: 
% Change = ((Iafter MTS/Iinitial) – 1) * 100 
2.8.4 MTSET Reaction Rates of β2(+)/β2(-) and α4(+)/β2(-) Interfaces 
To determine whether nicotinic ligands recognize the agonist site at the 
β2(+)/β2(-) interface, and distinguish differences between α4(+)/β2(-) sites, we 
assayed the effect of nicotinic ligands (termed ‘protectant’) on the rate of MTSET 
modification of the three β2(-)L146C residues (Figure 2.3). If reversible ligands 
reduce MTSET reaction rates, it was initially considered that the reversible ligands 
bind the site, thus impeding, likely by steric hindrance, the modification of the 
introduced cysteine residue by MTSET (Figure 2.4). The rate of MTSET covalent 
modification of introduced cysteines was determined by measuring the effect of 
sequential applications of sub-saturating concentrations of MTSET on IACh responses 
in the presence and absence of ‘protectant’. These rates were then compared. The 
concentrations of MTSET reagent used were 10μM. Preliminary experiments 
established that these concentrations of MTSET were optimal to describe adequately 
the early and plateau phases of the MTSET reaction rate data. The rate of MTSET 
covalent modification of introduced cysteines was initially obtained in the absence of 
protectant ligand as control studies. 
Because α4β2 nAChRs are highly prone to long-term desensitisation when 
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exposed to agonists, the protectant was applied in the control experiments prior to 
the MTS reagent to correct for any process of desensitisation that could develop 
during the protection assays, when the protectant is added together with the MTSET 
reagent. Responses to ACh prior to MTSET reagent application were first stabilised 
as follows:  
1. ACh (EC80) pulses were applied for 5 s 
2. Step 1 was followed by a recovery time of 125 s 
3. The protectant (EC20 or EC80) was then applied for 10 s  
4. Step 3 was followed by a washing period of 3 min and 40 s with ringer 
solution.  
• The 6 min total cycle was repeated until the responses to ACh were stable 
(<5% on four successive applications of EC80 ACh). 
 
MTS reagent was then applied using the following sequence of reactions:  
1. At time = 0s, ACh (EC80) was applied for 5 s 
2. Step one was followed by a period of recovery of 95 s 
3. MTSET was then applied for 10 s 
4. Step 3 was then followed by a recovery period of 20 s.  
5. Immediately after the recovery time, the protectant was applied for 10s 
6. Cells were then washed with Ringer’s solution for 3 min and 40s.  
• The 6 min total cycle was repeated until MTSET applications produced less 
than 5% changes in IACh on four successive applications of EC80 ACh). 
 
MTSET application was repeated 9 times to give a total cumulative application 
time of 90 s. To confirm that any observed decrease in IACh was due to the effects of 
MTSET and not to receptor desensitisation, ACh and protectant pulses (following the 
same scheme used to stabilize the ACh responses prior the MTSET application) were 
applied at the end of the protocol as illustrated in Figure. 2.4. 
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Figure 2.4. Exponential decay assay control experiment for ACh at a α4(+)/β2(-) 
interface of the β2L146C_α4_β2_α4_β2 mutant. (A) General scheme of the exponential 
decay assay control experiment. After short (10s) application of low concentration MTS-ET 
(10μM) a given population of receptors will be modified at the introduced cystine residue 
which remains after ringer wash time. The degree of this modification is then assessed by 
decrease of following ACh current output. (B) Representative traces of exponential decay 
assay protocol. Green dashed line shows ACh current stabilisation prior to MTS-ET 
applications. Black line shows duration of accumulative MTS-ET application and blue line 
shows receptor stabilisation after MTS-ET exposure and the reaction is complete. Agonist is 
applied prior to MTS-ET (red arrows) to ensure desensitisation does not effect current and 
results can be compared to those of protection assay protocol. The application duration is 
acumulative to determine the k1 for the exponential decay of IACh  as a result of MTS-ET 
modification to give a rate of reaction with introduced cystine. 
 
 
 
 
 
A 
 B 
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2.8.5 Protection Assays with Agonists 
The effects of agonists and antagonists on the rate of MTSET modification 
were tested by co-applying MTSET with agonist (EC80). The protocol used was 
identical to the one used to determine the rate of MTSET reaction, except that the 
reversible ligand (protectant) was co-applied with MTSET reagent. The sequence of 
steps illustrated in Figure 2.5 was as follows: 
IACh was stabilised by: 
1. Applying EC80 pulses of ACh for 5 s 
2. Step 1 was followed by a 95s period of recovery 
3. The protectant was then applied for 10s 
4. Step 3 was followed by a recovery period of 4 min and 10s 
5. This cycle was repeated until stability was achieved. ( <5%change in IACh 
elicited by four  successive applications of EC80 ACh).  
 
The sequence of MTSET reactions was as follows: 
1. At time 0, ACh (EC80) was applied (5 s) 
2. Step 1 was then followed by a brief period of recovery (95 s) 
3. MTSET and the protectant were co-applied for 10 s 
4. Step 3 was followed by a recovery period of 4 min and 10 s. This cycle was 
repeated until the application of MTSET produced no further changes in IACh 
( <5% on four successive applications of EC80 ACh).  
 
To exclude receptor desensitisation as responsible for decreases in IACh, ACh and 
protectant pulses (following the same scheme used to stabilize the ACh responses 
prior the MTSET application) were applied at the end of the protocol as a control. 
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Figure 2.5. Protection assay experiment for ACh at a α4(+)/β2(-) interface of the 
β2L146C_α4_β2_α4_β2 mutant. (A) Schematic of protection assay experiment 
mechanism. When agonist (eg ACh) and MTS-ET are co-applied (protected reaction), the 
ligand competes with MTS-ET, impeding the MTS-ET reaction with the free cysteine 
introduced in the agonist site at the α4(+)/B2(-) interface, thus the reaction rate is slower. (B) 
Representative traces of protection assay protocol. Green dashed line shows ACh current 
stabilisation prior to MTS-ET applications. Black line shows duration of accumulative MTS-
ET application and blue line shows receptor stabilisation after MTS-ET exposure and the 
reaction is complete. MTS-ET application duration is accumulative to determine the k1 for 
the exponential decay of IACh  as a result of MTS-ET modification to give a rate of reaction 
with the introduced cysteine. 
 
 
 
 
 
 
A 
B 
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The change in current was plotted versus cumulative time of MTSET 
exposure. A pseudo–first-order rate constant was calculated from the change in IACh. 
Peak values at each time point were normalized to the initial peak at time 0 s, and a 
pseudo–first-order rate constant (k1) was determined by fitting the data with a single 
exponential decay equation: 
Y = (Y0 - Plateau)*exp (-K*X) + Plateau 
using Prism v.5.0 (GraphPad Software). Because the data are normalized to values at 
time 0, span (Y0 - Plateau) = 1 - plateau. Data analyses were performed using 
Graphpad-Prism software. Data were pooled from at least three different 
experiments.The second order rate constant (k2) for MTSET reaction was 
determined by dividing the calculated pseudo–first-order rate constant by the 
concentration of MTSET reagent used.  
 
2.10 Statistical Analysis 
 
For ligand CRC data, F-tests determined whether the one-site or biphasic 
model best fit the data; the simpler one-component model was preferred unless the 
extra sum-of-squares F test had a value of p less than 0.05. Log EC50 values for 
ligand responses changes in current amplitudes in response to mutations or MTS 
application were analysed using one-way ANOVA (analysis of variance) with 
Dunnett or Bonferroni post hoc corrections for the comparison of all mutated 
receptors to determine significance between wild type and mutant receptors. 
Significance levels between mutant receptors were determined using unpaired t tests. 
Data are plotted as mean ± Standard Error Mean (SEM) of n number of experiments. 
Parameter values are the best fitting values with the SEM values estimated from fit. 
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2.11 Structure Homology Modelling and Docking 
 
Homology modelling and docking studies were kindly performed by Dr 
Maria Musgaard and Professor Philip C Biggin from the Department of 
Biochemistry, Oxford University. The following is a brief description of the 
approaches used to build the homology models and carry out the docking studies. 
Homology models of the α4β2 nAChRs were constructed using MODELLER 9.12 
(Šali,. and Blundell,  1993) and were based on the murine 5-HT3 receptor X-ray 
structure (PDB ID: 4PIR) at 3.5 Å resolution (Hassaine et al., 2014). The template 
X-ray structure comprises the ECD, the TMD and part of the intracellular domain. 
Four residues are missing in the extracellular M2-M3 loop, and more than 60 
residues are missing in the intracellular linker between M3 and M4. Sequences of the 
human α4 and β2 nAChR subunits were obtained from the ExPASy proteomics 
server with accession numbers P43681 (α4) and P17787 (β2) and aligned to the 5-
HT3R subunits using the alignment function of MODELLER (align2d) and, for 
comparison, also using two different alignment tools from the European 
Bioinformatics Institute (EBI), EMBOSS Stretcher and EMBOSS Needle, 
respectively. The sequence identity is 25% and the sequence similarity is 
approximately 45%. The three alignments were compared and the final alignment 
constructed with manual changes in regions where the alignment algorithms were 
not optimal. Disulphide bonds were included and 50 models for each of (α4)3(β2)2 
(α4-β2-α4-β2-α4) and (α4)2(β2)3 (α4-β2-α4-β2-β2) were constructed. The models 
mainly varied in regions where the template was missing, and the best models were 
chosen based on analysing the MODELLER scores (molpdf, DOPE and GA341). 
The 3-4 best models in terms of all of these scores were further assessed with 
 
Chapter 2 – Materials and Methods 
79 
 
QMEAN (Benkert et al., 2010) and the best QMEAN scoring model from this 
process was chosen as the appropriate model for docking.   
Protein and ligand models were prepared for docking using Autodock Tools  
(Morris et al., 2009) and docking calculations were performed with Autodock Vina 
(Trott and Olsen, 2010). A large box of 74x74x40 Å3 centered in the extracellular 
half of the ion channel and covering a large part of the TMD of all five chains was 
used as the search space for docking calculations. 20 binding models were generated 
for each ligand docked into each protein model, i.e. 80 poses were generated in total. 
The binding models were analysed visually as the docking scores were all very 
similar (best score among 80 posed was -7.5 and the worst -6.2). 
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β2(+)/β2(-) interface of the HS α4β2 
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3.1 INTRODUCTION 
 
Functional differences of the α4β2 nAChR stoichiometries have been shown 
to have strong structural basis (Grady 2010). Disentangling the structural mechanism 
underlying the functional differences between the alternate receptors is of general 
structural and functional interest and has the potential to aid the design of new drugs 
more rationally than can be done at present.  In common with all members of the 
pLGIC, the functional properties of the α4β2 nAChRs are determined by subunit 
receptor composition. 
Although the molecular mechanisms underpinning the dominant role of the  
α4(+)/α4(-) on the sensitivity to agonists have not been identified yet, studies of non-
concatenated (Harpsoe et al., 2011) and concatenated (Mazzaferro et al., 2014) α4β2 
nAChRs have highlighted the importance of non-conserved E loop residues on the 
complementary side of the α4(+)/α4(-) interface for both agonist potency and 
macroscopic efficacy. More recently, Lucero et al., (2016) using concatenated α4β2 
nAChRs found that introducing non-conserved E residues on the β2(+)/α4(-) 
interface greatly decreased ACh EC50, suggesting that all interfaces flanking agonist 
sites contribute to define the functional properties of the receptors.  
The additional agonist site in the α4(+)/α4(-) interface forms because the α4 
subunit conserves non-α agonist-binding aromatic residues such as W88 (Mazzaferro 
et al., 2011). In this respect, it is significant that key aromatic residues forming part 
of the primary side of canonical agonist sites in the α4β2 nAChR are conserved in 
the β2 subunit (i.e., W182 and Y126) (Figure 3.1). By analogy to the α4(+)/α4(-) 
interface, the conserved residues could contribute to agonist binding in the 
β2(+)/β2(-) interface, leading to unique HS (α4β2)2β2 functional properties. To 
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examine this possibility the effects of the cysteine-modifying sulphydryl reagent 
MTSET on concatenated HS receptors with a cysteine substituted β2(+)/β2(-) 
interface were examined.  
The aim of the studies described in this Chapter was to determine whether 
there is an agonist binding site at the β2(+)/β2(-) interface of the HS α4β2 nAChR 
that could account for the pharmacological properties of this receptor, including high 
sensitivity to ACh. To circumvent ambiguities in data analysis brought about by 
expression of both forms of the α4β2 nAChR, the studies described here were carried 
out using fully concatenated HS α4β2 nAChR (β2_α4_β2_α4_β2  nAChRs). For 
clarity, in the concatenated HS α4β2 nAChR, the first subunit in the linear sequence 
of the concatemer (a β2 subunit) interfaces with the fifth subunit of the linear 
sequence of the concatemer (a β2 subunit)  to give signature β2(+)/β2(-) interface 
(Figure 3.1B). The first subunit contributes the principal face, whilst the fifth 
subunit contributes the complementary interface (Figure 3.1B). Canonical agonist 
sites in the concatenated receptors are formed at the interface between the first 
subunit of the linear sequence of the concatmer and the second subunit (henceforth 
termed agonist binding site 1) and between the third and fourth subunits (hereafter 
termed agonist site 2) (Figure 3.1B). Note that the fifth subunit was often termed 
‘auxilliary’ subunit, however, it is clear from studies of Cys loop receptors, including 
α4β2 nAChRs (Harpsoe et al., 2011; Mazzaferro et al., 2011; 2014), Torpedo nAChR 
(Unwin and Fujiyosi, 2012) and GABA-A receptors (Sigel and Steinmann, 2012), 
that the fifth subunit makes important contributions to the function of Cys loop 
receptors. 
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Figure 3.1. Subunit arrangement of two stoichiometries of α4β2 nAChRs . (A) 
Schematic representations of the high sensitivity (HS) (i) and low sensitivity (LS) (ii) 
stoichiometries of α4β2 nAChRs. β2-subunits are shown in blue and the α4 in red. Agonist 
binding sites at α4(+)/β2(-) interfaces are indicated by yellow asterisk. The fifth subunit is 
highlighted by a green circle. The stoichiometry specific subunit interfaces β2(+)/β2(-) and 
α4(+)/α4(-) are shown by a green arrow. (B) Cartoon depicting the linear sequence of the 
concatenated form of the HS α4β2 nAChR. The orientation of the principal and 
complementary side of the subunits is shown. The position of the canonical agonist binding 
sites (ABS) is shown by arrows. 
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3.2 RESULTS 
3.2.1 – The ECD of the Fifth Subunit Subunit Confers α4β2 nAChR 
properties 
Preliminary experiments were designed to determine if the fifth subunit in the 
HS α4β2 impacted the functional properties of this receptor type. This was carried 
out using concatenated receptors with chimeric fifth subunit subunits.  These 
contained either the ECD of the α4 subunit and the remaining part (TM regions and 
C-terminus) of the β2 subunit (α4/β2), or the ECD of the β2 subunit and the 
remaining part of the α4 subunit (β2/α4) (Figure 3.2A).  
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Figure 3.2. Chimeric fifth subunits confer functional changes to α4β2 nAChRs.  (A) 
Homology models of the chimeric β2/α4 (left) and α4/β2 (right) subunits demonstrating 
regions of chimeric subunit comprised of α4 (red) and β2 (blue) nAChR subunits. (B) 
Concentration response curves of ACh at wild type and chimeric α4β2 nAChRs. Recordings 
were carried out as described in Materials and Methods. Data were analysed using non-
linear regression with GraphPad 5 software. Each data point represents the mean ± SEM of 
at least 3 individual recordings. (C) Representative traces of the responses of wild type and 
chimeric receptors. 
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Table 3.1. Concentration Response Data for ACh activation of concatemeric α4β2 HS 
nChRs with chimeric fifth subunit. Data are the mean ± SEM for all experiments from at 
least two different batches of oocytes. Statistical analysis was performed using One-way 
ANOVA with Bonferroni post-test (*** and ^^^, p < 0.0001; * ).or ^, p < 0.05). * indicates 
values compared to β2_α4_β2_α4_β2, and ^ indicates values compared to β2_α4_β2_α4_α4. 
Imax values reported are normalised to responses elicited by 1mM ACh in order to 
demonstrate differences in receptor efficacies. 
 
 Figure 3.2B and C (see Table 3.1 for estimated values of ACh sensitivity) 
show that the ACh sensitivity of receptors containing a chimeric α4/β2 subunit at the 
fifth position was statistically different from β2_α4_β2_α4_β2 (high sensitivity) 
nAChRs (p < 0.001) but not different from that of β2_α4_β2_α4_α4 (low sensitivity) 
nAChRs. In contrast, when the chimeric fifth subunit contained the extracellular N-
terminal region of the β2 subunit (i.e., β2_α4_β2_α4_β2/α4 nAChRs), the sensitivity 
to ACh was comparable to that of β2_α4_β2_ α4_β2 nAChRs and was statistically 
different (p < 0.001) from that of β2_α4_β2_α4_α4. These findings indicate that the 
presence of the extracellular domain of the β2 subunit in the fifth subunit of α4β2 
nAChRs brings about ACh sensitivity similar to that of β2_α4_β2_α4_β2 nAChRs, 
supporting the view that the fifth subunit plays a key role in determining the ACh 
sensitivity of the (α4β2)2β2 nAChR and further suggests that the N-terminal is the 
region contributing to the differences seen in responses to ACh from the two receptor 
stoichiometries. 
Concatemer EC50 (uM) nHill Imax 
β2_α4_β2_α4_β2 7.19 ± 1.5 ^^^ 0.73 ± 0.08 1.01 ± 0.018^ 
β2_α4_β2_α4_β2/α4 8.03 ± 1.2 ^^^ 0.67 ± 0.09 1.01 ± 0.05^ 
β2_α4_β2_α4_α4 53.79± 8.0 *** 0.77 ± 0.08 1.24 ± 0.06* 
β2_α4_β2_α4_α4/β2 58.19± 12 *** 1.15 ± 0.25 1.19 ± 0.07* 
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3.2.2 – The β2(+)/β2(-)interface of HS α4β2 nAChRs contributes to 
Ach efficacy 
Sequence alignment and  examination of a homology model of the HS α4β2 
nAChR suggested that the β2(+)/β2(-) interface in the HS α4β2 nAChR may house 
an agonist binding pocket contributed by conserved aromatic residues that line the 
agonist binding pocket in the α4(+)/β2(-) interfaces (Figure 3.3A, B). An additional 
operational agonist binding site has been identified in the α4(+)/α4(-) interface of the 
LS α4β2 nAChR (Harpsoe et al., 2011; Mazzaferro et al., 2011), and this site plays a 
dominant role in defining the apparent agonist affinity and maximal current 
responses of the LS receptor (Harpsoe et al, 2011; Mazzaferro et al., 2011; 2014). To 
test the possibility of an operational binding site at the β2(+)/β2(-) interface, a 
cysteine residue was introduced in lieu of β2 L146 (an E loop residue) on the 
complementary side of β2(+)/β2(-) interface to determine the functional 
consequences of modifying it with MTSET. 
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Figure 3.3. Conserved aromatic residues in the α4(+)/β2(-) and β2(+)/β2(-) subunit 
interfaces in HS α4β2 nACh and relative position of β2(-)L146C. (A) Sequence 
alignment of conserved aromatic residues lining the agonist binding pocket in α4(+)/β2(-) 
interface are conserved in the β2(+)/β2(-) interface). (B) Homology model of the α4(+)/β2(-) 
and β2(+)/β2(-) subunit interfaces in the HS α4β2 nAChRs 
 
Following introduction of a free cysteine into a desired region of a protein, 
the MTS reagent MTSET reacts with the available sulphydryl group and covalently 
attaches a small positively charged moiety to that residue. When introduced to a 
putative ACh binding pocket, this modification can sterically or electrostatically 
block ACh access to the site, preventing agonist accessing the putative binding. The 
outcome of this upon receptor function and thus degree of binding perturbation can 
then be investigated (Karlin and Akabas, 1998; Mazzaferro et. al., 2011; 2014).  
The residue β2L146 is within loop E on the complimentary face of the β2 
subunit and structural homology modelling of the ECD of the β2(+)/β2(-) interface 
predicts L146 to reside within the putative agonist site in a position homologous to 
that occupied by β2L146 on the canonical agonist site in α4(+)/β2(-) interfaces 
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(Figure 3.3B). This position within both interface trypes is confirmed by x-ray 
crystallography of (α4β2)2β2 as just above and projecting into the conserved 
aromatic pocket (Morales-Perez et. al., 2016). 
Importantly, previous studies have shown that derivatisation of β2(-)L146C 
in α4(+)/β2(-) interfaces by MTS reagents reduces agonist-driven current responses 
by reducing access to the agonist site (Papke et al., 2011; Mazzaferro et al., 2011; 
2014).  
HS α4β2 concatemers with this mutation in the 5th β2 subunit 
(β2_α4_β2_α4_β2L146C) were thus engineered to investigate effects of MTS-ET 
modification at the β2(+)/β2(-) interface. As a measure of control and in order to gain 
insight to binding site differences, this substitution was also individually introduced 
to the α4(+)/β2(-) interfaces housing orthosteric ligand binding sites. Cysteine 
substitution of L146 on the 1st β2 subunit produces a β2L146C_α4_β2_α4_β2 
concatemer, and this construct can be used to study agonist binding site 1.  
Incorporation of L146C on the third position (a β2 subunit) of the concatenated HS 
receptor produced β2_α4_β2L146C_α4_β2, which can be used to study agonist 
binding site 2. 
 Substitution of L146 for a free cysteine at these positions had no significant 
functional consequences on the sensitivity of the receptors to activation by ACh 
(Figure 3.4, Table 3.2). This indicates that the L146C in any of the sites introduced 
is well tolerated. Importantly, it also suggests that any changes in receptor function 
following exposure to MTSET can be attributed to the covalent modification of the 
cysteine substituted concatenated nAChRs with MTS-ET.  
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Figure 3.4. ACh concentration-response relationships for wild type and β2(-)L146C 
substituted concatemeric HS α4β2 nAChRs. The β2(-)L146 residue of each β2 subunit 
was individually substituted to cysteine in the α4(+)/β2(-) (A and B) and β2(+)/β2(-) (C) 
interfaces. The consequences of the mutations upon sensitivity to activation by ACh were 
examined using two-electrode voltage clamping, as described in Materials and Methods. 
Data points represent the mean ± SEM of at least three independent experiments. Data were 
fit by nonlinear regression, as described under Materials and Methods. Dashed lines are 
curve fits for wild type (WT) receptors. ACh EC50 and nHill coefficient values are 
summarised in Table 3.2. 
 
 
Table 3.2. Effects of MTSET on the ACh responses of wild type and cysteine substituted 
concatenated HS α4β2 nAChRs.  Ooocytes expressing wild type or cysteine substituted 
concatenated HS α4β2 nAChRs were exposed to 1 mM ACh prior and after a 1 min 
application of 1 mM MTSET. The percentage of remaining activation by 1 mM ACh after 
MTSET treatment was defined as (IafterMTSET/Iinitial) x 100. Data are the mean ± SEM of n 
number of experiments. Significant differences between mutant and wild type receptors 
(noted by *) or between β2_α4_β2_α4_β2L146C  and the β2L146C_α4_β2_α4_β2 and β2_α4_β2 
L146C_α4_β2 receptors were estimated using One-way ANOVA with Dunnett’s post-test (***, 
p < 0.0001). ++ indicates that the values for β2L146C_α4_β2_α4_β2 and 
β2_α4_β2L146C_α4_β2 are statistically different from each other (p < 0.001). Statistical 
comparison of the values obtained for β2_α4_β2_α4_β2 L146C and β2L146C_α4_β2_α4_β2 
showed p < 0.0001 levels of significance (noted by ^^^), whilst comparisons between the  % 
change obtained for β2_α4_β2_α4_β2L146C and β2_α4_β2L146C_α4_β2 receptors showed a p 
< 0.05 level of significance (noted by ^). 
Receptor ACh EC50  
(µM) 
n nHill Remaining IAch 
Post MTS-ET 
(%) 
n 
β2_α4_β2_α4_β2 7.19 ± 1.5 14 0.7458 ± 0.12 85.67 ± 2.5 6 
β2_α4_β2_α4_β2 L146C 3.71 ± 0.8 6 0.9348 ± 0.12 41.10 ± 2.9 
*** 
10 
β2L146C_α4_β2_α4_β2 3.77 ± 1.3 6 0.8738 ± 0.16 34.77 ± 2.0 
***,++,^^^ 
11 
β2_α4_β2 L146C _α4_β2 3.19 ± 1.4 6 0.6756 ± 0.09 23.36 ± 2.1 
***,++,^ 
13 
A B C 
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Following this, the accessibility of the substituted cysteines to MTS reagent 
MTSET was determined. This was achieved by exposing the receptors to a maximal 
MTSET concentration (1 mM) (Zhong and Karlin, 1997), as described in Materials 
and Methods. MTSET reduced ACh EC80-evoked currents recorded from all cysteine 
substituted receptors, showing not only that the substituted cysteines are available to 
MTS-ET, but that covalent modification at the cysteine substituted β2(+)/β2(-) 
interface substantially reduces the efficacy of ACh (Figure. 3.5). Since agonist 
binding sites must be exposed to water for the agonist to access the site, the 
accessibility of the substituted cysteine to MTSET is consistent with the presence of 
an agonist site at the β2(+)/β2(-) interface. In accord with studies showing that 
canonical agonist sites in LS α4β2 (Mazzaferro et al., 2011; 2014) and HS (Lucero et 
al., 2016) α4β2 nAChRs contribute asymmetrically to receptor function, the extent of 
ACh EC80 current reduction by MTSET reaction was 1.2 fold greater for 
β2L146C_α4_β2_α4_β2 than for β2_α4_β2L146C_α4_β2 receptors (p < 0.001) (Figure 
3.5, Table 3.2). Significantly, reduction of β2_α4_β2_α4_β2 L146C function by 
MTSET was 1.3-fold (p < 0.001) and 1.1-fold (p < 0.05) lesser pronounced than on 
β2L146C_α4_β2_α4_β2 receptors and β2_α4_β2L146C_α4_β2 receptors, respectively 
(Table 3.1). Overall, these findings show that L146 in the β2(+)/β2(-) is accessible to 
MTSET and while it does appear to be important for ACh macroscopic efficacy, 
canonical agonist sites play a dominant role in receptor function. 
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Figure. 3.5. Maximal effects of MTSET on ACh responses of wild type and mutant 
concatenated HS α4β2 nAChRs. (A) Bar graphs show the percentage of original current 
response to ACh EC80 remaining following MTSET modification. The percentage of 
remaining responses elicited by EC80 ACh after MTSET treatment was defined as 
((IafterMTSET/Iinitial) x 100). Data are the mean ± SEM of n number of experiments. Significant 
differences between mutant and wild type receptors or between β2_α4_β2_α4_β2 L146C  and 
the β2L146C_α4_β2_α4_β2 and β2_α4_β2 L146C _α4_β2 receptors were estimated using One-
way ANOVA with Dunnett’s post-test (***, p < 0.0001). ++ indicates that the values for 
β2L146C_α4_β2_α4_β2 and β2_α4_β2 L146C _α4_β2 are statistically different from each other 
(p < 0.001).  (B) Representative current traces from oocytes expressing mutant or cysteine 
substituted concatenated HS α4β2 nAChRs showing ACh EC80 current response prior and 
after a 1 min exposure to 1 mM MTSET. Arrows indicate the application of ACh (red) or 
MTSET (green). 
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3.2.3 - Rates of MTS-ET Reaction at  α4(+)/β2(-) and β(+)/β(-) 
Interfaces in the Presence and Absence of ACh 
This effect of MTS-ET at the β2(+)/β2(-) interface and the contribution of 
this region to receptor function was further investigated by measuring the rate of 
MTS-ET modification of β2_α4_β2_α4_β2L146C in the presence or absence of ACh.  
If ACh binds the putative agonist pocket in the β2(+)/β2(-) interface, ACh and MTS-
ET co-application should  impede MTS-ET modification of L146C in 
β2_α4_β2_α4_β2L146C receptors, thus slowing down the rate of the MTSET reaction. 
This effect can occur because the substituted cysteine is a contact point for ACh, 
steric hindrance, changes in electrostatic potentials or allosteric structural changes 
(Boileau et al., 2002; Mercado and Czajkowski, 2006; Mazzaferro et al., 2011; 
2014).  
 Consistent with the role of the agonist sites in the α4(+)/β2(-) interfaces in 
receptor activation, presence of ACh significantly decreased the rate of MTSET 
modification of β2L146C_α4_β2_α4_β2 and β2_α4_β2L146C_α4_β2  receptors (Figure 
3.6; Table 3.3). ACh was more effective at protecting β2L146C_α4_β2_α4_β2 from 
MTS-ET modification than β2_α4_β2L146C_α4_β2 receptors (5.0 vs 1.5-fold 
decrease), further confirming the functional asymmetry of the canonical agonist sites 
in α4β2 nAChRs (Mazzaferro et al., 2011; 2014; Lucero et al., 2016). In accord with 
a role in receptor activation, the rate of MTSET reaction with β2(+)/β2(-) interface 
decreased in the presence of ACh (Figure 3.6,  Table 3.3). Interestingly, although 
ACh was more effective at protecting β2L146C_α4_β2_α4_β2 from MTSET 
modification than β2_α4_β2_α4_β2L146C (5.0-fold versus 3.9-fold), the rate of 
protection measured for β2_α4_β2L146C_α4_β2 and β2_α4_β2_α4_β2L146C receptors 
was not (3.9 versus 1.5-fold decrease) (Table 3.3). When the protectant ACh 
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concentration was reduced to EC20, the rate of MTSET reaction with 
β2_α4_β2_α4_β2L146C also decreased, however the impact of ACh on MTSET 
reaction rate diminished (Table 3.4). 
 
Receptor 
Control 
k2 
(M-1s-1) 
n 
+ ACh EC80 
k2 
(M-1s-1) 
n 
k2 /k2 + 
ACh EC80 
β2_α4_β2_α4_β2 L146C 1864 ± 263+++ 4 475.0 ± 131** 4 3.9 
β2L146C_α4_β2_α4_β2 5639 ± 758+++ 4 1134 ± 139*** 5 5.0 
β2_α4_β2 L146C _α4_β2 1022 ± 91+++ 5 683.2 ± 46* 5 1.5 
 
Table 3.3. Rates of MTSET modification of cysteine substituted concatemeric HS α4β2 
nAChR in the absence or presence of ACh. Rates of MTSET reaction with introduced 
cysteine were measured, and second-order rate constant (k2; M-1s-1) were calculated as 
described in the Materials and Method Chapter. Second order rate constants represent the 
mean ± SEM of n number of experiments. The rate of MTSET reaction of the three mutant 
receptors studied were significantly different (+++, p < 0.0003) (One-way ANOVA test with 
post-Dunnett’s correction. Asterisks show levels of significance between rates of reaction in 
the presence and absence of ACh (*, p < 0.05; **,p <0.005 ***, p < 0.0001) (Student t-tests). 
 
[ACh] (µM) 3.0 (EC80) 1.0 (EC20) 
k1 (s-1) (decay) 0.019 ± 0.002 0.012 ± 0.002 
k1(s-1)(protection) 0.005 ± 0.001*** 0.01 ± 0.002+++ 
k2 (M -1s-1) (decay) 1864 ± 263 1208 ± 160 
k2 (M -1s-1) (protection) 475.0 ± 131*** 1010 ± 233+++ 
 
Table 3.4. Rates of MTSET modification of β2_α4_β2_α4_β2L146C in the absence or 
presence of ACh. Rates of MTSET reaction with introduced cysteine were measured, and 
second-order rate constant (k2; M-1s-1) were calculated as described in the Materials and 
Method Chapter. Second order rate constants represent the mean ± SEM of n number of 
experiments. The rate of MTSET reaction across the two conditions of ACh application were 
significantly different (+++, p < 0.0001) (Students t-test). Asterisks show levels of 
significance between rates of reaction in the presence and absence of ACh, ***, p < 0.0001). 
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Figure 3.6. Effect of ACh on the rate of MTSET-modification of cysteine substituted 
α4(+)/β2(-) and β2(+)/β2(-) interfaces of concatemeric HS α4β2 nAChRs. (A) normalised 
ACh currents in the presence or absence of ACh were plotted versus cumulative time of 
exposure to MTSET and fit with a single exponential function, as described in Materials and 
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Methods. Data points were normalised to ACh currents at time 0 and represent the mean ± 
SEMs of at least three experiments. Second-order rate constants for MTSET modification of 
the cysteine substituted receptors are summarised in Table 3.4. (B) Representative ACh EC80 
current responses of current of β2_α4_β2_α4_β2L146C receptors showing the protocol used to 
measure the rate of the derivatization of the cysteine substituted β2_α4_β2_α4_β2  receptors 
by a 2 min application of sub-maximal concentration of MTSET (10 µM) in the absence (B) 
or presence (C) of ACh. EC80 ACh was applied during the stabilisation of the responses to 
ACh in (B) and (C) to correct for any receptor desensitisation that could developduring the 
experiment. For the measurement of the rate of reaction in the presence of ACh, the agonist 
was co-applied with MTSET. 
 
3.2.4 -  Is There an ACh Binding Site in the β2(+)/β2(-) Interface? 
The discovery that ACh prevents MTS-ET modification of β2(+)/β2(-)L146C, 
and furthermore that MTS-ET modification of β2(+)/β2(-)L146C perturbs receptor 
function, supported the hypothesis that the conserved agonist-binding aromatic 
residues may form an operational agonist binding site in the β2(+)/β2(-) interface. 
This hypothesis was further examined by mutating the conserved aromatic residues 
to alanine, a small inert residue that does not interact with ACh. Previous work has 
shown that impairment of individual agonist sites by alanine substitution yields 
biphasic ACh concentration response curves, comprising a high-affinity and a low-
affinity component (Mazzaferro et al., 2011; 2014; Lucero et al., 2016). The high-
sensitivity component of the bi-phasic curves is contributed mostly by intact agonist 
sites whereas the low-sensitivity component is contributed by both intact and 
mutated agonist sites (Mazzaferro et al., 2011; 2014). 
3.2.4.1 – Alanine substitutions of β2(+)/β2(-) 
Individual or simultaneous alanine substitution of Y120, W175 and Y221 on 
the (+) face of the β2(+)/β2(-) interface and W82 on the (–) face, which are 
equivalent to α4Y126, α4W182, α4Y223 and α4W88 (Figure. 3.3), had no effect on 
sensitivity to ACh, compared to wild type (Figure 3.8; Table 3.5). Further analysis 
Chapter 3 - Results 
 
97 
 
of the homology modelling of the β2(+)/β2(-) interface suggested that two aspartic 
acid residues on the (+) face present in the middle of the putative agonist binding 
pocket, (D217 and D218), and a phenylalanine on the (-) face juxtaposed to the L146 
side chain (F144)  could interact with ACh, forming part of the cavity proposed to 
house an agonist site (Figure. 3.7). Positions of these amino acid side-chains were 
confirmed withint the x-ray crystaolgraphy data of (α4β2)2β2 nAChRs (Morales-
Perez et. al., 2016. Alanine substitution on these residues had no effect on the 
sensitivity of β2_α4_β2_α4_β2 nAChRs to ACh (Table 3.5). Thus, overall, the 
results strongly suggest that none of the residues tested are contact-points for ACh on 
the β2(+)/β2(-) interface to form a functional binding site. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.7. Homology model of the β2(+)/β2(-) interface of the HS α4β2 nAChR. α-
aromatic residues conserved in β2 are shown in gray sticks. Additional residues that could 
contribute to agonist binding due to the orientation of their side chain towards the putative 
agonist binding pocket are shown as red sticks. 
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Figure 3.8. ACh Concentration-response relationships for wild type and β2(+)/β2(-) 
interface alanine substituted concatemeric HS α4β2 nAChRs.  Conserved aromatic 
residues that interact with agonists in canonical agonist sites in nAChRs were mutated to 
alanine in the β2(+)/β2(-) interface , and the consequences of the mutations for sensitivity to 
activation by ACh were examined using two-electrode voltage clamping, as described in 
Materials and Methods. Data points represent the mean ± SEM of at least three independent 
experiments. Data were fit by nonlinear regression, as described under Materials and 
Methods. Dashed lines are curve fits for wild type (WT) receptors. ACh EC50 and nHill 
coefficient values are summarised in Table 3.3. 
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Table 3.5. Concentration Response Data for ACh activation on concatemeric α4β2 HS 
nChRs with alanine substituted β2(+)/β2(-) interface. Data are the mean ± SEM for no 
experiments from at least two different batches of oocytes. Mutant/wild type (mut/wt) were 
calculated. None of the mutant EC50 values were significantly different from wild type (One-
way Anova with Dunnett’s post-test). 
 
3.2.4.2 - MTS-ET Modification of β2_α4_β2_α4_β2L146C in the presence and 
absence of Competitive antagonist dihydro-β-erythroidine (DhβE) 
  As alanine mutations in the β2(+)/β2(-) interface did not affect receptor 
function, to further test for the presence of an operational agonist binding site in the 
β2(+)/β2(-), the rate of MTSET modification was measured in the absence or 
presence of the α4β2 nAChR competitive antagonist dihydro-β-erythroidine DhβE. 
Outcomes of “protection” seen with both classes of ligand (agonist and antagonist) 
are regarded as affirmative of presence of a binding site in region probed (Liapkis, 
2001). Functional studies of alanine-mutated agonist binding sites (Iturriaga-
Vásquez et al., 2010) as well as crystal structures of Lymnea AChBP bound with 
Receptor 
ACh EC50 ± SEM 
(µM) 
nHill ± 
SEM 
mut/wt n 
β2_α4_β2_α4_β2 7.19 ±1.6 0.89±0.22 1 20 
Y120Aβ2_α4_β2_α4_β2 10.74 ±5.4 0.94±0.24 1.5 6 
Y221Aβ2_α4_β2_α4_β2 8.62 ±2.1 0.90±0.1 1.2 3 
W176Aβ2_α4_β2_α4_β2 7.15 ±0.93 0.93±0.17 0.99 5 
β2_α4_β2_α4_β2W82A 7.79 ±2.3 0.82±0.19 1.08 10 
Y120A,Y221Aβ2_α4_β2_α4_β2 3.89 ±0.35 0.97±0.21 0.54 5 
Y120Aβ2_α4_β2_α4_β2W82A 4.64 ±2.2 0.85±0.14 0.65 4 
Y120A,W176A, Y221Aβ2_α4_β2_α4_β2W82A 7.56±2.4 0.83±0.34 1.05 5 
Y120Aβ2_α4_β2_α4_β2F144A 5.9 ±3.4 0.76±0.25 0.82 6 
Y120A,D217Aβ2_α4_β2_α4_β2 3.17 ±1.8 0.82±0.5 0.44 3 
Y120A,D218Aβ2_α4_β2_α4_β2 3.10 ±0.9 0.84±0.15 0.43 3 
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DhβE (Shahsavar et al., 2012) show that as a competitive antagonist it interacts with 
the same residues as ACh in the agonist binding pocket. However, unlike ACh, DhβE 
stabilises the receptor in a closed state. This means that during co-application with 
MTSET, if binding sites are occupied by DhβE the receptor will remain in the closed 
conformation, and not undergo the structural changes induced by ACh binding. If 
there is a difference in k1 values between applications of MTS-ET alone and when 
co-applied with DhβE, it can be concluded that the protection seen with co-
application with ACh is not due to alteration in exposure of introduced cysteine to 
MTSET due to movement of this residue during receptor activation following 
agonist binding. Therefore the site is being protected from MTS-ET by the 
competitive antagonist, signifying a binding site as the competitive antagonist and 
binds in same nature as ACh.  
As shown in Figure 3.9 (Table 3.6), when the rate of MTSET reaction was 
measured in the presence of DhβE IC80, there was little if any shift in the rate of 
reaction (13.-fold difference). Importantly, decreasing the concentration of DhβE had 
no impact on the rate of reaction (Table 3.6). If DhβE competes with MTSET for 
access to the putative agonist site, the rate of MTSET reaction should be perturbed in 
the presence of DhβE. Thus, this finding, together with the lack of functional effects 
of alanine substituted β2(+)/β2(-) interface do not support the presence of an 
operational agonist site in the β2(+)/β2(-) interface. 
As ligand occupation of putative binding site eliciting no conformational 
change does not alter the MTSET modification of substituted β(+)/β(-) L146C, it is 
more than likely that disparity rates in ACh studies is not due to functional binding 
site at the β(+)/β(-) interface, but reveals important movements of the substituted 
residue following agonist binding at orthosteric sites and subsequent receptor 
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activation. 
 
Figure 3.9. Effects of the competitor antagonist DhβE on the rate of MTSET 
modification of the β2(+)/β2L146C(-) interface of the HS α4β2 nAChR.  Rates 
experiments were carried out as described in Materials and Methods. Normalised 
EC80 current responses were plotted versus cumulative time of MTSET exposure in 
the absence or presence of DhβE IC80 or IC20. Data were were fit to a single-phase 
exponential decay as described in Materials and Methods. Each data point represents 
the mean ± SEM of at least three independent experiments. 
 
 
 
Reaction Conditions 
k2 
(M -1s-1) 
DhβE IC80 DhβE IC20 
- DhβE 1340 ± 323 1398 ± 498 
+ DhβE 985 ± 208 1134 ± 526 
 
Table 3.6. Rates of MTSET modification of the β2(+)/β2(-)L146C interface in the presence 
or absence of the competitive nicotinic inhibitor DhβE. Rates of MTSET reaction with 
the introduced cysteine were measured, and second-order rate constants (k2, M-1s-1) were 
calculated as described under Materials and Methods. Second-order rate constants are the 
mean ± SEM of at least three independent experiments. Rates were measured using two 
different concentrations of DhβE (IC80 and IC20) but none of these conditions perturbed the 
rate of MTET reaction as suggested by lack of significant differences shown by students t-
tests. 
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3.2.5 – Effect of Modification of β(+)/β(-) Interface upon Macroscopic 
Properties of the (α4β2)2β2 nAChR  
The discovery that ACh, but not DhβE, affects derivatisation of 
β2_α4_β2_α4_β2L146C receptors with MTSET further suggests the absence of an 
operational agonist site at the β2(+)/β2(-) interface. However, since modification of 
L146C at β2(+)/β2L146C(-) impedes receptor function and ACh slows down the rate of 
MTSET modification, it may be that L146C or a neighbouring residue on the (-) side 
of the fifth subunit is a macroscopic efficacy element, whose accessibility is affected 
by binding of agonists to the canonical agonist sites on the α4(+)/β2(-) interfaces. To 
test this possibility, the full ACh CRC of β2_α4_β2_α4_β2 L146C was determined 
before and after a 2 min of application of 1 mM MTSET. If MTSET modification of 
β2(+)β2L146C(-) perturbs an agonist efficacy mechanisms encoded by the fifth subunit 
or the β2(+)β2(-) interface, the maximal macroscopic maximal ACh responses 
should decrease with no significant changes in ACh EC50. Alternatively, if 
modification affects agonist binding or agonist-binding and gating, the ACh CRC 
after the reaction should be characterised by a decrease in ACh maximal currents and 
a shift in the value of ACh EC50. As shown in Figure 3.10 (Table 3.10), MTSET 
modification of β2(+)/β2(-) resulted in decreased maximal currents for ACh without 
changes in the ACh EC50 (EC50 before MTSET = 6.1 ± 1.7 µM; EC50 after MTSET = 
6.03 ± 1.0 µM). 
 In combination, the outcomes of studies outlined above suggest that the fifth 
subunit in HS α4β2 nAChRs modulates response to ACh efficacy, but not through 
the presence of an operational agonist site at the β2(+)/β2(-) interface.  
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Figure 3.10. Effects of MTSET reaction on the ACh concentration-response curve of 
β2_α4_β2_α4_β2L146C receptors. The full ACh concentration response curve for 
β2_α4_β2_α4_β2L146C receptors was determined prior and after 2 min exposure to 1 mM 
MTSET. After application of MTSET the cells were washed with Ringer until the response 
to ACh EC80 were stable (less than 5% change), after which time the ACh concentration-
response curve was determined again. The concentration response data were fit by nonlinear 
regression, as described under Materials and Methods.  
 
 
 
 
Table 3.7. Effects of maximum blockage of β2(+)/β2 interface on concentration 
response relationships of ACh. Concentration dependent responses to ACh were measured 
and responses stablised prior to MTSET application. 1mM MTSET was then applied to 
oocytes to achieve saturating levels and full modification of receptors. The same 
concentration  response measurement protocol was then carried out with responses 
normalised to responses achieved during stabilisation period. No significant difference of 
sensitivity parameters (EC50) was observed, but as previously seen, students t-test showed 
difference in maximal efficacy following MTSET treatment (***,p<0.0001). 
 
Condition EC50 nHill Top 
β2_α4_β2_α4_β2L146C Pre MTSET 6.1 ± 1.7 0.7 ± 0.05 1 ± 0.04 
β2_α4_β2_α4_β2L146C Post MTSET 6.03 ± 1.0 0.69 ± 0.1 0.41 ± 0.01*** 
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3.3 DISCUSSION 
 
The fifth subunit in the two stoichiometries of α4β2 nAChR differs, thus 
producing two structurally distinct subunit interfaces within the alternate (α4β2)2β2 
and (α4β2)2α4 receptors. One of which, α4(+)/α4(-) in (α4β2)2α4, contains an ACh-
binding site that plays a dominant role in defining the pharmacology (Harpsoe et al, 
2011; Mazaferro et al., 211; Absalom et al., 2013; Olsen et al., 2013; Mazzaferro et 
al., 2014) and desensitisation (marks etal., 2010; Benallegue et. al., 2013) of the 
(α4β2)2α4 stoichiometry.  
Here, by combining voltage-clamp electrophysiological recordings in 
Xenopus oocytes, site-directed mutagenesis, homology modelling, along with SCAM 
approaches, it is shown for the first time that the fifth subunit in the (α4β2)2β2 
receptor makes a significant contribution to agonist-driven receptor activation. In 
contrast to the (α4β2)2α4 stoichiometry, this effect is not through occupation of an 
agonist site at the β2(+)/β2(-) interface contributed by the fifth subunit, but likely 
through conformational changes in the fifth subunit brought about by agonist 
occupation of the agonist binding sites in the α4(+)/β2(+) interfaces. This is the first 
time that it is shown functionally that the fifth subunit subunit in a pLGIC plays a 
role in receptor gating. In addition to residues that directly contact the agonists or 
that facilitate occupancy of the site, there are residues in the agonist-binding  
α(+)/β(-) interfaces that communicate the agonist binding event down to the 
ECD/TM interface and ultimately to the channel gate. These include residues in the 
β1-β2 and Cys loops, M2-M3 linker and TM residues in M1, M3 and M4 (reviewed 
in Miller and Smart, 2010). However, recent structural studies of the Torpedo 
nAChR have suggested that asymmetric motions of the receptor subunits brought 
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about by agonist binding to the canonical agonist sites induces conformational 
transitions in the fifth subunit subunit (a β1subunit), which plays the key role in 
transmitting gating signals from adjacent agonist sites to the ion channel g ate 
(Unwin and Fujiyoshi, 2012).  
 
Several lines of evidence support the conclusion that the fifth subunit is an 
important element of the gating pathways of the (α4β2)2β2 receptor. First, MTSET 
modification of L146C in the fifth subunit decreased the maximal ACh current in a 
manner consistent with removal by MTSET derivatisation of a gating element. 
Second, although ACh slowed covalent modification of L146C in the fifth subunit, 
the competitive antagonist DhβE did not. If there was an agonist binding site in the 
β2(+)/β2(+) interface, one would expect both ACh and DhβE to slow down the 
derivatisation of L146C. Available DhβE-bound crystal structures of Lymnaean 
AChBP (Shasavara et al., 2012), together with mutagenesis studies (Iturriaga-
Vásquez et al., 2010), have established that DhβE and ACh contact the same 
conserved aromatic residues in the agonist sites in α4(+)/β2(-) interfaces. 
Additionally, although homology models of the (α4β2)2β2 receptor suggested 
conserved aromatic residues line a pocket in the β2(+)/β2(-) interface homologous to 
the canonical agonist sites in α4(+)/β2(-), individual or multiple alanine substitution 
of those residues did not perturb receptor function. Third, MTS-ET modification of 
the fifth subunit did not perturb the apparent affinity of the receptor for ACh but 
reduced the maximal ACh responses, indicating that MTSET-derivatisation removes 
a gating element only. If MTS-ET reduced the ACh responses by preventing agonist 
access to a binding site or changing the electrostatic environment of agonist contact 
points in the site, the ACh EC50 should be affected. 
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Despite being structurally equivalent, the agonist sites in the (α4β2)2β2 
nAChR contribute asymmetrically to receptor function, as suggested by the 
differential effects of MTSET modification of individually cysteine substituted 
agonist sites in the presence and absence of ACh. These findings therefore add to the 
increasing body of evidence indicating that structurally equivalent agonist sites in 
heteromeric Cys-loop LGICs function asymmetrically (Baumann et al., 2003; 
Mazzaferro et al., 2011; Lucero et al., 2016). Functional asymmetry in structurally 
equivalent agonist sites likely results from the nature of the subunit flanking the 
agonist binding subunit pairs. Subunits flanking the agonist sites could alter the 
conformation of the sites through the action of modulatory sites (e.g., the 
benzodiazepine site on the α/γ interface of the GABAAγ receptors), additional 
agonist sites (e.g., the LS α4β2 nAChRs) or inter-subunit interactions, as suggested 
by the findings of previous studies (Lucero et al., 2016) and the findings reported in 
this Chapter. Significantly, the most recent structures of the Torpedo nAChR suggest 
that the outward movement of the β1 subunit, suggested to open the gate, is driven 
primarily by the agonist site on the α/γ interface (Unwin and Fujiyoshi, 2012). In this 
respect, the findings reported in this Chapter raise the question of whether the fifth 
subunit subunit is functionally coupled to the agonist sites and whether coupling is 
asymmetrical. These issues are examined in the next Chapter.  
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Chapter 4 
Long-Range Coupling Between 
Agonist Sites and the β2(+)/β2(-) 
Interface  
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4.1 INTRODUCTION 
 
When looking at alosteric mechanism of cys-loop receptor activation, 
attention has primarily focused on understanding the gating movements of the 
interfacial loops (β1-β2 loop, the Cys and M2-M3 linker), which form the primary 
allosteric pathway connecting the agonist sites to the ion channel gate (Xiu et al., 
2005; Lee and Sine 2005; Lee et al., 2009; Grutter et al., 2005; Bouzat et al., 2008; 
Andersen et al., 2011), as reviewed by Bouzat (2012).  However, studies of the TMD 
have suggested that other pathways not involved in the primary coupling path such 
as interactions between α helix M4 and membrane lipids and inter-helical 
interactions between M4 and M1 and M3 also modulate channel function (Carswell 
et al., 2015).  
Structurally, gating involves a large re-organisation of the ion channel 
mediated by a global twisting and blooming of the whole ECD (Calimet et al., 2013, 
Cecchini and Changeux, 2015), which suggest that all subunits, thus interfaces, 
including non- agonist-binding ones may contribute to gating, directly or indirectly. 
Indeed, the most recent cryo-structures of Torpedo nAChR in closed and open 
conformations have suggested a key role for the fifth subunit subunit (β1) in gating 
(Unwin and Fujijoshi, 2012). In this respect, the findings described in the previous 
chapter are highly relevant. Does the effect of the fifth subunit on efficacy of ACh on 
the HS α4β2 nAChR represent an additional agonist-binding coupling pathway? And 
if this is the case, how is the agonist binding signal transmitted to the fifth subunit?  
This chapter examines possible functional links between the agonist sites and the 
fifth subunit by using subunit-targeted single point mutations and MTS-ET 
derivatisation of substituted cysteines. 
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4.2. RESULTS 
 
The discovery that the fifth subunit has an effect on ACh maximal current 
responses in the presence of agonist suggests that binding of ACh to the canonical 
agonist binding sites  may induce conformational changes in the fifth subunit that 
alters access to the substituted cysteine  of β(+)/β(-)L146C. To initially probe any 
functional link between the fifth subunit and the agonist sites, double mutant 
concatemers were engineered to introduce the L146C on the fifth subunit alongside 
alanine substitutions of α4W182 on the agonist sites on α4(+)/β2(-)binding sites. As 
the α4W182A mutation is known to perturb agonist binding (Mazzaferro et al., 
2011), the degree to which mutated agonist sites may affect MTS-ET modification of 
the cysteine substituted fifth subunit may provide insight into possible functional 
coupling between agonist sites and the fifth subunit. 
4.2.1 - Alanine Substitution of Conserved Residues in α4(+)/β2(-) 
Interfaces 
α4W182, one of the conserved aromatic residues contributing to the binding 
pocket in Cys loop receptors, establishes a direct cation-π interaction with the 
quaternary amine group of ACh in nAChRs (Zhong et al., 1998) and is responsible 
for the high-affinity of nicotine for α4β2 nAChRs (Xiu et al., 2009).  It has also been 
implicated in the initiation of the gating isomerisation, rendering it a highly 
important feature of receptor function. Modification of this residue in the structurally 
identical binding sites can highlight any functional differences between the two 
regions.  
Introduction of W182A into the agonist sites on the α4(+)/β2(-) interfaces 
Chapter 4 - Results 
 
110 
 
affected receptor sensitivity to activation by ACh and MTS-ET modification of the 
cysteine substituted fifth subunit, dependent on which site W182A was incorporated. 
When incorporated into agonist binding site 1 (i.e., β2_W182Aα4_β2_α4_β2), W182A 
caused a biphasic ACh sensitivity profile (Figure 4.1, Table 7). The higher 
sensitivity component comprises about half (55%) of the curve, and has an ACh 
EC50 (EC50_1) similar to wild type (Table 4.1). As previously published (Mazzaferro 
et al., 2011), biphasic agonist concentration response curves in concatenated α4β2 
nAChRs represent the contribution of wild type agonist sites (high-sensitivity 
component) and mutant and wild type sites (low-sensitivity component).The low 
sensitivity component, with an EC50 (EC50_2) tenfold higher than wild type (Table 
4.1), therefore reflects mostly the altered activity of the mutated binding site, as seen 
by the very uncharacteristically high gradient of the slope and corresponding nHill 
coefficient (Table 4.1). In contrast, incorporation of W182A into agonist site 2 (i.e., 
β2_α4_β2_W182Aα4_β2) did not perturb the sensitivity to activation by ACh, 
compared to wild type (Figure 4.1; Table 4.1). When the α4W182A was introduced 
simultaneously on both agonist sites (i.e., β2_W182Aα4_β2_W182Aα4_β2), the 
concentration response curved was biphasic. As of these two substitutions one 
produces a shift from monophasic to a biphasic curve and the other does not appear 
to affect sensitivity, this is expected from the presence of the mutation on both sites 
(Mazzaferro et al., 2011). The potency of ACh decreased by 20-fold (Figure 4.1, 
Table 4.1) highlighting an allosteric connection between two binding interfaces. 
Taken together, the findings so far are in accord with previous findings that suggest 
that the agonist sites contribute asymmetrically to the function of α4β2 nAChRs 
(Mazzaferro et al., 2011; Lucero et al., 2016).  Interestingly, the findings also suggest 
that agonist site 1 plays a dominant role in the function of HS α4β2 nAChRs.  
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The asymmetric effects of W182A may be residue-specific due to the key 
role that W182 plays in binding agonists in the α4β2 nAChR (Williams et al., 2009; 
Xiu et al., 2009) or may reflect overall functional differences between the sites. To 
examine these possibilities, further binding residues (highlighted in Figure 3.2) 
were alanine substituted and the functional consequences of the substitutions were 
examined using two-electrode voltage-clamping.  α4Y126A from loop A produced 
biphasic ACh responses when introduced in agonist site 1 (Figure 4.1; Table 4.1). In 
contrast, when introduced in site 2, it produced monophasic ACh concentration 
response curves, albeit with increased EC50 (Figure 4.1; Table 4.1). Y230A, from 
the loop C, did not yield functional expression when incorporated in agonist site 1, 
but in agonist site 2 produced biphasic ACh concentration response curves with 
increased ACh EC50 (Figure 4.1; Table 4.1). No functional expression was seen 
when β2W82A was introduced to either agonist site, implying high importance of 
this residue in receptor function. This finding is in agreement with previous studies 
that have shown that the W82 position does not tolerate structural changes, probably 
due to a role of this residue in gating (Williams et al., 2009). Overall, the findings 
suggest that the agonist sites bind the agonist in a site-specific manner, which is in 
accord with the findings of Mazzaferro et al., (2011) and Lucero et al. (2016).  
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Figure. 4.1. Effect of alanine substitutions of conserved residues of binding pockets 
subunit on the ACh sensitivity of β2_α4_β2_α4_ β2 nAChR. ACh concentration response 
relationships were obtained, producing a range of mono and biphasic curves and altered 
ACh sensitivity. EC50 and Hill coefficient values are summarised in Table 4.1. In order to 
detect biphasic relationships, a wide range and many intermediate concentrations were 
utilised. Data was then fit by non-linear regression in Graph-Pad Prism 5, as outlined in 
Materials and Methods. 
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Concatemer 
EC50_1 
(µM) 
nHill_1 
EC50_2 
(µM) 
nHill_2 HFrac 
β2_α4_β2_α4_β2 7.58 ± 2.6 
0.74 ± 
0.12 
--- --- --- 
β2_W182Aα4_β2_α4_β2 2.2 ± 0.3 
0.64 ± 
0.21 
62.0 ± 
3.01 
5.35 ± 1.1 
0.55 ± 
0.14 
β2_α4_β2_W182Aα4_β2 11.5 ± 2.1 
0.67 ± 
0.018 
--- --- --- 
β2_W182Aα4_β2_W182Aα4_β2 221 ± 19 3.2 ± 0.5 
31.9 ± 
8.1 
5.14 ± 0.49 
0.13 ± 
0.07 
β2_α4_β2_Y230Aα4_β2 14 ± 0.32 
0.66 ± 
0.17 
270 ± 
32.0 
2.97 ± 0.89 
0.58 ± 
0.13 
β2_Y126Aα4_β2_α4_β2 0.71 ± 0.03 
4.06 ± 
0.07 
30.0 ± 
0.04 
2.30 ± 0.35 
0.28 ± 
0.03 
β2_α4_β2_Y126Aα4_β2 
86.8  ± 
3.9*** 
0.72 ± 
0.05 
--- --- --- 
 
 
 
Table 4.1. Summary of ACh effects on wild type and β2_α4_β2_α4_ β2 nAChRs 
containg alanine substituted binding sites. Data was analysed with non-linear regression 
asare the mean ± SEM for at least 3 experiments. ACh EC50 values, Hill coefficients and 
where applicable high sensitivity fractions (HFrac) are reported. Where the data is 
monophasic only one of each is reported (EC50_1 and nHill_1), whereas bi-phasic 
relationships are denoted by two of each parameter (EC50_1 and nHill_1+ EC50_2 nHill_2). 
Bi-phasic data is taken as significantly different to wild type. Significant differences of 
monophasic data in comparison to wild type are denoted by asterix (***,p<0.0001). 
 
 
 
  In these results, agonist binding sites of (α4β2)2β2 nAChRs are shown to be 
functionally diverse but alosterically linked. This raises questions of linkage between 
other interfaces - it is known that alosteric modulators can exert their effects via 
interaction at the β2(+)/α4(-), and it may be that the  β2(+)/β2(-), modulates receptor 
activation in a similar manner. As subunit environment is suggested to underlie 
functional differences of binding sites, any functional linkage with the fith subunit of 
(α4β2)2β2 may give insight to this. 
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4.2.2 – Effects of W182A on MTS-ET Modification Of Cysteine 
Substituted Fifth Subunit 
To probe effects of agonist sites on the fifth subunit, MTS-ET modification of 
the cysteine substituted fifth subunit was measured on β2_W182Aα4_β2_α4_β2L146C 
and  β2_α4_β2_W182Aα4_β2L146C   receptors.  
 
 
 
 
 
 
 
Figure 4.2.  Schematic diagrams of (α4β2)2β2 demonstrating which α4(+)/β2(-) binding 
interface will be individually modified and blocked in each double mutant, highlighting 
differences in proximity to the β2(+)/β2(-) interface. Intact binding sites are shown by 
presence of yellow asterix, interfaces hosting the α4(+)W182 modification are shown by 
black and yellow X and molecular structure of MTSET is shown linked to β(+)/β(-) where it 
will be present following covalent modification of β(-)L146C here. (A) shows 
β2_W182Aα4_β2_α4_β2L146C in which site 1 will be modified, (B) represents  
β2_α4_β2_W182Aα4_β2L146C  - in which site 2 hosts the alanine. 
 
  
 
 
 
 
 
 
 
β2_W182Aα4_β2_α4_β2L146C β2_α4_β2_W182Aα4_β2L146C 
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In the first instance, β2_W182Aα4_β2_α4_β2L146C and 
β2_α4_β2_W182Aα4_β2L146C ACh concentration responses were analysed against their 
non-cysteine substituted counterparts. β2_W182Aα4_β2_α4_β2L146C ACh responses 
were biphasic, with a small non-significant reduction of the high sensitivity 
component, compared to β2_W182Aα4_β2_α4_β2 receptors, suggesting that 
incorporation of L146C does not significantly alter the function of 
β2_W182Aα4_β2_α4_β2 receptors (Figure 4.2, Table 4.2). Incorporation of L146C 
into β2_α4_β2_W182Aα4_β2 did not alter the monophasic nature of the ACh 
concentration, although L146C significantly increased, ACh potency (Figure 4.2, 
Table 4.2). This is particularly interesting considering that individually neither 
mutation has any effect on ACh responses. This suggests functional connections 
between binding sites and the fifth subunit.  
 
 
Figure 4.3. ACh concentration response relationships of concatemers in which binding 
impairment is introduced alongside cysteine substituted fifth subunit. Data are plotted 
alongside single point mutations of α4W182A in individual binding sites and changes of 
double substitution are seen. As can be seen in the case of β2_W182Aα4_β2_α4_β2L146Cthis is 
only small, whereas the leftward shift of β2_α4_β2_W182Aα4_β2L146C can be seen more 
prominently. This is reflected in data summarised in Table 4.2 analysed by non-linear 
regression, as outlined in Chapter 2.  
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Concatemer 
EC50_1 
(µM) 
nHill_1 
EC50_2 
(µM) 
nHill_2 HFrac 
β2_α4_ β2_α4_ β2L146C 
3.710 ± 
0.8 
0.93 ± 
0.12 
--- --- --- 
β2_W182Aα4_ β2_α4_ β2L146C 320 ± 5.6 
1.02 ± 
0.21 
76 ± 
0.32 
3.32 ± 
1.18 
0.50 
±0.09 
β2_α4_ β2_W182Aα4_ β2L146C 
2.92 ± 
0.62*, ++ 
0.69 ± 
0.08 
--- --- --- 
β2_α4_ β2_Y230Aα4_ β2L146C 
43.2 ± 
8.15*** 
0.68 ± 
0.07 
--- --- --- 
 
Table 4.2. Summary of ACh concentration-response relationship parameters at 
concatenated HS (α4β2)2β2 nAChR containing the β(+)/β(-)L146Cand alanine 
substitutions of binding sites. Data was analysed with non-linear regression and are the 
mean ± SEM for at least 3 experiments. ACh EC50 values, Hill coefficients and where 
applicable high sensitivity fractions (HFrac) are reported. Where the data is monophasic 
only one of each is reported (EC50_1 and nHill_1), whereas bi-phasic relationships are 
denoted by two of each parameter (EC50_1 and nHill_1+ EC50_2 nHill_2). Differences 
between monophasic and biphasic relationships of curves are concluded as a significant 
difference (such as in the case of β2_α4_ β2_Y230Aα4_ β2L146C vs β2_α4_ β2_Y230Aα4_ β2). 
Statistical deviation from equivalent concatemer without L146C substitution is shown by 
++,p=0.05 and Statistical differences from wild type are shown by asterix (*,p=0.03; 
***,p<0.0001), as determined by student t-tests. 
 
The accessibility of the cysteine substituted fifth subunit to the MTS-ET 
reagent was then determined in receptors with the mutated agonist site. As shown in 
Table 4.3, the accessibility of L146C did not change with incorporation of W182A 
into any of the two agonist sites or the presence of Y230A in site 2. Thus, when the 
cysteine substituted fifth subunit is derivatised by MTS-ET in the absence of ACh, 
the accessibility of the introduced cysteine is not perturbed. 
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Concatemer Remaining IAch Post MTS-ET (%) 
β2_α4_ β2_α4_ β2L146C 41.1 ± 2.92 
β2_W182Aα4_ β2_α4_ β2L146C 50.3 ± 2.34 
β2_α4_ β2_W182Aα4_ β2L146C 38.3 ± 2.72 
β2_α4_ β2_Y230Aα4_ β2L146C 40.1 ± 1.68 
 
Table 4.3. Effects of maximal application of MTSET on β2_α4_ β2_α4_ β2 with L146C 
substitutions within the β(+)/β(-) interface and individual alanine substitutions of 
conserved binding residues in α(+)/β(-) interfaces. β2_α4_ β2_α4_ β2L146C data included 
to demonstrate additional binding site substitution does not alter maximum effect of MTSET 
application and modification of β(+)/β(-)L146C. No significant difference is seen following 
ANOVA analysis with Dunnet’s corrections.  
 
4.2.2.1 - Rates of MTSET modification of β2_α4_β2_W182Aα4_β2L146C and 
β2_W182Aα4_β2_α4_β2L146C. 
To probe possible coupling of the agonist sites with the fifth subunit, the 
rate of reaction of MTS-ET with cysteine substituted fifth subunit on alanine 
substituted receptors was measured in the presence and absence of ACh. If the 
agonist sites couple functionally to the fifth subunit, the rate of reaction should be 
affected in the presence of ACh, i.e., when the binding site is engaged by the agonist. 
Thus, when α(+)/β(-) dependent receptor activation is modified by α(+)W182A, if 
the fifth subunit is coupled to the agonist sites, impairment of ACh binding to the 
sites by alanine substitution of α4(+)W182 should perturb coupling, altering the 
effects of bound agonist sites on MTSET derivatisation of L146C.  
Incorporation of W182A in agonist site 2 did not affect the rate of 
modification of cysteine substituted fifth subunit in the presence of ACh (Figure 4.4; 
Table 4.4). However, when incorporated in site 1, W182A markedly perturbed the 
rate of reaction. First, the presence of W182A decreased the rate of MTSET reaction 
with receptors in the closed state, in comparison to β2_α4_β2_α4_β2L146C
 
receptors 
Chapter 4 - Results 
 
118 
 
(Figure 4.4; Table 4.4). In the presence of ACh the rate of reaction was accelerated 
(Figure 4.4; Table 4.4). Although the mechanism of this cannot be elucidated via 
these experimental approaches, such outcomes provide very strong evidence of 
functional connections between agonist site 1 and the fifth subunit.  
 
 
 
Figure 4.4. Rates of MTS-ET modification of β2_W182Aα4_β2_α4_β2L146C and 
β2_α4_β2_W182Aα4_β2L146C nAChRs. Experiments were carried out with MTS-ET 
in the absence (black) and presence (red and blue) of EC80 concentrations of ACh. 
Data were fit to a single-phase exponential decay as described in Materials and 
Methods. 
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Table 4.4. First and second order rates of MTS-ET modification of β(+)/β2(-)L146C when 
substitutions of binding residues to alanine are present in HS α4β2nAChR 
concatemers. The only concatemer exhibiting differences to β2_α4_ β2_α4_ β2L146C was 
β2_W182Aα4_ β2_α4_ β2L146C, statistical differences shown by asterix (*,p = 0.02’ **,p = 
0.007). In all concatemers a significant difference was seen between conditions (+,p = 0.02; 
++, p<0.005) 
 
 
As introducing W182 to agonist site 2 did not affect MTS-ET-modification of 
the fifth subunit, the rate of modification of the fifth subunit was measured on 
β2_α4_β2_Y230Aα4_β2L146C receptors. Unlike W182A, introducing Y230A to agonist 
site 2 affected receptor function, as reflected by sensitivity to activation by ACh. As 
shown in Figure 4.5 (Table 4.3), β2_α4_β2_Y230Aα4_β2L146C receptors display 
monophasic ACh concentration response curves. When compared to the biphasic 
CRC of  β2_α4_β2_Y230Aα4_β2 receptors, this suggests functional links between 
agonist site and the fifth subunit. However, the rate of MTS-ET reaction with the 
cysteine substituted fifth subunit is not significantly altered in the presence of ACh 
(Figure 4.5; Table 4.4). The findings also show no significant differences between 
the rate of reaction in the absence of ACh measured for β2_α4_β2_α4_β2L146C and 
β2_α4_β2_Y230Aα4_β2L146C receptors (Figure 4.5; Table 4.4). 
k1 Values k2 Values 
Concatemer 
MTSET 
(control) 
MTSET + 
ACh 
MTSET 
(control) 
MTSET + 
ACh 
β2_α4_ β2_α4_ β2L146C 0.019 ± 0.002 0.005 ± 
0.001 
1864 ± 263 475.0 ± 
131++ 
β2_W182Aα4_ β2_α4_ β2L146C 0.009 ± 0.001 0.029 ± 
0.007 
883 ± 139* 2860 ± 
682**,+ 
β2_α4_ β2_W182Aα4_ β2L146C 0.021 ± 0.003 0.006 ± 
0.001 
2110 ± 303 593 ± 117++ 
β2_α4_ β2_Y230Aα4_ β2L146C 0.016 ± 0.003 0.007 ± 
0.001 
1604 ± 317 690 ± 101+ 
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Figure 4.5.. Studies performed with β2_α4_β2_Y230Aα4_β2L146C in order to investigate 
functional connection between agonist site 2 and the fifth subunit of (α4β2)2β2 
nAChRs. (A) ACh Concentration response curves of bi-phasic β2_α4_β2_Y230Aα4_β2 and 
monophasic β2_α4_β2_Y230Aα4_β2L146C. Data fit with non-linear regression as outlined in 
Chapter 2. (B) One phase decay fit data of rates of β2_α4_β2_Y230Aα4_β2L146C with MTSET 
in the presence and absence of ACh. It can be seen here that presence of α4Y230A at ABS2 
does not modify the effect of MTSET at β(+)/β(-)L146C or its rate of reaction with this 
cysteine in either condition. 
 4.2.3 - The β2(+)/β2(-) interface is central to functional coupling of 
agonist ABS 1 and the 5th  subunit of (α4β2)2β2 nAChRs 
The findings so far suggest that agonist site 1, but not 2, functionally links 
to te fifth subunit in the presence of ACh, when the site is occupied by the agonist. 
This possibility implies a linking path between the agonist site and the fifth subunit. 
In order to identify potential contributors to the pathway, the homology model of the 
HS α4β2 receptor was examined. As shown in Figure 4.6, the (+) side of the β2 
subunit contributing the complementary side of agonist site 1 interfaces with the fifth 
subunit. As leucine and tryptophan are hydrophobic residues, W176 and L146 could 
engage in hydrophobic interactions, which could in turn underlie the changes in the 
rate of L146C modification in the presence of ACh. 
β2_α4_β2_Y230Aα4_β2L146C 
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Figure 4.6. Homology model of (α4β2)2β2 nAChR highlighting 1β2 and flanking 5β2 
and 2α4 subunits. (A) Areal view of pentamer with three subunits of the ABS1 and β(+)/β(-
) interfaces highlighted in red (2α4), blue (1β2) and green (5β2). (B) Side view of (α4β2)2β2 
showing these three subunits only. 2α4(+)W182, 1β2(+)W176C and 5β2(-)L146C are shown 
as grey sticks. (C) Close up of interfaces within this triad of subunits, showing 2α4(+)W182, 
1β2(+)W176C and 5β2(-)L146C as grey sticks. 
 
To probe functional coupling between β2(+)W176 and β2(-)L146 in the 
β2(+)/β2(-) interface, W176A was introduced in the first subunit of 
β2_α4_β2_α4_β2L146C to engineer W176Aβ2_α4_β2_α4_β2L146C receptors. If 
interactions between W176 and L146 are part of a coupling pathway between agonist 
site 1 and the fifth subunit, the rate of reaction of W176Aβ2_α4_β2_α4_β2L146C in the 
presence of ACh should be comparable to that measured in the absence of the 
agonist, or at least differ to β2_α4_β2_α4_β2L146C. The same effect should also be 
seen for W176Cβ2_α4_β2_α4_β2L146A receptors. Furthermore, the effects of MTS-ET 
in the absence or presence of ACh on W176Cβ2_α4_β2_α4_β2 receptors should be 
comparable to those on β2_α4_β2_α4_β2L146C receptors. 
All three receptors displayed no alterations to ACh sensitivity (Table 4.5), 
indicating that HS α4β2 nAChRs tolerate well the presence of W175A on its own or 
together with L146C and this putative interaction does not have implications in 
agonist potency. 
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Figure 4.7. Concentration response relationships of β2_α4_β2_α4_β2 hotsting cysteine 
and alanine substitutions in the putatively functionally connected β2(+)W175 and β2(-
)L146 residues of the β2(+)/β2(-) interface. Data were fit using non-linear regression as 
outlined in Chapter 2 – no changes to wild type were observed. 
 
Concatemer EC50 (µM) nHill 
Remaining IAch 
Post MTS-ET (%) 
β2_α4_ β2_α4_ β2L146C 3.71 ± 0.80 0.93 ± 0.12 41.1 ± 2.92 
W176Cβ2_α4_ β2_α4_ β2 6.74 ± 0.56 1.18 ± 0.06 45.7 ± 2.67 
W176Aβ2_α4_ β2_α4_ β2L146C 5.40 ± 0.66 0.78 ± 0.04 52.3 ± 2.6 
W176Cβ2_α4_ β2_α4_ β2L146A 4.64 ± 0.83 0.84 ± 0.05 55.7 ± 2.5  
 
 
Table 4.5. ACh sensitivity parameters and maximal effect of MTSET on ACh activation 
of β2_α4_β2_α4_β2 hotsting cysteine and alanine substitutions in the putatively 
functionally connected β2(+)W175 and β2(-)L146 residues of the β2(+)/β2(-) interface. 
No significant change in sensitivity is seen in these mutants compared to wild type or 
β2_α4_ β2_α4_ β2L146C and although small and similar change seen in maximal MTSET 
effects of W175Aβ2_α4_β2_α4_β2L146C and W175Cβ2_α4_β2_α4_β2L146A, this is not significant. 
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ACh EC80 current responses of W176Aβ2_α4_β2_α4_β2L146C receptors were 
inhibited by 1 mM MTSET, showing that accessibility of L146C to MTSET was not 
perturbed compared to β2_α4_β2_α4_β2L146C receptors (Table 4.5). In contrast,  the 
rate of MTSET modification in W176Aβ2_α4_β2_α4_β2L146C was six-fold slower than 
in β2_α4_β2_α4_β2L146C receptors, a significant difference expected to occur if 
W176 and L146 were functionally coupled in the β2(+)/β2(-) interface (Figure 4.8; 
Table 4.6). As shown in Figure 4.8 and Table 4.6, the rate of MTSET modification 
of W176Cβ2_α4_β2_α4_β2 receptors in the presence or absence of ACh was no 
different from that measured for β2_α4_β2_α4_β2L146C, showing a similar effect 
regardless of which of these two residues is mutated to cysteine. Furthermore, when 
L146A was introduced in the fifth subunit of W176Cβ2_α4_β2_α4_β2 receptors, the 
rate of MTSET reaction was comparable to that measured in 
W176Aβ2_α4_β2_α4_β2L146C receptors (Table 4.6), and in the presence of ACh 
modification by MTSET was almost abolished, as it was observed for 
W176Aβ2_α4_β2_α4_β2L146C receptors (Table 4.6). 
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Figure 4.8. 
 
 
 
 
 
 
 
 
 
Figure 4.8. Rates of MTSET modification of residues of β2(+)/β2(-) of HS α4β2 nAChR  
showing functional link between two subunits. (A) Homology model of β2(+)/β2(-) 
interface showing residues with putative functional interaction sa grey sticks. (B) One phase 
decay plots of MTSET modification of α4β2 nAChR concatemers with residue β2(+)W176 
(proposed to interact with β2(-)L146 at β2(+)/β2(-) interface) in the presence and absence of 
EC80 ACh and (C-D) plots when one functional group of putatively interacting pair is 
removed by substitution to alanine.  
 
 
 
 
 
W176Cβ2_α4_ β2_α4_ β2L146A W176Aβ2_α4_ β2_α4_ β2L146C 
W176Cβ2_α4_ β2_α4_ β2 
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k1 Values k2 Values 
Concatemer 
MTSET 
(control) 
MTSET 
+ACh 
MTSET 
(control) 
MTSET 
+ACh 
β2_α4_ β2_α4_ β2L146C 0.018 ± 0.002 0.005 ± 
0.001++ 
1864 ± 236 475 ± 131 
 ++ 
W175Cβ2_α4_ β2_α4_ β2 0.028 ± 0.006 0.007 ± 
0.0007 ++ 
2850 ± 368.0 690.2 ± 77.1 
++ 
W175Aβ2_α4_ β2_α4_ β2L146C 0.006 ± 
0.0004*** 
0.003 ± 
0.0005 
591.1 ± 42.6 
*** 
330.2 ± 46.4  
W175Cβ2_α4_ β2_α4_ β2L146A 0.006 ± 
0.0004 *** 
0.005 ± 
0.0006 
623.3 ± 40.9 
*** 
547.5 ± 68.6 
 
 
Table 4.6. Rates of MTS-ET reactions in HS α4β2 nAChR with cysteine substitution of 
putatively coupled residues of β2(+)/β2(-) interface. The rate of reaction of the substituted 
cysteines were measured in the presence and absence of ACh, as described in detail in 
Materials and Methods. The data points represent the mean ± SEM of at least three 
experiments carried out on different batches of oocytes. The data were fit to a one-
exponential decay equation using GraphPad software 5, as described in Materials and 
Methods. First and second order rates were then calculated as described in Materials and 
Methods and values analysed by ANOVA with Bonferroni post corrections. Statistical 
differences between conditions within receptor shown as ++, p<0.005. Compariston of 
receptors to their non-alanine substituted counterparts within the same conditions shown by 
***, p<0.0001. 
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4.3 DISCUSSION 
 
The findings presented in this Chapter strongly suggest that agonist site 1 and 
the fifth subunit in HS α4β2 nAChRs functionally couple to impact receptor 
activation. This is the first time that long-range coupling between an agonist site and 
the fifth subunit has been described. Significantly, recent cryo-structures of Torpedo 
nAChRs suggest that agonist binding induces asymmetric motions of the different 
subunits, which are transmitted primarily to the channel gate through the β subunit 
(Unwin and Fujiyoshi, 2012). Additionally, recent structures of the human Glycine 
receptor bound to glycine have confirmed that interactions between the β1-β2 loop 
and the Cys loop of the principal subunit, together with the β8-β9 and pre-M1/M1 of 
the complementary subunit, interact with the M2-M3 loop of the principal subunit 
(Du et al., 2015) to gate the ion channel. These interactions have been suggested by 
previous structural studies (Unwin, 2005) and by extensive mutagenesis and 
functional studies (Andersen et al., 2011; Bouzat et al., 2004; 2008; Grutter et al., 
2005;Jha et al., 2007; Lee et al., 2009; Lee and Sine, 2005).  
 
If interactions of primary and complementary subunits in the ECD/TMD 
interface are critical gating elements, what may be the role of functional coupling 
between the fifth subunit and agonist site 1? On the basis of the impact of the fifth 
subunit on macroscopic maximal ACh currents, it may be that gating signals 
transmitted through interactions between the agonist sites and fifth subunit subunit 
are needed for maximally efficacious gating. In the case of the LS α4β2 receptor 
maximal gating is achieved through the contribution of the additional agonist site at 
the α4/α4 interface (Harpsoe et al., 2011; Mazzaferro et al., 2011). However, in 
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comparison to the LS α4β2 nAChR, the gating interactions that occur within the 
β2(+)/β2(-) interface do not include agonist binding. 
 
The overall outcome of the studies presented here suggests that agonist site 1 
has a stronger connection to the fifth subunit than agonist site 2. Since the two 
agonist sites responded differently to single-point alanine mutations and to MTSET 
derivatisation, it is clear that the agonist sites are functionally different. Thus, the 
findings are in accord with the findings of Mazaferro et al (2011) and Lucero et al. 
(2016) that have previously shown functional differences between the agonist sites 
housed by the α(+)/β(-) interfaces. Although the binding sites are structurally 
equivalent, subtle differences in the conformation, hydrophobicity or electrostatic 
environment brought about by different flanking subunits may differentiate them.  
The fifth subunit is different in the alternate forms of the α4β2 nAChR, which in turn 
differentiate the canonical agonist sites. It is interesting that in the HS α4β2 nAChR, 
it is coupling to agonist site 1 that has a greater impact on receptor activation. This 
could be because agonist site 1 probably communicates with the fifth subunit via the 
interface that the fifth subunit establishes with the complementary subunit of agonist 
site 1. It is widely recognised that the complementary subunit is an important 
efficacy element in the Cys loop receptors (Nys et al., 2013). 
 
  The interaction of the fifth subunit with agonist site 1 resembles that of the γ2 
subunit of the benzodiazepine binding site with the complementary subunit (an α1 
subunit) of an agonist binding site of benzodiazepine-sensitive GABA-A receptors. 
In this receptor type, binding of benzodiazepines to the α(+)/γ(-) interface potentiates 
the agonist responses of the receptor (Prichett et al., 1989; Smith and Olsen, 1995) 
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and, critically, induces structural re-arrangements of the adjacent GABA binding site 
(Kloda and Czajkowski, 2007). The binding sites are located at β(+)/α(-) interfaces 
(the β subunit is the principal subunit in the GABA-A) and, the γ2 subunit, besides 
contributing key determinants for benzodiazepine binding (for review, see Sigel, 
2002), is the fifth subunit. Thus, coupling of agonist sites to the fifth subunit appears 
to be conserved among the Cys loop receptors.  
 
Regardless of the asymmetrical coupling to the fifth subunit, the agonist sites 
are functionally different. They respond differently to single-point mutations, 
substituted cysteines show different degrees of accessibility to MTS-ET 
derivatisation in the presence or absence of ACh. These findings suggest important 
structural differences, yet it is difficult to visualise the underlying structural 
mechanisms that sustain the observed functional differences. Could interactions 
between the (+) side of the complementary subunit of agonist site 1 and the (-) side 
of the fifth subunit be sufficient to account for the differences between the agonist 
sites? Work published by Lucero et al. (2016) supports such possibility. These 
authors found that the E loop, in agonist binding and non-agonist binding, impacted 
receptor signature properties, which is in accord with the view presented in this 
Chapter that interactions between the agonist sites and the fifth subunit differentiate 
the agonist sites. It is interesting that in the muscle nAChR, the most recently 
evolved nAChR (Ortells and Lunt, 1995), the agonist sites are different due to the 
complementary subunit being different (ε/γ and δ). 
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In summary, the findings of this chapter strongly suggest coupling of agonist 
site 1 to the fifth subunit subunit and that this coupling increases the efficacy of 
agonist-driven gating. Does this mechanism underlie the super-agonism of 
compounds such as TC-2559 on HS α4β2 nAChRs? Chapter 4 examines this 
possibility using the same experimental strategies used in this Chapter and Chapter 
3. 
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Chapter 5 
 
Does the β2(+)/β2(-) Interface Account 
for TC-2559 Super-Agonism at HS 
α4β2 nAChRs?
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5.1 INTRODUCTION 
 
The nicotinic agonist TC-2559 exhibits strikingly different efficacy at the HS 
and LS α4β2 nAChRs. At the LS α4β2 nAChR, it acts as a partial agonist (Moroni et 
al., 2006; Carbone et al., 2009), which is accounted for by the inability of this 
compound to enter the agonist site at the α4/α4 interface of the LS receptor 
(Mazzaferro et al., 2014). In the case of the high sensitivity α4β2 receptor, TC-2559 
displays 4-fold greater efficacy than ACh, thus behaving as a super-agonist. Since 
HS α4β2 nAChRs possess agonist sites only at the α4(+)/β2(-) interfaces, it is 
reasonable to suggest that the super-agonism of TC-2559 on HS α4β2 nAChRs may 
be encoded, at least partly, by structural elements in fifth subunit  and the β2(+)/β2(-) 
interface it establishes with the β2 subunit of agonist site 1.  
 
Agonist efficacy and the structural and molecular mechanisms that modulate 
it are a central preoccupation in the field of Cys loop receptor pharmacology. Seven 
years ago, a breakthrough on the understanding of the molecular mechanisms 
underlying agonist efficacy was made using kinetic analysis of microscopic currents.  
This showed that partial agonist and agonist open the gates similarly but what 
differentiates them is the ability to transit to closed states immediately preceding the 
open state (Lape et al., 2009). Intermediary closed states have been observed in 
glycine receptors using cysteine cross-bridging but it is not clear whether these states 
precede gating or represent desensitised states (Prevost et al., 2013). Despite these 
insights, the structural determinants of agonist efficacy remain unknown.  As 
expected from the critical role of the primary component of the agonist site in 
agonist binding and gating, electrophysiological studies suggest the principal side of 
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agonist sites as a key determinant of efficacy (Chavez-Noriega et al., 1997; 
Mukhtasimova et al., 2009). Consistently with this view, crystal structures of AChBP 
in complex with ligands have shown that partial agonists, but not full agonists, 
induce incomplete capping of loop C around the agonist site, which may decrease 
gating efficacy (Hibbs and Gouaux, 2011; Brams et al., 2011; Kletke et; al., 2013). 
However, although an attractive possibility in its simplicity, the degree of loop C 
contraction is not an accurate predictor of agonist efficacy as some partial agonists 
cause full capping of loop C (Hibbs and Gouaux, 2011) and competitive antagonists 
such as DhβE induce agonist-like capping of loop C (Shasavara et al., 2012). Studies 
of AChBP crystal structures in complex with partial agonists of nAChRs have noted 
that partial agonist, but not full agonists, establish water-mediated hydrogen-bonds 
between their hydrogen-bond acceptor moiety and the backbone atoms of 
hydrophobic residues on the complementary face, which could lead to reduced 
gating efficacy (Hibbs and Gouaux, 2011; Rohde et al., 2012). Significantly, studies 
of the interactions between agonists and α4β2 nAChRs by unnatural amino acid 
mutagenesis have shown hydrogen-bonds between the complementary face and the 
H-bond acceptor moieties of agonists, although not necessarily mediated by a water 
molecule (Harpsoe et al., 2012; Tavarez et al, 2012).  
 
Given the discovery that the fifth subunit, through functional coupling with 
agonist sites, modulates ACh efficacy, it may be that TC-2559 efficacy on HS α4β2 
nAChRs can be accounted for by coupling between the agonist sites and the fifth 
subunit. In this Chapter, using SCAM, mutagenesis and two-electrode voltage-
clamping, the contribution of the fifth subunit to TC-2559 efficacy was examined
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5.2 RESULTS 
5.2.1 - Chimeric Fifth Subunit Effects on Macroscopic Efficacy 
In order to determine whether the fifth subunit encodes efficacy elements 
for TC-2559, the chimeric receptors described in Chapter 3 were assayed for their 
sensitivity and maximal response to this compound. These receptors were 
characterised by analysis of TC-2559 concentration response relationships 
normalised to maximal (1 mM) ACh. These assays revealed that 
β2_α4_β2_α4_α4/β2 receptors behaved as LS (α4β2)2α4 nAChR, in respect of 
sensitivity to TC-2559 (Figure 5.1; Table 5.1).  In contrast, β2_α4_β2_α4_β2/α4 
receptors responded to TC-2559 in a fashion that was comparable to that of wild type 
HS receptors (Figure 5.1; Table 5.1). These findings suggest the N-terminal domain 
of the fifth subunit in HS α4β2 receptors as a key determinant of TC-2559 efficacy, 
as it is for ACh. 
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Figure 5.1. Effects of TC-2559 on wild type and chimeric concatenated α4β2 nAChRs. 
(A) Representative traces of the current responses elicited by TC-2559 on wild type and 
chimeric α4β2 nAChRs. Chimeric receptors were engineered as described in Materials and 
Methods. (B) Concentration responses curves for the effects of TC-2559 on wild type and 
chimeric receptors. The concentration response curves were fit to the Hill equation using 
non-linear regression, as described in materials and Methods. EC50 values, nHill coefficient 
and relative maximal responses of TC-2559 are shown in Table 5.1. 
 
 
 
 
Table 5.1. Effects of TC-2559 on wild type and chimeric concatenated α4β2 nAChRs. 
Data are the mean ± SEM from at least 4 independent experiments from at least two 
different batches of oocytes. Concentration response data were analysed by non-linear 
regression, as described in Materials and Methods. Statistical differences between wild type 
HS α4β2 nAChR and LS and chimeric receptors were determined by One-way Anova with 
Bonferoni post-test. ***, p < 0.0001. 
 
Receptor 
 
EC50 (µM) nHill Imax TC2559/Imax ACh 
β2_α4_β2_ α4_β2 1.84 ± 0.1 0.86 ± 0.19 3.81 ± 0.39 
β2_α4_β2_ α4_β2/α4 2.74 ± 0.44 0.65 ± 0.07 3.43 ± 0.03 
β2_α4_β2_ α4_α4 5.67 ± 1.95 0.64 ± 0.07 0.23 ± 0.01*** 
β2_α4_β2_ α4_ α4/β2 4.85 ± 1.43 0.73 ± 0.15 0.21 ± 0.03*** 
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5.2.2 - MTS-ET modification of the β2(+)/β2(-) Interface Affects      
TC-2559 Efficacy 
To assess whether the fifth subunit contributes to the efficacy of TC-2559 in 
a manner comparable to its contribution to ACh efficacy, the rate of MTS-ET 
derivatisation of β2_α4_β2_α4_β2L146C concatemeric receptors was measured in the 
presence or absence of TC-2559. Prior to the rate measurements, the concentration 
effects of TC-2559 on β2_α4_β2_α4_β2L146C were determined. For comparative 
purposes, the concentration effects of TC-2559 on individually cysteine substituted 
receptors (i.e., β2L146C_α4_β2_α4_β2 and β2_α4_β2L146C_α4_β2) were also 
determined. Comparison of concentration response curves for TC-2559 on the three 
mutant receptors showed interesting differences. First, TC-2559 EC50 was decreased 
only when the L1456C mutations was introduced into agonist site 1 and 2, in accord 
with these two regions contributing to TC-2559 binding. (Figure 5.2; Table 5.2). 
Efficacy decreased significantly when L146C was in the fifth subunit or in the 
complementary side of site 1 (Figure 5.2; Table 5.2) and the decrease was 
comparable (approx.1.8-fold) (Table 5.2). In contrast, cysteine substituted agonist 
site 2 (i.e., β2_α4_β2 L146C_α4_β2 receptors) had no impact on TC-2559 efficacy 
(Figure 5.2, Table 5.2). These findings further confirm both the importance of the 
fifth subunit as an element of agonist efficacy and the asymmetric contribution to 
receptor gating of the agonist sites in HS α4β2 nAChRs. 
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Figure 5.2. Concentration response curves for TC-2559 on β2(-)L146C substituted HS 
α4β2 nAChRs. L146C was substituted individually on agonist sites and the β2(+)/β2(-) 
interface and the consequences of the substitution on TC-2559 EC50 and relative efficacy 
were determined, as described in Materials and Methods.  Concentration response curves 
were obtained by non-linear regression analysis, as described in Materials and Methods. 
Parameters estimated from the curve are shown in Table 5.2. β2_α4_β2_α4_β2L146C. 
 
 
 
 
 
 
Receptor EC50 (µM) nHill 
Imax 
TC2559/Imax ACh 
β2_α4_β2_ α4_β2 1.84 ± 0.1 0.86 ± 0.19 3.81 ± 0.39 
β2_α4_β2_ α4_β2L146C 4.11 ±0.49 0.94 ± 0.21 2.19 ± 0.21*** 
β2 L146C_α4_β2_ α4_ β2 9.80 ± 1.86** 0.96 ± 0.12 2.63 ± 0.26 ** ++ 
β2_α4_β2 L146C_ α4_ β2 7.17 ± 1.21** 0.71 ± 0.11 3.73 ± 0.21 
 
 
Table 5.2. Concentration-response effects of TC-2559 on β2(-)L146C substituted 
concatenated HS α2β2 nAChRs. Current responses elicited by a range of concentrations of 
TC-2559 were normalised to ACh EC100 (1 mM). Concentration-response data were fit with 
non-linear regression, as described in Materialas and Methods. Statistical differences 
between mutant and wild type receptors are shown by asterisks: **, p < 0.001; ***, p < 
0.0001 (One-way Anova tests with Dunnett’s post-test). Statistical differences between 
binding sites are shown by +: ++, p < 0.001 (One-way Anova tests with Dunnett’s post-test). 
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5.2.2.1 - Maximal effects of MTS-ET modification of β2L146C on TC-2559 efficacy 
   As expected, maximal modification of the cysteine substituted receptors 
following responses to TC-2559 was comparable to the pattern observed when ACh 
was used to monitor the accessibility of the substituted cysteines. Thus, agonist site 1 
(i.e., β2L146C_α4_β2_α4_β2) showed the largest reduction in TC-2559 induced 
activation following MTSET modification (64%), followed by site 2 (58%) and the 
fifth subunit (57%), although these differences were not statistically different (Table 
5.3).     
 
Table 5.3. Cysteine accessibility in β2(-)L146C substituted concatenated HS α4β2 
nAChRs. Ooocytes expressing mutant or cysteine substituted concatenated HS α4β2 
nAChRs were exposed to EC80 TC-2559 prior and after a 2 min application of 1 mM 
MTSET. The percentage change in the responses elicited by TC-2559 ACh after MTSET 
treatment was defined as ((IafterMTSET/Iinitial) -1) x 100]. Data are the mean ± SEM of at least 
three independent experiments. Significant differences between mutant and wild type 
receptors (noted by asterisks) were estimated using One-way ANOVA with Dunnett’s post-
test. **, p < 0.001 
 
 
 
 
 
 
 
 
 
Concatemer ITC-2559 after  MTS-ET Exposure (%) 
β2_α4_β2_ α4_β2 0.88 ± 0.07 
β2_α4_β2_ α4_β2L146C 0.43 ± 0.07** 
β2 L146C_α4_β2_ α4_ β2 0.36 ± 0.06** 
β2_α4_β2 L146C_ α4_ β2 0.42 ± 0.06** 
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5.2.2.2 - Rates of MTS-ET modification of cysteine substituted fifth subunit 
To assess whether TC-2559 activation of HS α4β2 nAChRs protected 
cysteine substituted fifth subunit from modification by MTS-ET, the rate of 
modification of β2_α4_β2_α4_β2L146C receptors in the presence or absence of TC-
2559 was measured. As expected, TC-2559 decreased the rate of reaction (k1 in the 
absence of TC-2559: 0.025 ±0.005 s-1 vs k1 in the presence of TC-2559, 0.012 ± 
0.002 s-1). However, comparison of the rate constants measured in the presence of 
ACh or TC-2559 showed that ACh was approximately 2-fold more efficacious than 
TC-2559 at protecting the substituted fifth subunit from MTS-ET modification 
(Figure 5.3, Table 5.4). If the fifth subunit were solely responsible for TC-2559 
super-agonism, the decrease in the rate of MTS-ET reaction in the presence of TC-
2559 should have been greater than in the presence of ACh. This also suggests that 
movements of the 5th β2 are agonist specific.  
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Figure 5.3. MTSET studies of TC-2259 activation of β2_α4_β2_α4_β2L146C. (A) Rate of 
modification of β2_α4_β2_α4_β2L146C by MTS-ET. The rate of reaction of MTS-ET with 
β2_α4_β2_α4_β2L146C was measured in the presence and absence of EC80 TC-2559. The 
rate data were fit to a single exponential equation, as detailed on Materials and Methods. 
Each data point represents the mean ± SEM of three-four independent experiments. 
Estimated rate constants are shown in Table 5.4. (B) Representitive traces of maximal TC-
2559 responses of β2_α4_β2_α4_β2L146C before and after MTSET exposure. 
  
 
Table 5.4. Rates of MTS-ET reaction in absence or presence of ACh or TC-2559 on 
β2_α4_β2_ α4_β2L146C receptors. The rate of modification of L146C on the β2(+)/β2(-) 
interface was measured in the absence or presence of TC-2559 EC80. Data from three 
experiments were fit to a single exponential rate equation, as described in Materials and 
Methods. k2 values were calculated by dividing k1 values by the concentration of MTS-ET 
used in the experiments. Data analysed using unpaired t-tests.  *** depicts significant 
differences between MTSET application condition using the same agonist (*** p < 0.0007, 
**p <0.003). ^ depicts significant differences between agonist tested in same conditions (p< 
0.05) 
 
k1 Values k2 Values 
Agonist 
MTSET 
(control) 
MTSET + ACh 
MTSET 
(control) 
MTSET + ACh 
ACh 0.018 ± 0.002 
0.005 ± 0.001 
**,^ 
1864 ± 236^ 
474.8 ± 
130**,^ 
TC-2559 0.026 ± 0.002 
0.012 ± 0.002 
***,^ 
2600 ± 191^ 
1150 ± 
202***,^ 
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5.2.3 – Effect of Alanine Substitution of Canonical Agonist sites on 
TC-2559 Activation of    (α4β2)2 β2 
Given that the fifth subunit does not account for the super-agonism of TC-
2559 at HS α4β2 nAChRs, it was examined whether canonical agonist sites encode 
defining efficacy elements for TC-2559. Docking on homology models of the HS 
α4β2 nAChR suggested that α4W182, α4E224 and β2S63 contact TC-2559 (Figure 
5.4).   
 
Figure 5.4. Docking of TC-2559 on a homology model of α4(+)/β2(-) interface. TC-2559 
is predicted to make contacts with W182, E224 and S63. (A) is view from the membrane bi-
layer, (B) is arial view of receptor 
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To determine if these residues affect the efficacy of TC-2559, they were 
alanine substituted and the consequences of the substitutions were assayed by two-
electrode voltage clamp electrophysiology. Efficacy of TC-2559 decreased by 
approximately half when W182A was introduced individually in either binding site 
(Figure 5.5A; Table 5.5). When W182A was simultaneously present in both agonist 
sites, TC-2559 did not evoke responses (Figure 5.5B). To determine whether TC-
2559 was still able to bind the agonist sites but unable to evoke responses, ACh EC80 
responses were measured alone or in the presence of either 1µM, 10µM or 100µM 
TC-2559 and the two conditions compared. As seen by representative traces in 
Figure 5.5E, the level of impairment of ACh response was TC-2559 concentration 
dependent. To test if TC-2559 behave as a competitive antagonist at  
β2_W182Aα4_β2_W182Aα4_β2 receptors, the concentration response curve for ACh 
was obtained in the presence or absence of EC50 TC-2559. If TC-2559 behaves as a 
competitive inhibitor on β2_W182Aα4_β2_W182Aα4_β2 receptors, the ACh 
concentration response should be shifted to the right in the presence of TC-2559, 
compared to wild type. As shown in Figure 5.5.C, TC-2559 co-application induced 
a rightward displacement in the ACh concentration response curve. 
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Figure 5.5. Concentration response effects of TC-2559 on the HS α4β2 nAChRs 
containing W182A agonist sites.  W182A was introduced individually or simultaneously in 
the agonist sites of concatenated HS α4β2 nAChRs. (A) The concentration-response curves 
for TC-2559 on the mutated receptors were obtained as described in Materials and Methods. 
EC50 and relative efficacy determined from the fit curves are shown in Table 5.5.(B) 
Representative traces showing that ACh responses are inhibited in the presence of TC-2559. 
(C) Concentration response curve for ACh on β2_W182Aα4_β2_W182Aα4_β2 in the absence 
and presence of TC-2559. EC50 and relative efficacy values are shown in Table 5.5. 
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Table 5.5. Concentration-response effects of alanine substituted agonist sites on TC-
2559 effects on HS α4β2 nAChRs. Responses elicited by a range of TC-2559 
concentrations were normalised to ACh EC100 peak responses and the data were then 
analysed by non-linea regression, as described in Materials and Methods. Data points 
represent the mean ± SErM of at least three independent experiments. Statistical differences 
between mutant and wild type receptors were carried out by One-Way Anova with Dunnett’s 
post-test. *, p < 0.05;  ***, p < 0.0001. NA, no agonist effects. 
 
 
Double mutant β2_E224Aα4_β2_E224Aα4_β2 and β2S63A_α4_β2S63A_α4_β2 
were then  tested. The β2S63A substitutions did not have significant effects on TC-
2559 or efficacy effect on the responses of TC-2559 (Figure 5.6; Table 5.5), hence 
the β2S63 mutation was not further analysed. In contrast, simultaneous incorporation 
of E224A on both agonist sites decreased efficacy by 2.7-fold, indicating this residue 
as an important component of for TC-2559 efficacy. The sensitivity of 
β2_E224Aα4_β2_E224Aα4_β2 receptors to activation by TC-2559 was comparable to 
wild type, indicating that E224 is likely to impact gating rather than agonist binding. 
Significantly, when E224A was introduced only in agonist site 1, efficacy was 
reduced by 2.8-fold, but when introduced in site 2 only, efficacy was not perturbed 
compared to wild type. Thus, as for ACh agonist site 2 appears to make a lesser 
contribution to receptor function than binding site 1.  
Concatemer EC50 (µM) nHill 
Maximum ITC-
2559/ IACh 
β2_α4_β2_ α4_β2 5.73 ± 1.89 0.86 ± 0.19 3.81 ± 0.39 
β2_W182Aα4_β2_ α4_ β2 3.04 ± 0.72 0.82 ± 0.11 2.01 ± 0.1**8 
β2_α4_β2_W182Aα4_ β2 6.31 ± 0.99 0.98 ± 0.014 1.81 ± 0.14 (***) 
β2_W182Aα4_β2_W182Aα4_ β2 N/A N/A 0 
β2S63A_α4_S63Aβ2_ α4_β2 3.77 ± 0.54 0.92 ± 0.06 3.47 ± 0.43 
β2_E224Aα4_β2_E224Aα4_β2 2.45 ± 1.10 0.65 ±0.10 1.41 ± 0.20(***) 
β2_E224Aα4_β2_α4_β2 2.67 ± 1.19 0.99 ± 0.12 2.76 ± 0.29(*) 
β2_α4_β2_E224Aα4_β2 1.84 ± .026 0.82 ± 0.05 3.43 ± 0.22 
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Figure 5.6. Concentration effects of TC-2559 on E224A or S63A substituted HS α4β2 
nAChRs. E224A or S63A were individually or simultaneously introduced in the agonist 
binding sites. The concentration effects of TC-2559 on the mutant receptors were 
determined as described in Materials and Methods. Dta points represent the mean ± SEM of 
at least thre independent experiments. Estimated EC50 and relative efficacy are shown in 
Table 5.5. 
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5.2.4 - Functional Link of α4(+)/β(-) Binding Interfaces to 5β2 subunit 
and β(+)/β(-) interface 
 Lucero et al. (2016) have recently shown that E loop residues in β2 and α4 
subunits can modulate α4β2 nAChR function at all receptor interfaces. L146 is an E 
loop residue, and taken with studies with ACh above, a role of L146 in efficacy was 
considered. This was first tested in terms of functional connection with β(+)/β(-). 
 Double mutant concatemers with substitutions in the biding sites alongside 
the L146C substitution within the β2(+)/β2(-) were assayed for maximum efficacy in 
order to gain insight to connections of these functional regions. An additive effect of 
two substitutions would imply mechanisms of efficacy reduction employed by these 
regions would be different. As double mutants (β2_W182Aα4_β2_α4_β2L146C and 
β2_α4_β2_W182Aα4_β2L146C) did not display additive effect compared to single 
substitutions, a functional connection between each binding site and the β2(+)/β2(-) 
is assumed (Figure 5.7, Table 5.6). 
 
Figure 5.7. Histogram of effects of maximal TC-2559 efficacy of HS α4β2 nAChRs 
witth substitutions of binding and β2(+)/β2(-) interfaces. Binding site W182A and 
β2(+)/β2(-)L146C substitutions shown for clarity. All differed from wild type significantly 
(***p<0.0001). Only one small but significant difference was seen in double substitutions 
between β2_α4_β2_W182Aα4_β2L146C and β2_α4_β2_α4_β2L146C (++, p=0.003) 
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Concatemer 
Maximum ITC-
2559/ IACh 
β2_α4_β2_ α4_β2 3.81 ± 0.39 
β2_W182Aα4_β2_ α4_ β2 L146C 1.97 ± 0.05*** 
β2_α4_β2_W182Aα4_ β2 L146C 1.61 ± 0.006***,++ 
 
 
Table 5.6. maximal TC-2559 efficacy of HS α4β2 nAChRs witth substitutions of binding 
and β2(+)/β2(-) interfaces. Binding site W182A and β2(+)/β2(-)L146C substitutions shown 
for clarity. All differed from wild type significantly (***p<0.0001). Only one small but 
significant difference was seen in double substitutions between β2_α4_β2_W182Aα4_β2L146C 
and β2_α4_β2_α4_β2L146C (++, p=0.003) 
 
 
 Following this it was considered that other E loop residues may affect TC-2559 
efficacy. The residues substituted were as follows (shown in Figure 5.8): 
• β2(-)V135 - equivalent to α4(-)H142, a determinant of TC-2559 low efficacy 
on LS α4β2 nAChRs (Mazzaferro et al., 2014) 
• β2(-)F144 -  equivalent to α4(-)Q150 
• β2(-)L146 - shown here to be important for agonist efficacy in HS α4β2 
nAChRs and equivalent to α4(-)T152 
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Figure 5.8. Homology model of the E loop shown within β(+)/β(-) (A) and α(+)/β(-) 
interfaces (B). Residues considered to be implicated in receptor function are shown in grey 
sticks. 
 
 
 
 
 
 
 
A 
B 
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Some of these residues are in close proximity, suggesting they may interact 
with each other (Figure 5.7; Table 5.6). Each of the identified E-loop residues were 
individually substituted to alanine or to their equivalent α4 residues in the β(+)/β(-) 
interface to construct the following: 
• β2_α4_β2_α4_β2V135A 
• β2_α4_β2_α4_β2F144A 
• β2_α4_β2_α4_β2L146A 
• β2_α4_β2_α4_β2V135H 
• β2_α4_β2_α4_β2L146Q 
• β2_α4_β2_α4_β2F144T 
 
These mutants were assayed for their sensitivity to activation by TC-2559 
using two-electrode voltage-clamp electrophysiology, as described in Materials and 
Methods (Chapter 2). The concentration-response parameters obtained by non-linear 
regression analysis of the data are summarised in Table 5.7. None of the mutants 
tested affected TC-2559 potency (Table 5.7).  TC-2559 efficacy was not affected by 
β2V135A or β2V135H (Table 5.7). As expected, the βL146A mutant decreased TC-
2559 efficacy to the same level obtained by introducing L146C in the β2(+)/β2(-) 
interface (Figure 5.8; Table 5.7). A novel revelation of this work is the reduction in 
overall function following the F144 side chain removal, a structural alteration that 
renders TC-2559 efficacy 2.4 times that of ACh (Figure 5.8; Table 5.7). This puts 
forward another component of the E-loop as partaking in determination of ligand 
efficacy at the HS α4β2 nAChR. Interestingly, when mutants of F144 and L146 were 
simultaneously present in the β2(+)/β2(-) interface, the reduction in efficacy was not 
multiplicative. Efficacy was reduced to the same level obtained with the individual 
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alanine substitutions, suggesting that F144 and L146 may be functionally coupled 
(Figure 5.8; Table 5.7). Thus, overall the findings indicate that at least two residues 
of the E loop, F144 and L146, are important for the contribution of the fifth subunit 
to agonist-driven recptor function.  
 
 
 
Figure 5.9. Histogram showing variation in TC-5229 efficacy with E loop substitutions 
to alanine or α4-subunit equivalent . The relative efficacy of TC-2559 was calculated by 
dividing the peak TC-2559 current responses by the peak current elicited by ACh EC100 (1 
mM). Statistical differences between wild type and mutant receptors were estimated using 
one-way Anova with Dunnett’s post-tests (***, p<0.0001) ANOVA with Bonferroni 
corrections were performed to assess variances between residues withinin alanine or α-
subunit equivalent substitutions (+++,p<0.0001’ ++,p < 0.0005). Only one difference of 
residues between alanine and α equivalent substitutions as determined by students t-test 
(^^,p=0.005). Concentration response parameters EC50 and relative efficacy are shown in 
Table 5.7. 
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Receptor EC50 (µM) ImaxTC2559/ImaxACh 
β2_α4_β2_α4_β2 1.84 ± 0.1 3.81 ± 0.39 
β2_α4_β2_ α4_β2V135A 2.98±0.98 3.55 ± 0.22 
β2_α4_β2_ α4_β2F144A 2.01±0.84 2.44 ± 0.04 *** 
β2_α4_β2_ α4_β2L146A 3.7±0.7 2.06 ± 0.04 *** 
β2_α4_β2_ α4_β2V135H 3.0±1 3.91±0.01 
β2_α4_β2_ α4_β2F144Q 2.84±0.98 1.67 ± 0.06 *** 
β2_α4_β2_ α4_β2L146T 3.05± 1.63 ± 0.09 *** 
β2_α4_β2_ α4_β2F144Q, L146T 3.6±1.1 1.68 ± 0.06 *** 
β2_α4_β2_ α4_β2V135H, F144Q, L146T 3.87±1 1.81±0.1*** 
β2_α4_β2_H142Aα4_β2 3.21 ± 0.82 3.81 ± 0.39 
β2_α4_β2_Q150Aα4_β2 2.65 ± 2.21 3.45 ± 0.36 
β2_α4_β2_T152Aα4_ β2 3.1 ± 1.34 3.88 ± 0.24 
β2_H142Aα4_β2_α4_β2 2.97 ± 0.82 3.85 ± 0.05 
β2_Q150Aα4_β2_α4_β2 2.78 ± 2.21 3.7±0.01 
β2_T152Aα4_β2_α4_ β2 3.00 ± 1.34 3.2±0.1 
 
Table 5.7. Effects of E loop residues on TC-2559 effects on concatenated HS α4β2 
nAChRs. Loop E  residues were mutated to alanine or their equivalents on their interfacing 
subunit. The concentration effects on the responses of the mutants to TC-5299 were analysed 
by non-linera regression, as described on Materials and Methods. Statistical differences 
between mutant and wild type receptors were determined by One-way Anova with Dunnett’s 
post-test. ***, p < 0.0001. 
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5.2.5 - Functional links in β2(+)/β2(-) Implicated in TC-2559 Efficacy 
Examination of the homology model of the β2(+)/β2(-) interface suggest that 
residues that could couple functionally include β2(-)L146 and β2(-)F144 on the 
complementary side of the β2(+)/β2(-) interface and β2(+)W176, β2(+)T177, 
and1β2(+)Y178 on the principal side of the β2(+)/β2(-) interface. As shown in Table 
5.8, these residues are in close proximity and could engage in hydrophobic or π 
stacking interactions, depending on the nature of the residues involved. Of the 
residues mentioned above, β2(+)W176 has already been suggested as being couple 
to β2(-)L146 to contribute to ACh efficacy (Chapter 4). The additional two residues 
suggested by this approach (1β2T177 and 1β2Y178) were individually substituted by 
alanine to produce T177Aβ2_α4_β2_α4_β2 and Y178Aβ2_α4_β2_α4_β2 concatemers, 
and the TC-2559 concentration response relationships of each were analysed. 
Removal of the Y178  had no effect upon TC-2559 potency or efficacy (Table 5.9). 
In contrast, β2T177 reduced TC-2559 efficacy 2.2 times, compared  to wild type 
(Table 5.9).  
To determine whether β2(-)L146 and the β2(+)W176 and β2(+)T177 of the 
β(+)/β(-) interface are coupled, the effect of double substitutions here upon TC-2559 
efficacy was examined. If these residues are not coupled functionally, then the effect 
on efficacy of the double mutants and single mutants should be multiplicative. 
Neither of these mutants displayed EC50 values different from wild type, but, 
compared to wild type, TC-2559 efficacy was reduced to the same level obtained 
with the individual substitutions (Table 5.9). 
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Taken together, all data concerning β2(+)/β2(-) residues strongly suggest 
presence of inter-subunit interactions between the fifth subunit and the neighbouring 
β2, and the importance of these interactions in determination of receptor efficacy.   
 
 
 
Table 5.8. Possible inter-residue interactions in the β2(+)/β2(-) interface. Homology 
models of the β2(+)/β2(-) interface predict several residues in loop A and loop E to be in 
close proximity to be able to engage in inter-facial interactions. 
 
 
 
 
 
 
 
 
1β2 (+) 5β2 (+) Distance (Å) 
Possible Nature of 
Interaction 
W176 V135 9.85 Hydrophobic 
T177 V135 3.40 Hydrophobic 
Y178 V135 3.20 Hydrophobic 
W176 F144 6.83 π Stacking 
T177 F144 5.04 π Stacking 
Y178 F144 6.10 (backbone) π Stacking 
W176 L146 3.20 Hydrophobic 
T177 L146 4.83 Hydrophobic 
Y178 L146 4.46 Hydrophobic 
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Figure 5.10. Histogram of effects of TC-2559 efficacy following removal of putatively 
linked residues in β2(+)/β2(-) interface. Maximal responses of single and double 
substitutions shown for clarity. All are significantly different to wild type receptors as 
measuresd by ANOVA with Dunnets corrections (***,p<0.0001). As determined by ANOVA 
with Bonferroni correction, only W176Aβ2_α4_β2_α4_β2 was significantly different from its 
double mutant counterpart (++,p=0.01), but reduction following L146A substitution was not 
additive.  
. 
 
 
 
 
Table 5.9. Effects of β2(+)/β2(-) interface residues on TC-2559 effects on concatenated 
HS α4β2 nAChRs. Loop A or B residues were mutated to alanine or their equivalents on 
their interfacing subunit. The concentration effects on the responses of the mutants to TC-
5299 were analysed by non-linear regression, as described on Materials and Methods. All are 
significantly different to wild type receptors as measuresd by ANOVA with Dunnets 
corrections (***,p<0.0001). As determined by ANOVA with Bonferroni correction, only 
W176Aβ2_α4_β2_α4_β2 was significantly different from its double mutant counterpart 
(++,p=0.01), but reduction following L146A substitution was not additive 
Receptor EC50 (µM) ImaxTC2559/ImaxACh 
β2_α4_β2_ α4_β2L146A 3.7±0.7 2.06 ± 0.04 *** 
W176Aβ2_α4_β2_α4_β2 4.36 ± 1.09 2.66 ±  0.16 *** 
T177Aβ2_α4_β2_α4_β2 2.96±1.1 2.18 ± 0.06 *** 
Y178Aβ2_α4_β2_α4_β2 2.45±0.67 3.29 ± 0.11 
W176Aβ2_α4_β2_α4_β2L146A 4.19 ± 0.22 2.12 ± 0.09 
T177Aβ2_α4_β2_α4_β2L146A 3.04 ± 0.51 1.99 ± 0.06 
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5.3 DISCUSSION 
 
The findings of this study confirm the findings of Chapter 3 and 4 that the 
fifth subunit contributes to receptor activation through functionally linking to the 
agonist sites of the HS receptor. The importance of interaction between the 
β2(+)/β2(-) and α4(+)/β2(-) interfaces in maximum activation and ligand specific 
response is highlighted, while suggesting that the α4(+)/β2(-) site coupling to the 
fifth subunit through the β2(+)/β2(-) interface may be a gating mechanisms 
additional to the pathway linking the agonist site to the ECD/TMD interface and M2. 
Thus, the findings further support the most recent cryo-structures of Torpedo 
nAChRs showing a key role for the fifth subunit in channel gating (Unwin and 
Fujiyoshi, 2012).  
The most novel of findings concerning TC-2559 activation of HS α4β2 
nAChRs are those pertaining to the α4(+)/β2(-) binding interfaces. Taken together, 
the double mutant concatemers β2_W182Aα4_β2_W182Aα4_β2 and 
β2_E224Aα4_β2_E224Aα4_β2 suggest that ACh and TC-2559 bind the agonist sites 
with different poses, Such differences were also suggested by docking stimulations. 
This implies different energy release profiles following the interaction of these two 
agonists at binding site that will then lead to unique activities throughout the 
pentamer during activation events leading to opening of the channel (Taly et al., 
2013). Binding interactions are thus shown to be the initial and major determinant of 
receptor response to particular agonists. Because the double mutants led to almost 
(E224A) or complete (W182A) ablation of the super-agonism of TC2559, which was 
not obtained with mutants β2(+)/β2(-)-containing receptors, it is clear that binding of 
the agonist to the agonist sites is the dominant determinant of agonist efficacy. \this 
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is in accord with studies that show that agonist binding site residues, wheather in the 
principal or complementary side of the agonist site are key determinants of efficacy 
(Chavez-Noriega et al., 1997; Mukhtasimova et al., 2009; Hibbs and Gouaux, 2011; 
Brams et al., 2011; Harpsoe et al., 2012 Rohde et al., 2012; Tavarez et al, 2012; 
Kletke et; al., 2013).  
 
As shown in ACh studies, the binding site characteristics contribute largely to 
the unique functional features of the α4β2 nAChRs, primarily via their individual 
modes of action and the dominance of site 1, closest to the β(+)/β(-) interface. In 
respect of TC-2559 activation, this is shown here to also be the case. When 
introducing single mutants of binding residues in the α4 subunits (α4(+)W182A or 
α4(+)E224A), the reduction of TC-2559 responses are significantly different 
between the two binding sites. In the case of α4E224A, the additional TC-2559 
binding residue identified by this work, the usual pattern of site 1 alteration having 
the largest effect is witnessed. In contrast, alanine substitution of the well-established 
conserved binding residue α4W182 resulted in larger perturbation of receptor 
function when introduced in site 2. This is not seen in any other studies, including 
those of ACh effects at receptors with this substitution in individual sites and shows 
that site 1 is not strictly dominant in all aspects of activation. Sensitivity effects as a 
result of this substitution are constant between ACh and TC-2559, supporting the 
findings of no effect to the ACh EC50 in site 2, while site 1 produced bi-phasic CRC.   
 
The studies reported here demonstrate that binding sites also work together to 
determine efficacy as well as potency of agonists, most evident in comparison of the 
three mutants containing α4E224A substitutions. This glutamate is suggested to be 
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important in TC-2559 binding at site 1, by reduction in activation following removal 
of its side chain. However, receptor activation by TC-2559 is not affected by the 
α4E224A substitution in site 2 alone, and its binding interaction with the E224 at this 
interface doesn’t appear to be central to the maximum response elicited. As the 
effects of this alanine substitution in site 2 does have an impact on receptor response 
to TC-2559 when the E224 binding is interrupted at site 1 (double mutant 
significantly perturbed compared to β2_E224Aα4_β2_α4_β2), it appears that altered 
binding at site 1 will in turn alter activity of site 2. This suggests that specific 
binding profiles will initiate different conformational changes throughout the 
pentamer, in turn impacting conformational changes and any additional binding that 
follows this and consequentially channel gating and activation. This process has 
previously been outlined in ACh activation, but these studies are only able to 
highlight the effects of agonist potency and the action of conserved binding residues. 
The data with additional non-conserved binding residues suggests that this may be a 
consequence of interfaces moving as a whole as opposed to specific residues. Thus, 
it may be an effect of global conformational changes throughout the receptor 
(reviewed by Cecchini and Changeux, 2015). Thus, the involvement of agonist-
binding and non-binding interfaces is consistent with the current view of gating in 
the Cys loop receptors (Cecchini and Changeux, 2015). Agonist binding appears to 
close the loop C, promoting a concerted anti-clockwise rotation around the pore axis 
of all five subunits and pushing the fifth subunit outwardly (Unwin anf Fujiyoshi, 
2012; Du et al., 2015). Thus, the whole protein undergoes extensive rearrangements, 
which are likely to involve inter and intra-interactions between residues. 
An important observation of this collection of studies is that none of the mutations 
studies decreased the efficacy of TC-2559 to the level seen for LS α4β2 nAChR 
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(Moroni et al., 2006; Carbone et al., 2009; Mazzaferro et al., 2014). LS α4β2-like 
efficacy is only achieved when the complete ECD of the fifth subunit is replaced 
with the ECD of an α4 subunit. Thus, it may be possible that the α4(+)/α4(-) 
interface impairs efficacy of TC-2559. This ligand does not bind the α4(+)/α4(-) 
interface (Mazzaferro et al., 2014), but it may be that communicating pathways 
between the agonist sites on α4(+)/β2(-) and the α4(+)/α4(-) interface regulate 
agonist efficacy in the same fashion the equivalent pathway does in the HS receptor. 
 
Overall the findings highlights well the importance of information 
transmission between subunits and in turn the inter-subunit interactions governing 
this. Knowing from ACh studies the role that the E-loop of the fifth subunit β2 plays 
in these events; TC-2559 data here has supported the importance of this region and 
allowed identification of specific amino acids conducting the interface specific 
interactions. From work by others (Harpsoe et al., 2011 and most recently Whiteaker 
et. al., 2016) and ourselves (Mazzaferro et al., 2011; 2014), it is known that the E-
loop, situated on the complementary face of subunit interfaces is important in α4β2 
nAChR function. The findings of this thesis shows the E loop within the β2(+)/β2(-) 
interface as an important efficacy element. Alongside chimera studies, MTS-ET 
modification of residues at this location revealed its importance in levels of ACh 
activation, as well as intersubunit connections central to this mechanism. 
Considering this, and the findings of Whiteaker et. al. (2016) that all subunit 
interfaces contribute to receptor activation in distinct manners, it seems that gating of 
Cys loop receptors is more complex than previously thought (reviewed by Miller and 
Smart, 2010), even considering recent structural studies of nAChRs (Unwin and 
Fujiyoshi, 2012). The challenge for the future is to determine how all these various  
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pathways combine to achieve efficacious gating. 
 
This Chapter confirms the link of agonist site 1 to the fifth subunit and the 
asymmetrical function of the agonist sites. As discussed in previous chapters, it 
seems that asymmetrical function of agonist sites may be the norm in heteromeric 
Cys loop receptors (Baumann et al., 2005; Price et al., 2002 ). This is not surprising, 
the Cys loop receptors and its prokaryotic homologs are asymmetric proteins and 
their gating, even when considered purely from the subunits binding agonist is 
highly asymmetric (Cecchinni and Changeux, 2015). It is in this asymmetric 
function that offers the possibility of developing highly specific drugs. So far, drug 
discovery projects have not being highly fructiferous in developing stoichiometry-
specific α4β2 nAChR-drugs (Bruce et al., 2005; Olsen et al., 2013), but the 
identification of receptor unique gating pathways may provide a new impetus and 
focus to drug discovery programs. 
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Through extraordinary advances in a multitude of experimental approaches 
that have been applied to studies of the atomic structure and function of pLGICs, our 
understanding of how these allosteric proteins couple agonist binding to ion channel 
gating has been increased to a level that we could not even imagine fifteen years ago, 
when the crystal structure of the AChBP, the homolog of the ECD of the nAChR, 
was resolved (Brejc et al., 2001). The last three years have had a tremendous impact 
on our understanding of the pLGICs. The resolution of the crystal structures of 
prokaryotic (Hilf and Dutzler, 2008, 2009; Bocquet et al., 2009; Sauguet et al., 2014; 
and eukaryotic pLGICs in resting, open and desensitised states (Hibbs and Gouaux, 
2011; Nury et al., 2010; Calimet et al., 2013; Miller and Aricescu, 2014; 5-HT3; 
Hassaine et al., 2014; Althoff et al., 2014), cryo-EM structures (Unwin, 2005; Unwin 
and Fujiyosi, 2012; Du et al., 2015), molecular dynamics analysis of the gating of 
pLGICs (Nury et al., 2010; Calimet et al., 2013) as well as REFER studies of the 
microscopic kinetics of these ion channels (Purohit et al., 2007) have insight how 
these channels transit energetically and structurally from the resting (unbound close) 
to the open (bound) and then desensitised (close bound) states.  This thesis builds 
upon these achievements, demonstrating that gating involves all subunits, including 
those not directly involved in agonist binding.  The most important finding of this 
study is that the fifth subunit (previously considered an auxiliary or structural 
subunit) participates in gating, albeit by functionally linking to one the agonist sites 
on α4/β2. This link is asymmetrical; it takes place only with the agonist site whose 
complementary subunit interfaces with the fifth subunit (agonist binding site 1 in the 
concatemer HS α4β2).  
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 The widely accepted mechanism of channel gating, known as the principal 
pathway, constitutes transmission of ligand binding energies through the structure of 
the receptor downwards to the distally located gate via a series of conformational 
changes. This signal propagates from the binding site to the region known as the 
coupling region at the interface between the extracellular domain and the pore 
containing transmembrane domain (reviewed by Miller and Smart, 2010; see also 
Chapter 1). This involves displacement of the alpha helices lining the pore and 
subsequent movement of all subunits to widen the channel and permit flow of ions 
into and out of the cell (Unwin, 2005; Unwin and Fujiyoshi, 2012; Du et al., 2015). 
However, pLGIC activation does not constitute a simplistic binary phenomena 
consisting of purely closed and open states. First, in addition to the principal 
pathway, interactions between M4 and M1 and M3 (Carswell et al., 2015) and M4, 
post-M4 and the Cys loop modulate gating. The findings of this thesis, together with 
the most recent cryo-EM structures of the Torpedo nAChR (Unwin and Fujiyoshi, 
2015) add interactions between the fifth subunit and an agonist site as an additional 
gating element. How do all these gating elements work together to define agonist 
efficacy?  Through structural and functional diversity of receptors as well as ligands, 
gating can vary e.g. full, partial and super-agonism and be modulated (e.g., allosteric 
modulators). Gating efficacy is currently thought to be determined by closed states 
preceding gating (Lape et al., 2009; Mukhtasimova et al., 2009). The structures that 
underlie the transition to or these closed states themselves are not known but one can 
surmise that they will likely multiple intra- and inter-subunit interactions. The 
observation that twisting and blooming involves the whole protein supports this 
view. 
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The findings of this thesis shows the importance of the fifth subunit as a 
gating element, in accord with the interpretation of the most recent cryo-EM 
structures of Torpedo nAChRs by Unwin and Fujiyoshi (2012). These authors 
propose that both bound-agonist sites asymmetrically push the auxiliary subunit (β1) 
to gate the channel. Thus, it is the displacement of the fifth subunit that ultimately 
opens the gate. The functional studies presented here do not fully agree with Unwin 
and Fujiyoshi (2014). The fifth subunit in the HS α4β2 nAChR appears to increase 
the efficacy of agonist-driven gating, thus acting like a gating modulator. Thus, the 
effect of the fifth subunit on agonist efficacy (gating) depends on agonist binding to 
the agonist site coupled to the fifth subunit, and when the sites are engaged, the fifth 
subunit increases gating. Indeed, this thesis, through the work carried out on the 
functional effects of TC-2559, a super-agonist at HS α4β2 nAChRs, shows clearly 
that agonist binding sites are the principal determinant of agonist efficacy or gating. 
How this interplay between agonist sites and agonists and coupling between engaged 
agonist sites and the fifth subunit define gating efficacy remains to be elucidated.  
However, one can anticipate that gating efficacy, at the structural level, will be 
complex and comprise many pathways. The gating of pLGICS is likely to be as 
complex as the physiological functions they mediate. 
 
Gating efficacy, in respect of microscopic receptor kinetics, is determined by 
how efficiently agonist-bound binding sites reach closed states preceding gating 
(Lape et al., 2009). Once the flipped or primed states are reached, full and partial 
agonists gate the channel similarly. Thus, one can surmise that conformational 
transitions occurring immediately after agonist binding cause the flipping states. It is 
tempting to speculate that a structural factor underlying the flipping states may be 
Bibliography 
 
 
163 
 
different degrees of 5th β2 subunit movement, just as the degree of loop C capping 
has been linked to agonist efficacy (Hansen et al., 2005). This possibility is 
consistent with REFER data that suggests that agonist dependent differences in 
gating are likely to be defined by events occurring  close to the  binding steps, 
whereas the final activating step of channel opening is very similar between full and 
partial agonists (Jadey and Auerbach, 2012). Clearly the challenge today for the field 
of pLGIC is the identification of intermediate activation states such as the “flipped” 
or “primed” states in which receptors are ligand bound and active but closed 
provides a basis of understanding how distinct ligands achieve unique responses. As 
movements and subsequent interactions of the 5th β2 subunit are agonist specific, this 
thesis suggests there is a structural basis to these intermediate states, determined by 
the binding sites but propagated at the non-binding subunit interfaces. The flipped 
receptor has a higher affinity for the agonist than the resting receptor, and in turn, a 
higher affinity for full over partial agonists low affinity for the flipped state, relative 
to the resting state, that makes an agonist partial, rather than low affinity for the open 
state, relative to the resting state. This places interaction energies defining agonist 
efficacies earlier in the chain of events that follow binding than if the defining state 
was an open state. 
   
Mukhtasimova (2009) attributed a structural element to the primed 
‘intermediate states’ as the capping of loop C of binding sites. This stated that 
capping of a single binding site results in one priming state with an intermediate 
duration that triggers brief channel openings. Capping of two sites results in the 
second primed state that has a brief duration and leads to longer open states. 
Significantly, the two closed primed states (one vs two liganded binding sites) are 
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distinct from each other and exhibit conformational changes of loop C that are 
independent of the agonist eliciting the response. The difference that is conferred by 
ligands is their ability to prompt receptors to reach this primed state, which in turn 
depends on bi-directional communication between the binding regions and channel. 
These findings, taken in conjunction with the findings of this thesis, suggest that 
although binding interactions within the sites differ between agonists and the sites 
themselves, eliciting agonist-dependent conformational or energetic transitions in the 
binding sites, some conformational changes within the sites elicited by ligands are 
not dependent on the nature of the agonists. Findings here suggest that the functional 
coupling between agonist site 1 and the fifth subunit has the same effect on gating 
regardless of whether ACh or TC-2259 occupy the site.  
 Significantly, this study found that changes in one agonist site through 
alanine or cysteine mutations affected the function of the other agonist site. Thus, the 
findings suggest that the sites are somehow functionally coupled. Akk (2002) 
observed a similar phenomenon for the muscle nAChR. Incorporation of α1Y93F 
substitutions in a single binding site showed that the receptor behaved functionally 
as if both agonist sites were mutated. Thus, the agonist sites in the muscle nAChR 
appear to be coupled, just like the agonist sites in the HS α4β2 nAChR.  
Using single channel analysis, Jadey et al. (2012) found that that each 
binding site in the muscle nAChR appears to undergo two conformational changes 
following agonist interaction, termed the “catch” and “hold conformations. These 
conformational changes were suggested to underlie the switching of the sites from a 
low to high agonist affinity state. This was thought to be due to loop C capping as 
well as movement of other loops in the binding sites. Agonists that open the channel 
more effectively bind to resting nAChRs with higher affinity and, this close 
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correlation between affinity and efficacy implies that binding and the affinity change 
are two stages of a single integrated process. The energies of these structural re-
arrangements leading to affinity changes are able to predict the efficacy of responses 
and vice versa as they correlate to the gating equilibrium constant (Purohit et al., 
2014). A similar correlation between affinity binding and efficacy has been observed 
in the GABA-A receptor (Jones et al., 2001). The correlation of agonist affinity and 
efficacies have been taken to indicate that these catch and hold conformational 
changes associated with low affinity binding and switching from low to high affinity 
respectively, are not independent and that all of the intermediate steps in AChR 
activation including re-arrangement of binding loops comprise a single, energetically 
coupled process. This work supports notions of intermediate flipped states, and the 
two mechanisms can be incorporated to give the scheme:  
 
 
 
 
Considering the findings of this thesis, it is tempting to suggest that 
movements in the fifth subunit are involved in the process of reaching the flipping 
states. Functional connection of the 5th β2 with site1 was suggested by the findings 
of the SCAM and mutagenesis studies reported in Chapter 3 and 4. On the other 
hand, the only demonstration of functional linkage between the fifth subunit andv 
agonist site 2 comes mutagenesis studies that perturbed the ACh concentration 
response curves of the mutant receptors, compared to wild type. This may suggests a 
weaker functional connection between the fifth subunit and site 2, compared to that 
with agonist site 1. 
flipped   
---------------------------- 
open 
------- 
dock 
-------
- 
hold  
-------
- 
catch
-------
- A+R  ↔  A-R  ↔  ARL  ↔  ARH  ↔  AF2  ↔  AF3  ↔  AR* 
(AF1) 
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Considering the number of functional binding sites of LGIC’s from an 
evolutionary perspective provides leads provoking thoughts on the roles of subunit 
interfaces and modes of action of these proteins. Within the ancient homomeric Cys-
loop receptors, five structurally equivalent interfaces are present, all of which are 
able to bind agonists. With the development of the more recent heteromeric 
pentamers incorporating many subunit types, a greater diversity of receptors is seen. 
However, this is at a cost; subunits shown in this thesis that are incapable of forming 
functional binding interfaces are introduced to the pentamer and ligand binding site 
numbers reduced to only 3 and even 2 within a pentamer. As the need for more 
complex and intricate physiological pathways arises, it fits that multiple receptor 
subtypes with a variation in the number of binding sites present and thus different 
modes of action came into existence.  
However, more interesting still is that these non-canonical binding interfaces 
and subunits have not completely lost function but serve a role in receptor activation 
in an alternate manner. This appears to predominantly be utilisation of the conserved 
binding sites to exert their modulatory effect as demonstrated in this thesis and more 
classically in the benzodiazepine binding interface of GABA-A receptors. These 
mechanisms of receptor modulation fit with the development of more complex 
organisms and biological systems as a finer tuning is required. a mechanism of 
compensation of loss of these orthosteric binding sites making way for modulatory 
regions may be a factor behind the and functional differences and coupling of 
conserved binding sites and resultant multiple gating pathways. All these 
considerations highlight how these receptors function in a complex manner to govern 
the complex behaviours we know them to govern. This raises the question of how far 
we can use these multiple pathways of function and gating to our advantage, in order 
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to understand how brain modulates activity and ultimately use this knowledge to 
develop theraputic drugs.  
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